TECNOLOGIA	Título
Nitazoxanida	Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial.
Plasma convalescente	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.
Hidroxicloroquina	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
Corticosteroides	Corticosteroid treatment has no efect on hospital mortality in COVID‐19 patients.
Vacina (Ad26.COV2.S)	Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Vacina (Ad26.COV2.S)	Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Prednisona	The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.
Cloroquina	Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis.
Hidroxicloroquina	Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis.
Imunoglobulina	Efficacy Evaluation of Intravenous Immunoglobulin in Non-severe Patients with COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.
Plasma convalescente	Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study.
Antagonistas da vitamina K (AVK)	Impact of oral anticoagulation on clinical outcomes of COVID‐19: a nationwide cohort study of hospitalized patients in Germany.
Anticoagulantes	Impact of oral anticoagulation on clinical outcomes of COVID‐19: a nationwide cohort study of hospitalized patients in Germany.
Própolis	Efficacy of propolis as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial.
Azitromicina	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.
Corticosteroides	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.
Heparina	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.
Tocilizumabe	Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.
Plasma convalescente	Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.
Ácido ascórbico	Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19; A Randomized Controlled open-label Clinical Trial.
Plasma convalescente	A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.
Remdesivir	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Remdesivir	Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Cloroquina	Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients—initial experience.
colchicina	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
daclastavir	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
interferon	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
plasma convalescente	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
Sofosbuvir	Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
Corticosteroides	Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.
Ácido ascórbico	The Role of Vitamin C as Adjuvant Therapy in COVID-19.
Antagonistas do Receptor da Angiotensina II	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Antagonistas do Receptor da Angiotensina II	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Antagonistas do Receptor da Angiotensina II	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Antagonistas do Receptor da Angiotensina II	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Antagonistas do Receptor da Angiotensina II	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Antagonistas do Receptor da Angiotensina II	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Interferon	Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
Lopinavir	Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
Ritonavir	Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
Antagonistas do Receptor da Angiotensina II	Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19.
Plasma convalescente	Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
Acetato de icatibanto	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Ácido alfa lipóico	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Ácido ascórbico	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Aprepitanto	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Auxora	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Azitromicina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Azivudina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Baloxavir marboxil	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Bromexina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Cloroquina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Cobicistato	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Colchicina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Corticosteroides	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Daclatasvir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Darunavir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Dexametasona	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Difosfonato de metila (99-mTc)	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Fator estimulador de colônias de granulócitos humano recombinante	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Favipiravir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Hidroxicloroquina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Imunoglobulina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Inibidor de C1 esterase/calicreína	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Interferon alfa	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Interferon beta	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Interferon gama	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lincocin	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Lopinavir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
N-acetilcisteína	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Novaferon	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Plasma convalescente	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Remdesivir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Ribavirina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Ritonavir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Sofosbuvir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Solução salina eletrolisada	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Terapia celular	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Tocilizumabe	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Triazavirina	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Umifenovir	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Vilobelimabe	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Vitamina D (25-hidroxivitamina D)	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Fluoxetina	Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.
Fluoxetina	Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.
Venlafaxina	Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.
Venlafaxina	Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.
Azitromicina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Azitromicina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Azitromicina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Azitromicina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Azitromicina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Dexametasona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Dexametasona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Dexametasona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Dexametasona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Dexametasona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Hidroxicloroquina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Hidroxicloroquina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Hidroxicloroquina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Hidroxicloroquina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Hidroxicloroquina	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Lopinavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Lopinavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Lopinavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Lopinavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Lopinavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Prednisona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Prednisona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Prednisona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Prednisona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Prednisona	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Remdesivir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Remdesivir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Remdesivir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Remdesivir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Remdesivir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Ritonavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Ritonavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Ritonavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Ritonavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Ritonavir	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Tocilizumabe	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Tocilizumabe	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Tocilizumabe	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Tocilizumabe	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Tocilizumabe	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.
Prednisona	Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.
Anticoagulantes	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.
Anticoagulantes	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.
Antagonistas do Receptor da Angiotensina II	Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
Vitamina D (25-hidroxivitamina D)	The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis.
Ivermectina	Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos.
Ivermectina	Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos.
Corticosteroides	Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2.
Prednisolona	Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2.
Estatina	Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy.
Vitamina D (25-hidroxivitamina D)	Low vitamin D status is associated with coronavirus disease 2019 outcomes: A systematic review and meta-analysis
Metformina	Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study.
Vacina mRNA-1273	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Vacina INO-4800	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
Vacina INO-4800	Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
Estatina	Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.
Azitromicina	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Ceftriaxona	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Doxiciclina	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Hidroxicloroquina	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Ivermectina	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Zinco	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.
Favipiravir	Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir.
Hidroxicloroquina	Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir.
Tocilizumabe	Tocilizumab in the Management of COVID-19: A Preliminary Report.
Vitamina D (25-hidroxivitamina D)	Lack of Association of Baseline 25-Hydroxyvitamin D Levels and Cholecalciferol Treatment With Disease Severity and Mortality in Indian Patients Hospitalized for Covid-19.
Hidroxicloroquina	No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.
Azitromicina	Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.
Estatina	Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.
Hidroxicloroquina	Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.
Corticosteroides	Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence.
Favipiravir	Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence.
Hidroxicloroquina	Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence.
Ivermectina	Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence.
Plasma convalescente	Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence.
Hidroxicloroquina	Prophylactic use of Hydroxychloroquine among Physicians working in Pandemic Hospitals.
Plasma convalescente	Safety and Efficacy of Convalescent Plasma for Severe COVID‐19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
Tocilizumabe	Effects of Tocilizumab in COVID-19 patients: a cohort study.
Bamlanivimabe	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
Bamlanivimabe	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
Dexametasona	Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials.
Dexametasona	Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials.
Hidroxicloroquina	Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials.
Hidroxicloroquina	Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials.
Tetraciclinas	Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting Real-World Data from a Multicenter Observational Study Targeting Inflammatory & Infectious Dermatoses.
Epoprostenol	Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia.
Hidroxicloroquina	Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai
Tocilizumabe	Early Clinical Outcomes with Tocilizumab for Severe Covid-19: A Two-Center Retrospective Study.
Hidroxicloroquina	QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.
Prednisona	Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases.
Corticosteroides	Corticosteroid therapy in critically ill patients with COVID‑19: a multicenter, retrospective study.
Corticosteroides	Corticosteroid therapy in critically ill patients with COVID‑19: a multicenter, retrospective study.
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
Azitromicina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Azitromicina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Azitromicina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Cloroquina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Cloroquina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Cloroquina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Hidroxicloroquina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Hidroxicloroquina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Hidroxicloroquina	A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment
Daclatasvir	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Daclatasvir	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Sofosbuvir	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Sofosbuvir	Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
Plasma convalescente	Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
REGN-COV2	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
Tocilizumabe	Tocilizumab in the Treatment of Critical COVID-19 Pneumonia: A Retrospective Cohort Study of Mechanically Ventilated Patients.
Enoxaparina	Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study.
Fondaparinux	Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study.
Anakinra	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Corticosteroides	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Corticosteroides	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.
Corticosteroides	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.
Lopinavir	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.
Lopinavir	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.
Ritonavir	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.
Ritonavir	Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.
Plasma convalescente	Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: A systematic review with meta-analysis.
Vitamina D (25-hidroxivitamina D)	Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.
Anticoagulantes	Coagulation dysfunction in ICU patients with coronavirus disease 2019 in Wuhan, China: A retrospective observational study of 75 fatal cases.
Ivermectina	Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel.
Ivermectina	Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel.
Antagonistas do Receptor da Angiotensina II	Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients.
Antagonistas do Receptor da Angiotensina II	Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients.
Hidroxicloroquina	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. A Randomized Trial.
Umifenovir	Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
Antagonistas do Receptor da Angiotensina II	Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Plasma convalescente	Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study.
Indometacina	Efficacy and Safety of Indomethacin in Covid -19 patients.
Antagonistas do Receptor da Angiotensina II	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Antagonistas do Receptor da Angiotensina II	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Antagonistas do Receptor da Angiotensina II	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Antagonistas do Receptor da Angiotensina II	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
Covaxin	A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152.
Ivermectina	Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study.
Ivermectina	Ivermectin use associated with reduced duration of COVID-19 febrile illness in a community setting.
Celecoxibe	Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.
Corticosteroides	COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome.
Canaquinumabe	Blockage of interleukin‑1β with canakinumab in patients ith Covid‑19.
Corticosteroides	Corticosteroid use in COVID‑19 patients: a systematic review and meta‑analysis on clinical outcomes.
Antagonistas do Receptor da Angiotensina II	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System.
Heparina	Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.
Hidroxicloroquina	Incidencia de la COVID-19 en pacientes en tratamiento crónico con hidroxicloroquina
Vacina influenza	Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil.
Vacina influenza	Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil.
Corticosteroides	Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype.
Azitromicina	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Hidroxicloroquina	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Lopinavir	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Ritonavir	Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
Antagonista de β-adrenérgico	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.
Antagonistas do Receptor da Angiotensina II	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.
Bloqueadores do Canal de Cálcio	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.
Diuréticos	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.
Anticoagulantes	Sars-Cov-2 Associated Coagulopathy and Thromboembolism Prophylaxis in Children: a Single Centre Observational Study.
Hidroxicloroquina	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.
Hidroxicloroquina	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis.
Hidroxicloroquina	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis.
Anticoagulantes	Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States.
Anticoagulantes	Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States.
Favipiravir	Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.
Vitamina D (25-hidroxivitamina D)	High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study.
Baricitinibe	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Baricitinibe	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Baricitinibe	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Hidroxicloroquina	Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study
Anticorpos	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systemic Review of Clinical Trials.
Corticosteroides	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systemic Review of Clinical Trials.
Hidroxicloroquina	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systemic Review of Clinical Trials.
Interferon alfa	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systemic Review of Clinical Trials.
Plasma convalescente	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systemic Review of Clinical Trials.
Tocilizumabe	First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.
Remdesivir	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
Remdesivir	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
Corticosteroides	Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.
Vacina	Association between seasonal flu vaccination and COVID-19 among healthcare workers.
Anakinra	Anakinra treatment in critically ill COVID‑19 patients: a prospective cohort study.
Anakinra	Anakinra treatment in critically ill COVID‑19 patients: a prospective cohort study.
Vacina BNT162	BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans.
Vacina BNT162	BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans.
Vacina BNT162	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Vacina BNT162	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Vacina BNT162	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Vacina BNT162	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Vacina BNT162	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Tocilizumabe	Repurposed Tocilizumab in Patients with Severe COVID-19.
Corticosteroides	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A meta-Analysis of Randomized Clinical Trials.
Corticosteroides	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A meta-Analysis of Randomized Clinical Trials.
Corticosteroides	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A meta-Analysis of Randomized Clinical Trials.
Oseltamivir	Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19.
Hidroxicloroquina	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial.
Tocilizumabe	Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.
Interferon alfa	The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
Lopinavir	The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
Ritonavir	The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
Azitromicina	Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID‐19.
Hidroxicloroquina	Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID‐19.
Antivirais	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Antivirais	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Antivirais	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Antivirais	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Corticosteroides	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Corticosteroides	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Corticosteroides	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Corticosteroides	Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.
Estatina	Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study.
Estatina	Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study.
Vacina ChAdOx1 nCoV-19	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Vacina ChAdOx1 nCoV-19	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Vacina ChAdOx1 nCoV-19	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Prednisona	The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.
Ivermectina	The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial.
Plasma convalescente	COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study.
Pentoxifilina	Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.
Estatina	Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study.
Radioterapia	Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Final Results of a Pilot Study.
Corticosteroides	Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases.
Corticosteroides	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid‑19.
Corticosteroides	Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients’ Retrospective Study.
Corticosteroides	Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients’ Retrospective Study.
Azitromicina	Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID‐19.
Hidroxicloroquina	Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID‐19.
Prolactina-M	Galectin antagonist use in mild cases of SARS-CoV-2 cases; pilot feasibility randomised, open label, controlled trial.
Vacina (SCB-2019)	A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial.
Vacina (SCB-2019)	A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial.
Vacina (SCB-2019)	A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial.
Favipiravir	Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand.
Favipiravir	Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand.
Azitromicina	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Azitromicina	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Azitromicina	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Favipiravir	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Favipiravir	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Favipiravir	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Hidroxicloroquina	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Hidroxicloroquina	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Hidroxicloroquina	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Plasma convalescente	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Plasma convalescente	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Plasma convalescente	Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.
Interferon kappa	An open-label, randomized trial of the combination of IFN-k plus TFF2 with standard care in the treatment of patients with moderate COVID-19.
TTF2	An open-label, randomized trial of the combination of IFN-k plus TFF2 with standard care in the treatment of patients with moderate COVID-19.
Bromexina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Bromexina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Bromexina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Bromexina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Corticosteroides	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Corticosteroides	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Corticosteroides	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Corticosteroides	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Imunoglobulina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Imunoglobulina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Imunoglobulina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Imunoglobulina	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Tocilizumabe	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Tocilizumabe	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Tocilizumabe	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Tocilizumabe	Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Ciclosporina	Cyclosporine A plus low‐dose steroid treatment in COVID‐19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.
Esteroides	Cyclosporine A plus low‐dose steroid treatment in COVID‐19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.
Corticosteroides	A systematic review of corticosteroid treatment for noncritically ill patients with COVID‑19.
Metformina	Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.
Ácido ascórbico	Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is A Possible Guard for Front liners?
Quercetina	Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is A Possible Guard for Front liners?
Hidroxicloroquina	Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19.
Plasma convalescente	A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Itolizumabe	A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
Plasma convalescente	Convalescent Plasma in COVID-19. Mortality-Safety First Results of the Prospective Multicenter FALP 001-2020 Trial.
Tocilizumabe	INFLUENCE OF TOCILIZUMAB ON THE OUTCOME OF PATIENTS WITH COVID-19. RETROSPECTIVE OBSERVATIONAL STUDY.
Hidroxicloroquina	Low Dose Hydroxychloroquine is Associated with Lower Mortality in COVID-19: A Meta-Analysis of 27 Studies and 44,684 Patients.
Tenofovir	Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users.
Ivermectina	A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Ivermectina	A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Remdesivir	Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore.
Dieta eucalórica e cetogênica	Clinical Efficacy of Eucaloric Ketogenic Nutrition in the COVID-19 Cytokine Storm: a Retrospective Analysis of Mortality and ICU Admission.
Antagonistas do Receptor da Angiotensina II	Association between renin-angiotensin-aldosterone system inhibitor use and covid-19 hospitalization and death: a 1,4 million patient nation-wide registry analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association between renin-angiotensin-aldosterone system inhibitor use and covid-19 hospitalization and death: a 1,4 million patient nation-wide registry analysis.
Lopinavir	Systematic review on current antiviral therapy in COVID-19 pandemic.
Oseltamivir	Systematic review on current antiviral therapy in COVID-19 pandemic.
Remdesivir	Systematic review on current antiviral therapy in COVID-19 pandemic.
Ribavirina	Systematic review on current antiviral therapy in COVID-19 pandemic.
Ritonavir	Systematic review on current antiviral therapy in COVID-19 pandemic.
Praziquantel	Assessment of schistosomiasis endemicity and preventive treatment on coronavirus disease 2019 outcomes in Africa.
Ivermectina	A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.
Remdesivir	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
Remdesivir	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
Itolizumabe	Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.
Hidroxicloroquina	The efficacy and safety of hydroxychloroquine in COVID19 patients: a multicenter national retrospective cohort.
Hidroxicloroquina	The efficacy and safety of hydroxychloroquine in COVID19 patients: a multicenter national retrospective cohort.
Hidroxicloroquina	The efficacy and safety of hydroxychloroquine in COVID19 patients: a multicenter national retrospective cohort.
Vacina de vírus inativado	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Insulina	Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes.
Hidroxicloroquina	Comparison of clinical and laboratory features and treatment options of 237 symptomatic and asymptomatic children infected with SARS-CoV-2 in the early phase of the COVID-19 pandemic in Turkey.
Hidroxicloroquina	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine
Tocilizumabe	Tocilizumab and COVID-19: A Meta-Analysis of 2120 Patients with Severe Disease 1 and Implications for Clinical Trial Methodologies.
Plasma convalescente	Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial.
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.
Vacina influenza	A Case–Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers.
Vacina influenza	A Case–Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers.
Hidroxicloroquina	Safety of hydroxychloroquine for treatment or prevention of SARS‐CoV‐2 infection: A rapid systematic review and meta‐analysis of randomized clinical trials.
Prednisona	Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated Patients With Coronavirus Disease 2019: A Multicenter Cohort Study.
Antagonistas do Receptor da Angiotensina II	Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.
Tocilizumabe	Tocilizumab administration is associated with reduction in biomarkers of coronavirus disease 2019 (COVID-19) infection.
Receptor para os produtos finais de glicação avançada (RAGE)	Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers.
Corticosteroides	Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.
Heparina	The effectiveness of early anticoagulant treatment in Covid-19 patients.
Hidroxicloroquina	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
Zinco	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
Apixabana	Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.
Vitamina D (25-hidroxivitamina D)	Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality.
Antagonistas do Receptor da Angiotensina II	Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.
Antivirais	Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.
Corticosteroides	Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.
Antagonistas do Receptor da Angiotensina II	Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Antagonistas do Receptor da Angiotensina II	Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
Azitromicina	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Hidroxicloroquina	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Lopinavir	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Ritonavir	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Favipiravir	Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.
Plasma convalescente	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
Estradiol	Evidence for treatment with estradiol for women with SARS-CoV-2 infection.
Estradiol	Evidence for treatment with estradiol for women with SARS-CoV-2 infection.
Estradiol	Evidence for treatment with estradiol for women with SARS-CoV-2 infection.
Ivermectina	Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial.
Hidroxicloroquina	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Hidroxicloroquina	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Anticoagulantes	The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort.
Corticosteroides	Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.
Plasma convalescente	Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.
Danoprevir	First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients.
Azitromicina	Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial.
Azitromicina	Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial.
Hidroxicloroquina	Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial.
Hidroxicloroquina	Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial.
Imunoglobulina	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019
Prednisona	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019
Ivermectina	Therapeutic potential of ivermectin as add-on treatment in COVID 19: A systematic review and meta-analysis.
Tocilizumabe	A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.
Apixabana	Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Enoxaparina	Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Hidroxicloroquina	linical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran.
Favipiravir	The effects of favipiravir on hematological parameters of covıd-19 patients.
Sarilumabe	The effect of IL-6 inhibitors on mortality among hospitalized COVID-19 patients: a multicenter study.
Tocilizumabe	The effect of IL-6 inhibitors on mortality among hospitalized COVID-19 patients: a multicenter study.
Antagonistas do Receptor da Angiotensina II	Renin–angiotensin system inhibitors and mortality in patients with COVID‐19.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin–angiotensin system inhibitors and mortality in patients with COVID‐19.
Prednisona	High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia.
Azitromicina	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.
Azitromicina	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.
Hidroxicloroquina	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.
Hidroxicloroquina	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.
Darunavir	Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Hidroxicloroquina	Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Lopinavir	Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Antagonistas do Receptor da Angiotensina II	Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID‐19: a retrospective cohort study.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID‐19: a retrospective cohort study.
Plasma convalescente	Prevention of severe COVID-19 in the elderly by early high-titer plasma.
Plasma convalescente	Prevention of severe COVID-19 in the elderly by early high-titer plasma.
Dexametasona	Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19.
Remdesivir	Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19.
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	"Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - 
Systematic Review and Meta-Analysis."
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	"Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - 
Systematic Review and Meta-Analysis."
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	"Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - 
Systematic Review and Meta-Analysis."
Anti-inflamatórios não esteroidais	Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19.
Vitamina D (25-hidroxivitamina D)	Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital.
Anakinra	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.
Prednisona	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.
Corticosteroides	Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study.
Glicirrizinato de amônio	Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study.
Imunoglobulina	Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study.
Timosina	Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study.
Vacina BCG	BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers.
Heparina	Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study.
Ivermectina	Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Timosina	The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study.
Itolizumabe	An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.
Antagonistas do Receptor da Angiotensina II	Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.
Vacina ChAdOx1 nCoV-19	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Remdesivir	Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19.
Terapia celular	Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study.
Dutasterida	5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men.
CoronaVac	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years
Favipiravir	Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.
Favipiravir	Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.
Favipiravir	Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.
Cloroquina	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety.
Hidroxicloroquina	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety.
Vitamina D (25-hidroxivitamina D)	Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in 2 Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized 3 Controlled Trial.
Antagonistas do Receptor da Angiotensina II	Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Antagonistas do Receptor da Angiotensina II	Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Tocilizumabe	IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections.
Lopinavir	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Lopinavir	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Lopinavir	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Ritonavir	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Ritonavir	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Ritonavir	Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Tocilizumabe	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
Dexametasona	Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.
Prednisona	Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.
Heparina	Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.
Antagonistas do Receptor da Angiotensina II	Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.
Antagonistas do Receptor da Angiotensina II	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO).
Antagonistas do Receptor da Angiotensina II	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO).
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO).
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO).
Metformina	Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
Heparina	Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients.
Tocilizumabe	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.
Atazanavir	A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.
Hidroxicloroquina	A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.
Interferon	A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.
Lopinavir	A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.
Ritonavir	A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.
Tocilizumabe	Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
Vacina de vírus inativado	Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.
Heparina	Prophylactic or therapeutic doses of heparins for COVID‐19 infection? A retrospective study.
Anakinra	Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.
Anakinra	Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.
Imunoglobulina	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
Imunoglobulina	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
Doxiciclina	Utility of Ivermectin and Doxycycline combination for the treatment of SARS- CoV-2.
Ivermectina	Utility of Ivermectin and Doxycycline combination for the treatment of SARS- CoV-2.
Azitromicina	Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh
Dexametasona	Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh
Hidroxicloroquina	Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh
Tocilizumabe	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Vitamina D (25-hidroxivitamina D)	Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).
Hidroxicloroquina	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Hidroxicloroquina	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Hidroxicloroquina	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Interferon	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Interferon	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Interferon	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Lopinavir	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Lopinavir	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Lopinavir	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Ritonavir	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Ritonavir	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Ritonavir	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Tocilizumabe	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Tocilizumabe	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Tocilizumabe	Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.
Vitamina D (25-hidroxivitamina D)	Vitamin D Deficiency Is Inversely Associated with COVID-19 Incidence and Disease Severity in Chinese People.
Artemisinina	Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.
Piperaquina	Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.
Interferon	Peginterferon-lambda for the treatment of COVID-19 in outpatients.
Interferon	Peginterferon-lambda for the treatment of COVID-19 in outpatients.
Enoxaparina	Comparison between Prophylactic versus Therapeutic Doses of Low-Molecular-Weight Heparin in Severely Ill Coronavirus Disease 2019 Patients in Relation to Disease Progression and Outcome.
Hidroxicloroquina	Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic.
Ivermectina	Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic.
Adalimumabe	Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.
Etanercepte	Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.
Infliximabe	Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.
Ustekinumabe	Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.
Vedolizumab	Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.
Lenzilumabe	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study, Mayo Clinic Proceedings
Benralizumabe	Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.
Dupilumabe	Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.
Mepolizumabe	Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.
Omalizumabe	Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.
Reslizumabe	Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.
Cloroquina	Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria
Cloroquina	Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria
Hidroxicloroquina	Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria
Hidroxicloroquina	Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria
Remdesivir	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience
Vitamina D (25-hidroxivitamina D)	Vitamin D status and seroconversion for COVID-19 in UK healthcare workers who isolated for COVID-19 like symptoms during the 2020 pandemic.
Tocilizumabe	The efect of tocilizumab on cytokine release syndrome in COVID‐19 patients.
Favipiravir	The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
Vitamina D (25-hidroxivitamina D)	Mathematical analysis of Córdoba calcifediol trial suggests strong role for Vitamin D in reducing ICU admissions of hospitalized COVID-19 patients.
Favipiravir	Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.
Interferon beta	Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.
Dexametasona	Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection.
Hidrocortisona	Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection.
Prednisolona	Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection.
Prednisona	Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection.
Fluvoxamina	Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial.
Tocilizumabe	Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.
Tocilizumabe	Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.
Tocilizumabe	Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.
Interferon beta	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.
Antagonista de β-adrenérgico	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Antagonista de β-adrenérgico	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Antagonistas do Receptor da Angiotensina II	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Antagonistas do Receptor da Angiotensina II	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Anti-hipertensivos	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Anti-hipertensivos	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Bloqueadores do Canal de Cálcio	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Bloqueadores do Canal de Cálcio	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Diuréticos	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Diuréticos	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Dexametasona	Corticosteroid therapy for coronavirus disease 2019‑related acute respiratory distress syndrome: a cohort study with propensity score analysis.
Prednisolona	Corticosteroid therapy for coronavirus disease 2019‑related acute respiratory distress syndrome: a cohort study with propensity score analysis.
Prednisona	Corticosteroid therapy for coronavirus disease 2019‑related acute respiratory distress syndrome: a cohort study with propensity score analysis.
Eculizumabe	Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.
Antagonistas do Receptor da Angiotensina II	Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19.
CXCL10	CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS.
Plasma convalescente	Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency.
Plasma convalescente	Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG.
Hidroxicloroquina	Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience.
Tocilizumabe	Evaluating the Efficacy of Tocilizumab in Moderate to Severe COVID-19 with Progressive Illness despite Steroids: Identifying the Optimal Timing of its Administration in C3G study.
Vacina BCG	Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.
Plasma convalescente	Therapeutic Plasma Exchange followed by Convalescent Plasma transfusion in critical COVID-19- an exploratory study.
Metformina	Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?
Tocilizumabe	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
Tocilizumabe	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
Tocilizumabe	Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
Cloroquina	Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
Hidroxicloroquina	Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.
Azitromicina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Azitromicina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Cloroquina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Cloroquina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Hidroxicloroquina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Hidroxicloroquina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Imunoglobulina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Imunoglobulina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Interferon	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Interferon	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Lopinavir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Lopinavir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Plasma convalescente	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Plasma convalescente	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Remdesivir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Remdesivir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Ribavirina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Ribavirina	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Ritonavir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Ritonavir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Umifenovir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Umifenovir	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.
Vacina influenza	Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide.
Cloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Cloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Cloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Cloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Cloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Hidroxicloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Hidroxicloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Hidroxicloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Hidroxicloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Hidroxicloroquina	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.
Remdesivir	Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
Remdesivir	Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
Hidroxicloroquina	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19.
Antivirais	QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry.
Antivirais	QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry.
Tocilizumabe	Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Corticosteroides	Asociación entre el tratamiento esteroideo a dosis alta, la función respiratoria y el tiempo hasta el alta en pacientes con COVID-19: Estudio de cohortes.
Vacina influenza	The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature.
Vacina influenza	The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature.
Amoxicilina	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Azitromicina	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Cefdinir	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Cefepima	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Ceftriaxona	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Doxiciclina	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Levofloxacina	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Metronidazol	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Vancomicina	Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.
Hidroxicloroquina	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
Hidroxicloroquina	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
Hidroxicloroquina	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
Hidroxicloroquina	Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.
Tocilizumabe	Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.
Antagonistas do Receptor da Angiotensina II	Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.
Cloroquina	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Cloroquina	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Hidroxicloroquina	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Hidroxicloroquina	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Lopinavir	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Lopinavir	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Remdesivir	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Remdesivir	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Ritonavir	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Ritonavir	"Repurposing of drugs for Covid-19: a
systematic review and meta-analysis"
Vacina BCG	Investigation of the frequency of COVID-19 in patients treated with intravesical BCG.
Hidroxicloroquina	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.
Vacina BCG	Protection against SARS‐CoV‐2 by BCG vaccination is not supported by epidemiological analyses
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.
Anti-inflamatórios não esteroidais	Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.
Anti-inflamatórios não esteroidais	Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.
Ibuprofeno	Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.
Ibuprofeno	Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.
Azitromicina	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.
Hidroxicloroquina	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.
Anakinra	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Anakinra	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Sarilumabe	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Sarilumabe	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Siltuximabe	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Siltuximabe	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Tocilizumabe	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Tocilizumabe	A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.
Imunoglobulina	DEVELOPMENT OF A HYPERIMMUNE EQUINE SERUM THERAPY FOR COVID-19 IN ARGENTINA
Remdesivir	Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study
Tocilizumabe	Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study
Remdesivir	Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysis
Plasma convalescente	Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial
Ozonioterapia	Blood ozonization in patients with mild to moderate COVID‑19 pneumonia: a single centre experience
Vitamina D (25-hidroxivitamina D)	Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study
Metformina	Metformin is associated with Decreased 30-day Mortality among Nursing Home Residents Infected with SARS-CoV2
Plasma convalescente	Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy
Azitromicina	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
Hidroxicloroquina	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
Lopinavir	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
Ritonavir	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
Tocilizumabe	Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With SARS-CoV-2
Ácido ascórbico	Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Hidroxicloroquina	Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Ivermectina	Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Ivermectina	The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020
Plasma convalescente	Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.
Zinco	Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study
Azitromicina	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients
Hidroxicloroquina	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients
Vitamina D (25-hidroxivitamina D)	The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis
Vitamina D (25-hidroxivitamina D)	The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis
Vitamina D (25-hidroxivitamina D)	The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis
Hidroxicloroquina	No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Imunoglobulina	Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers
Favipiravir	Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19
Esteroides	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Hidroxicloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ivermectina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Lopinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Plasma convalescente	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Remdesivir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ritonavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Tocilizumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Atorvastatina	Effect of Statin Therapy on SARS-CoV-2 Infection-Related Mortality in Hospitalized Patients
Rosuvastatina	Effect of Statin Therapy on SARS-CoV-2 Infection-Related Mortality in Hospitalized Patients
Estatina	Statin Use and In-Hospital Mortality in Diabetics with COVID-19
Ácido ascórbico	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Dosagem de micronutrientes	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Vitamina A	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Vitamina B6	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Vitamina D (25-hidroxivitamina D)	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Vitamina E	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Zinco	Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study
Corticosteroides	Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study
Corticosteroides	Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis
Dexametasona	Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis
Prednisolona	Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis
Prednisona	Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis
Corticosteroides	Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome
Colchicina	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
Antagonistas do Receptor da Angiotensina II	COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
Vacina influenza	Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of HealthWorkers
Vacina BCG	Phase II Clinical trial for Evaluation of BCG as potential therapy for COVID-19
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 03 November 2020
Ad5-nCoV	Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
CoronaVac	Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Vacina BNT162	Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Vacina de vírus inativado	Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Vacina NVX-CoV2373	Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Vitamina D (25-hidroxivitamina D)	VITAMIN D TREATMENT IS ASSOCIATED WITH REDUCED RISK OF MORTALITY IN PATIENTS WITH COVID-19: A CROSS-SECTIONAL MULTI-CENTRE OBSERVATIONAL STUDY
Ácido ascórbico	Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients
Hidroxicloroquina	Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India
Vacina BCG	Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India
Tocilizumabe	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Tocilizumabe	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
Tocilizumabe	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
Tocilizumabe	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
Tocilizumabe	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
Tocilizumabe	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
Tocilizumabe	Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia
Antagonistas da vitamina K (AVK)	The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review
Anticoagulantes	The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review
Heparina	The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review
Daclatasvir	Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis
Sofosbuvir	Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis
Ozonioterapia	OZONE AS ADJUVANT SUPPORT IN THE TREATMENT OF COVID-19: A PRELIMINARY REPORT OF PROBIOZOVID TRIAL
Nitazoxanida	Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial
Hidroxicloroquina	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
Lopinavir	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
Ritonavir	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study
Interferon	Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19
Lopinavir	Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19
Novaferon	Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19
Ritonavir	Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19
Umifenovir	Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19
Leronlimab	Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab
Azitromicina	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Hidroxicloroquina	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Ivermectina	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Doxiciclina	Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
Ivermectina	Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
Antagonistas do Receptor da Angiotensina II	The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis
Antagonistas do Receptor da Angiotensina II	The Use of Renin–Angiotensin–Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The Use of Renin–Angiotensin–Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis
Hidroxicloroquina	Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial
Ivermectina	Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial
Nitazoxanida	Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial
Azitromicina	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Hidroxicloroquina	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Ivermectina	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Nitazoxanida	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Oseltamivir	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Prednisona	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Zinco	Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis
Azitromicina	COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin a retrospective case series study
Hidroxicloroquina	COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin a retrospective case series study
Zinco	COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin a retrospective case series study
Azitromicina	Safely Administering Potential QTc Prolonging Therapy Across a Large Healthcare System in the COVID-19 Era
Hidroxicloroquina	Safely Administering Potential QTc Prolonging Therapy Across a Large Healthcare System in the COVID-19 Era
Corticosteroides	Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population
Hidroxicloroquina	Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population
Corticosteroides	Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis
Dexametasona	Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis
Hidrocortisona	Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis
Prednisona	Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis
Dexametasona	Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study
Corticosteroides	Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.
Corticosteroides	Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and Intensive Care Unit admission in patients with COVID-19 according to patients' oxygen requirements.
Terapia celular	Intravenous Mesenchymal Stem Cells in Extracorporeal Oxygenation Patients with Severe COVID-19 Acute Respiratory Distress Syndrome
Terapia celular	Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial
Ácido acetilsalicílico	Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19
Bamlanivimabe	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Vitamina D (25-hidroxivitamina D)	Vitamin D and survival in COVID-19 patients: A quasi-experimental study
Umifenovir	Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial
Ezetimiba	Large population study identifies drugs associated with reduced COVID-19 severity
Flecainida	Large population study identifies drugs associated with reduced COVID-19 severity
Rosuvastatina	Large population study identifies drugs associated with reduced COVID-19 severity
Ubiquinona	Large population study identifies drugs associated with reduced COVID-19 severity
Ciclosporina	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Corticosteroides	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Hidroxicloroquina	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Lopinavir	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Ritonavir	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Tocilizumabe	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Corticosteroides	Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
Prednisona	Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
Tocilizumabe	Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness
Tocilizumabe	Tocilizumab is associated with reduction in inflammation and improvement in P/F ratio in critically sick COVID19 patients
Tocilizumabe	Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
Tocilizumabe	Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Tocilizumabe	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
Tocilizumabe	Efficacy and safety of tocilizumab in COVID-19 patients
Tocilizumabe	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Tocilizumabe	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial
Tocilizumabe	Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies
Tocilizumabe	Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence
Argatrobana	Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis
Enoxaparina	Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis
Fondaparinux	Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis
Heparina	Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis
Dexametasona	Pharmacological treatment for patients with coronavirus disease 2019: systematic review of randomized controlled trials
Hidroxicloroquina	Pharmacological treatment for patients with coronavirus disease 2019: systematic review of randomized controlled trials
Lopinavir	Pharmacological treatment for patients with coronavirus disease 2019: systematic review of randomized controlled trials
Remdesivir	Pharmacological treatment for patients with coronavirus disease 2019: systematic review of randomized controlled trials
Ritonavir	Pharmacological treatment for patients with coronavirus disease 2019: systematic review of randomized controlled trials
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Hidroxicloroquina	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Interferon beta	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Lopinavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Remdesivir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Ritonavir	Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results
Melatonina	Melatonin is significantly associated with survival of intubated COVID-19 patients
Antagonistas do Receptor da Angiotensina II	Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study
Imunoglobulina	Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19
Azitromicina	Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study
Hidroxicloroquina	Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study
Hidroxicloroquina	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients
Hidroxicloroquina	QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study
Hidroxicloroquina	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Hidroxicloroquina	A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19
Hidroxicloroquina	HCQ is effective for COVID-19 when used early: analysis of 118 studies
Hidroxicloroquina	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis
Estatina	Statin use is associated with lower disease severity in COVID‑19 infection
Ezetimiba	Statin use is associated with lower disease severity in COVID‑19 infection
Fibratos	Statin use is associated with lower disease severity in COVID‑19 infection
Hidrocortisona	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
Prednisolona	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
Antagonistas do Receptor da Angiotensina II	No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort
Antagonista de β-adrenérgico	CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY
Anticoagulantes	CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY
Corticosteroides	CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY
Hidroxicloroquina	CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY
Remdesivir	CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 19 October 2020
Vacina BBIBP-CorV	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Magnésio	Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19)
Vitamina B12	Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19)
Vitamina D (25-hidroxivitamina D)	Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19)
Umifenovir	Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients
Tocilizumabe	Preemptive interleukin‐6 blockade in patients with COVID‐19
Tocilizumabe	Tocilizumab in Treatment of Severe COVID-19 Patients: A Systematic Review and Meta-Analysis of Cohort Studies
Enoxaparina	Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study.
Enoxaparina	Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients
Heparina	Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients
Enoxaparina	Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19
Heparina	Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Final Report
REGN-COV2	Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Plasma convalescente	Convalescent plasma for patients with severe COVID-19
Plasma convalescente	Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review (Review)
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review (Review)
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review (Review)
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review (Review)
Nitazoxanida	Nitazoxanide against COVID-19 in three explorative scenarios
Montelucaste	Montelukast in Hospitalized Patients Diagnosed with COVID-19
Doxiciclina	Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline
Ivermectina	Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline
Ivermectina	Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
Ivermectina	Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Ivermectina	COVID-19: Ivermectin prophylaxis in adult contacts. Report on First Cases of Prophylaxis for Healthcare Personnel and PostExposure Prophylaxis
Antagonistas do Receptor da Angiotensina II	Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients
Antagonistas do Receptor da Angiotensina II	Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients
Azitromicina	Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
Ciclesonida	Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
Hidroxicloroquina	Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
Azitromicina	Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Hidroxicloroquina	Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Ivermectina	Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Hidroxicloroquina	Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality
Hidroxicloroquina	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Bicalutamida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Bicalutamida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Bicalutamida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Bicalutamida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Dutasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Dutasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Dutasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Dutasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Espironolactona	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Espironolactona	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Espironolactona	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Espironolactona	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Finasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Finasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Finasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Finasterida	Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
Esteroides	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Hidroxicloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ivermectina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Lopinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Plasma convalescente	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Remdesivir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ritonavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Tocilizumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Dexametasona	Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving the Partial Pressure of Arterial Oxygen and Fraction of Inspired Oxygen Ratio among COVID-19
Prednisona	Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving the Partial Pressure of Arterial Oxygen and Fraction of Inspired Oxygen Ratio among COVID-19
Azitromicina	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Azitromicina	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Espironolactona	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Espironolactona	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Hidroxicloroquina	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Hidroxicloroquina	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Ivermectina	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Ivermectina	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Nitazoxanida	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Nitazoxanida	An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
Azitromicina	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Azitromicina	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Dutasterida	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Dutasterida	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Hidroxicloroquina	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Hidroxicloroquina	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Ivermectina	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Ivermectina	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Nitazoxanida	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Nitazoxanida	Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)
Azitromicina	Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Betaferon	Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Hidroxicloroquina	Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Lopinavir	Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Ritonavir	Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Anakinra	Anakinra After Corticosteroid and/or Tocilizumab Treatment in Patients with Severe COVID-19 Pneumonia and Moderate Hyperinflammation. A Retrospective Cohort Study
Vacina BNT162	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Vacina BNT162	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Vacina BNT162	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Vilobelimabe	Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Vilobelimabe	Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Tocilizumabe	Tocilizumab Therapy of COVID-19: A Comparison of Subcutaneous and Intravenous Therapies
Tocilizumabe	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
Tocilizumabe	IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: na observational study
Favipiravir	Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Tocilizumabe	Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Enoxaparina	Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience
Fondaparinux	Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience
Enoxaparina	Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study
Fondaparinux	Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study
Heparina	Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study
Anticoagulantes	Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies
Antagonistas da vitamina K (AVK)	Prophylactic anticoagulants for patients hospitalised with COVID-19
Anticoagulantes	Prophylactic anticoagulants for patients hospitalised with COVID-19
Heparina	Prophylactic anticoagulants for patients hospitalised with COVID-19
Pentassacarídeos	Prophylactic anticoagulants for patients hospitalised with COVID-19
Interferon	Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies
Lopinavir	Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies
Remdesivir	Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies
Ribavirina	Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies
Ritonavir	Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies
Plasma convalescente	Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis
Plasma convalescente	Convalescent plasma treatment of severe COVID-19: A matched control study
Plasma convalescente	Convalescent plasma therapy in patients with COVID-19.
Plasma convalescente	Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality
Oseltamivir	Is oseltamivir suitable for fighting against COVID-19: In silico assessment,in vitro and retrospective study
Novaferon	A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19
Interferon alfa	Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study
Lopinavir	Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study
Ritonavir	Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study
Lopinavir	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Ritonavir	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Antagonistas do Receptor da Angiotensina II	Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension
Antagonistas do Receptor da Angiotensina II	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Ii Receptor Blockers and Prognosis of Hypertensive Patients Hospitalized With Covid-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Ii Receptor Blockers and Prognosis of Hypertensive Patients Hospitalized With Covid-19
Antagonistas do Receptor da Angiotensina II	RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
Hidroxicloroquina	Hydroxychloroquine as Post-Exposure Prophylaxis for Covid-19: Why simple data analysis can lead to the wrong conclusions from well-designed studies
Hidroxicloroquina	Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers - a Retrospective cohort
Hidroxicloroquina	Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study
Hidroxicloroquina	Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 -A Pandemic Hospital Experience
Hidroxicloroquina	Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review
Glutationa	Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital
Inosina	Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital
Potássio	Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital
Favipiravir	A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far?
Hidroxicloroquina	A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far?
Corticosteroides	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Dexametasona	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Hidrocortisona	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Prednisolona	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Prednisona	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Prednisona	Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19
Corticosteroides	Corticosteroid pulses for hospitalized patients with COVID-19: Effects on mortality and in-hospital stay
Prednisona	Corticosteroid pulses for hospitalized patients with COVID-19: Effects on mortality and in-hospital stay
Corticosteroides	Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis
Azitromicina	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo
Cloroquina	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo
Vitamina D (25-hidroxivitamina D)	SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 02 October 2020
Vacina influenza	Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide
Vacina BNT162	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses
Ácido ascórbico	Serum levels of Vitamin C and Vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A Pilot Study
Vitamina D (25-hidroxivitamina D)	Serum levels of Vitamin C and Vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A Pilot Study
Azitromicina	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Cloroquina	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Cobicistato	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Darunavir	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Hidroxicloroquina	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Lopinavir	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Remdesivir	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Ritonavir	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients
Cloroquina	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Hidroxicloroquina	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Imunoglobulina	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Lopinavir	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Plasma convalescente	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Remdesivir	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Ritonavir	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Umifenovir	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis
Esteroides	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Hidroxicloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ivermectina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Lopinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Plasma convalescente	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Remdesivir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ritonavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Tocilizumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Cloroquina	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Corticosteroides	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Danoprevir	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Favipiravir	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Hidroxicloroquina	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Imunoglobulina	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Lopinavir	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Meplazumabe	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Remdesivir	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Ritonavir	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Siltuximabe	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Tocilizumabe	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Umifenovir	Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments
Tocilizumabe	Impact of tocilizumab administration on mortality in severe COVID-19
Corticosteroides	Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort
Heparina	Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort
Fondaparinux	Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines
Heparina	Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines
Heparina	Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
Enoxaparina	Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
Solução salina eletrolisada	Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial
Sitagliptina	Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study
Interferon alfa	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study
Lopinavir	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study
Ribavirina	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study
Ritonavir	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study
Prednisona	Evaluation of the Efficacy of Methylprednisolone Pulse Therapy in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized
Metformina	Risk of metformin in type 2 diabetes patients with COVID-19: a preliminary retrospective report
Azitromicina	A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Doxiciclina	A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Hidroxicloroquina	A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Ivermectina	A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients
Ivermectina	Ivermectin treatment may improve the prognosis of patients with COVID-19
Ivermectina	Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study
Interferon supercomposto recombinante (rSIFN-co)	Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients
Interferon kappa	An open-label, randomized trial of the combination of IFN-k plus TFF2 with standard care in the treatment of patients with moderate COVID-19
TFF2	An open-label, randomized trial of the combination of IFN-k plus TFF2 with standard care in the treatment of patients with moderate COVID-19
Antagonistas do Receptor da Angiotensina II	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy
Heparina	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy
Antagonistas do Receptor da Angiotensina II	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
Ibuprofeno	Ibuprofen use and clinical outcomes in COVID-19 patients
Paracetamol	Ibuprofen use and clinical outcomes in COVID-19 patients
Cloroquina	Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients
Hidroxicloroquina	Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients
Azitromicina	Assessing QT interval in COVID-19 patients: Safety of Hydroxychloroquine-azithromycin combination regimen
Hidroxicloroquina	Assessing QT interval in COVID-19 patients: Safety of Hydroxychloroquine-azithromycin combination regimen
Hidroxicloroquina	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
Hidroxicloroquina	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
Hidroxicloroquina	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings
Hidroxicloroquina	Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients
Hidroxicloroquina	Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial
Hidroxicloroquina	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers A Randomized Clinical Trial
Hidroxicloroquina	Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis
Hidroxicloroquina	Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19
Hidroxicloroquina	Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19
Favipiravir	Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
Famotidina	Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Famotidina	Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-analysis
Corticosteroides	Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
Corticosteroides	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study
Dexametasona	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study
Prednisona	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study
Corticosteroides	Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.
Corticosteroides	Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis
Colchicina	The Impact of Colchicine on The COVID-19 Patients: A Clinical Trial Study
Azitromicina	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study
Cloroquina	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study
Hidroxicloroquina	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study
Radiofármaco (99mTc-MDP)	Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment
Vitamina D (25-hidroxivitamina D)	Vitamin D sufficiency, a serum 25hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 28 September 2020
Vacina mRNA-1273	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Vacina	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Vacina	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Vacina	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
Ácido ascórbico	Could Vitamins Help in the Fight Against COVID-19?
Vitamina A	Could Vitamins Help in the Fight Against COVID-19?
Vitamina D (25-hidroxivitamina D)	Could Vitamins Help in the Fight Against COVID-19?
Vitamina E	Could Vitamins Help in the Fight Against COVID-19?
Ácido ascórbico	"High-dose vitamin C infusion for the treatment of
critically ill COVID-19"
Vacina ChAd-SARS-CoV-2-S	A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Tocilizumabe	Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study
Tocilizumabe	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched case-control study
Tocilizumabe	"Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with
bilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial"
Tocilizumabe	Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Tocilizumabe	Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies
Imunomoduladores	Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review
Plasma convalescente	Convalescent Plasma for the Treatment of Patients with Severe Coronavirus Disease 2019; a Preliminary Report
Plasma convalescente	Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial
Pentoxifilina	Pentoxifylline and Covid-19: A Systematic Review
Pentoxifilina	Pentoxifylline and Covid-19: A Systematic Review
N-acetilcisteína	Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19
Prednisona	Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Leflunomida	Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial
Antagonistas do Receptor da Angiotensina II	Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19
Imunoglobulina	The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: A randomised placebo-controlled double-blind clinical trial
Azitromicina	Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
Esteroides	Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
Hidroxicloroquina	Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
Hidroxicloroquina	Hydroxychloroquine and Interferons for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances
Interferon	Hydroxychloroquine and Interferons for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances
Hidroxicloroquina	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients’ characteristics: a review of the literature and simulations
Hidroxicloroquina	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
Hidroxicloroquina	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Hidroxicloroquina	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Hidroxicloroquina	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial
Corticosteroides	Glucocorticoid therapy does not delay viral clearance in COVID-19 patients.
Favipiravir	A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
Famotidina	Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Enxaguantes bucais	Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them (Review)
Spray nasal	Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them (Review)
Enxaguantes bucais	Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection
Spray nasal	Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection
Dexametasona	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Dexametasona	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Dexametasona	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Dexametasona	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Hidroxicloroquina	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Lopinavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Plasma convalescente	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Plasma convalescente	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Plasma convalescente	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Plasma convalescente	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Remdesivir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Ritonavir	Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Cobicistato	Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
Darunavir	Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
Cuidados paliativos	Palliative Care Utilization Among Patients With COVID-19 in an Underserved Population: A Single-Center Retrospective Study
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Cloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Hidroxicloroquina	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.
Baloxavir marboxil	Clinical Outcomes and Plasma Concentrations 1 of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Favipiravir	Clinical Outcomes and Plasma Concentrations 1 of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Hidroxicloroquina	Effect of Arbidol on COVID-19: A Randomized Controlled Trial
Lopinavir	Effect of Arbidol on COVID-19: A Randomized Controlled Trial
Ritonavir	Effect of Arbidol on COVID-19: A Randomized Controlled Trial
Umifenovir	Effect of Arbidol on COVID-19: A Randomized Controlled Trial
Antivirais	Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a singlecenter descriptive study
Corticosteroides	Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a singlecenter descriptive study
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 21 September 2020
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 23 September 2020
Zinco	Analysis of the predictive factors for critical illness of COVID-19 during treatment - Relationship between serum zinc level and critical illness of COVID-19
Vitamina D (25-hidroxivitamina D)	Impact of Vitamin D Deﬁciency on COVID-19—A Prospective Analysis from the CovILD Registry
Vitamina D (25-hidroxivitamina D)	Vitamin D Deficiency and Outcome of COVID-19 Patients
Triazavirina	Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial
Corticosteroides	Combination of Tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A spanish, multicenter, cohorty study
Tocilizumabe	Combination of Tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A spanish, multicenter, cohorty study
Tocilizumabe	Observational study on off-label use of tocilizumab in patients with severe COVID-19
Tocilizumabe	Efficacy of Tocilizumab in COVID-19: A Systematic review and Meta-Analysis
Solução salina heparinizada	A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients
Fator estimulante de colônia para granulócitos humano recombinante (rhG-CSF)	Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia
Favipiravir	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses
Lopinavir	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses
Remdesivir	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses
Ritonavir	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses
Umifenovir	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses
Plasma convalescente	Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Plasma convalescente	The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in Baghdad, Iraq
Plasma convalescente	Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma
Hidroxicloroquina	Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Lopinavir	Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Oseltamivir	Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Ribavirina	Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Ritonavir	Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Dexametasona	Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region
Hidrocortisona	Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region
Prednisona	Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region
Metformina	Mortality of COVID-19 with preadmission metformin use in patients with diabetes: a meta-analysis
Metformina	Mortality of COVID-19 with preadmission metformin use in patients with diabetes: a meta-analysis
Hidroxicloroquina	The effect of antivirals on COVID-19: a systematic review
Interferon beta	The effect of antivirals on COVID-19: a systematic review
Lopinavir	The effect of antivirals on COVID-19: a systematic review
Remdesivir	The effect of antivirals on COVID-19: a systematic review
Ritonavir	The effect of antivirals on COVID-19: a systematic review
Umifenovir	The effect of antivirals on COVID-19: a systematic review
Ácido acetilsalicílico	Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Dexametasona	Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Enoxaparina	Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Ivermectina	Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Iodopovidona	Early viral clearance among COVID-19 patients when gargling with Povidone-iodine and essential oils – a clinical trial
Heparina	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.
Hidroxicloroquina	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.
Interferon alfa	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.
Lopinavir	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.
Ritonavir	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.
Umifenovir	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.
Cloroquina	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Cloroquina	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Hidroxicloroquina	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Hidroxicloroquina	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Plasma convalescente	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Plasma convalescente	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Remdesivir	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Remdesivir	Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis
Azitromicina	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
Hidroxicloroquina	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
Zinco	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
Azitromicina	Utilidad y seguridad de la automonitorizacion electrocardiográfica durante el tratamiento con hidroxicloroquina y azitromicina en pacientes con COVID-19
Hidroxicloroquina	Utilidad y seguridad de la automonitorizacion electrocardiográfica durante el tratamiento con hidroxicloroquina y azitromicina en pacientes con COVID-19
Azitromicina	Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability
Hidroxicloroquina	Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability
Azitromicina	Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients
Hidroxicloroquina	Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients
Hidroxicloroquina	Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
Hidroxicloroquina	A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine’s Prophylactic Effect Against Infection With SARS-CoV-2
Hidroxicloroquina	Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics
Hidroxicloroquina	The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study
Hidroxicloroquina	Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study
Hidroxicloroquina	Towards evidence-based Emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2: Hydroxychloroquine in the treatment of COVID-19
Conestate alfa	Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
Colchicina	Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
CIGB-325 (Peptídeo anti-CK2)	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
Anakinra	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Canrenona	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Hidroxicloroquina	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Lopinavir	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Prednisona	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Ritonavir	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
Baricitinibe	Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
Remdesivir	Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
Antibióticos	Clinical characteristics of 132 healthcare workers cases with COVID-19: a retrospective study from a single center in Wuhan, China
Antivirais	Clinical characteristics of 132 healthcare workers cases with COVID-19: a retrospective study from a single center in Wuhan, China
Corticosteroides	Clinical characteristics of 132 healthcare workers cases with COVID-19: a retrospective study from a single center in Wuhan, China
Gamaglobulina	Clinical characteristics of 132 healthcare workers cases with COVID-19: a retrospective study from a single center in Wuhan, China
Interferon alfa	Clinical characteristics of 132 healthcare workers cases with COVID-19: a retrospective study from a single center in Wuhan, China
Anti-hipertensivos	Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study
Antidiabéticos	Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study
Corticosteroides	Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study
CPI-006	Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 17 September 2020
Vacina BCG	Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19
Vacina BCG	Correlation between immunity from BCG and the morbidity and mortality of COVID-19
Vacina de vírus inativado	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes - Interim Analysis of 2 Randomized Clinical Trials
Vitamina D (25-hidroxivitamina D)	The link between vitamin D deficiency and Covid-19 in a large population
TRIM56	Systematic review of the antiviral properties of TRIM56: a potential therapeutic intervention for COVID-19
Tocilizumabe	"Beneficial and Harmful Outcomes of Tocilizumab in Severe COVID-19:
A Systematic Review and Meta-Analysis"
Tocilizumabe	Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis
Tocilizumabe	Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
Tocilizumabe	Outcome of COVID-19 patients with use of Tocilizumab: A single center experience
Tocilizumabe	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial
Timosina	Analysis of the prophylactic effect of thymosin drugs on COVID‐19 for 435 medical staff: A hospital‐based retrospective study
Plasma convalescente	Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature
Plasma convalescente	Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy
Plasma convalescente	Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)
Plasma convalescente	Convalescent plasma as potential therapy for severe COVID-19 pneumonia
Lopinavir	Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review
Ritonavir	Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study
Antagonistas do Receptor da Angiotensina II	COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study
Antagonistas do Receptor da Angiotensina II	The Association of Renin-AngiotensinAldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The Association of Renin-AngiotensinAldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia
Azitromicina	COVID-19 mortality risk factors in older people in a long-term care center
Hidroxicloroquina	COVID-19 mortality risk factors in older people in a long-term care center
Hidroxicloroquina	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials
Hidroxicloroquina	Hydroxychloroquine is Effective and Safe for the Treatment of COVID-19, and May be Universally Effective When Used Early Before Hospitalization: A Systematic Review
Hidroxicloroquina	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis
Hidroxicloroquina	A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19
Hidroxicloroquina	Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
Hidroxicloroquina	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
Agentes anti-interleucinas	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Esteroides	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Hidroxicloroquina	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Imunoglobulina	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Plasma convalescente	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Terapia celular	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Terapia de purificação do sangue	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review
Esteroides	Are the steroids a blanket solution for COVID‐19? a systematic review and meta‐analysis
Cobicistato	"Use of Darunavir-Cobicistat as a Treatment Option
for Critically Ill Patients with SARS-CoV-2 Infection"
Darunavir	"Use of Darunavir-Cobicistat as a Treatment Option
for Critically Ill Patients with SARS-CoV-2 Infection"
Corticosteroides	Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China
Corticosteroides	Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study
Atazanavir	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Cloroquina	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Hidroxicloroquina	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Interferon	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Lopinavir	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Oseltamivir	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Ritonavir	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Tocilizumabe	Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia
Cloroquina	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis
Hidroxicloroquina	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis
Cloroquina	Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
Hidroxicloroquina	Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
Cloroquina	Chloroquine and Hydroxychloroquine in treatment of COVID-19 Disease
Hidroxicloroquina	Chloroquine and Hydroxychloroquine in treatment of COVID-19 Disease
Bromexina	Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
Bromexina	Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-label Randomized Controlled Pilot Study
Azitromicina	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
Azitromicina	Observational study of azithromycin in hospitalized patients with COVID-19
Heparina	The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study
Heparina	The Impact of the “Low Molecular Weight Heparin” Administration on the Clinical Course of the COVID-19 Disease
Heparina	Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study
Vacina (rAd26 and rAd5)	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 9 September 2020
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 8 September 2020
Hidroxicloroquina	L’hydroxy-chloroquine pour traiter les patients infectes du ´COVID-19: quelques lec¸ons d’an-thropologie medicale et d’histoire de la m ´ edecine
Anakinra	Evaluation of seventeen patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA and Brescia-COVID respiratory severity scale (BCRSS) scoring systems
Hidroxicloroquina	"Prolongation of QT interval due to
hydroxychloroquine overdose used in
COVID-19 treatment"
Oseltamivir	"Prolongation of QT interval due to
hydroxychloroquine overdose used in
COVID-19 treatment"
Corticosteroides	Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China
Azitromicina	Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection
Hidroxicloroquina	Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection
L-glutamina	Effect of oral L-Glutamine supplementation on Covid-19 treatment
Azitromicina	Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
Hidroxicloroquina	Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
Hidroxicloroquina	Hydroxicloroquine for pre-exposure prophylaxis for SARS-CoV-2
Cetirizina	Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients
Famotidina	Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients
Antagonistas do Receptor da Angiotensina II	Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia
Metformina	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes
Atazanavir	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
Hidroxicloroquina	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
Ritonavir	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir
Plasma convalescente	Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
Tocilizumabe	Tocilizumab use in COVID -19 associated pneumonia
Imunossupressores	Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak
Plasmaferese	Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study
Hidroxicloroquina	Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19
Ceftriaxona	A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort
Doxiciclina	A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort
Hidroxicloroquina	A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort
Lopinavir	A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort
Corticosteroides	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Tocilizumabe	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Antagonistas do Receptor da Angiotensina II	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Bloqueadores do Canal de Cálcio	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Heparina	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
Anakinra	High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Plasma convalescente	Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three Month Experience
Ruxolitinibe	Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
Hidroxicloroquina	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19
Moxifloxacina	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19
Interferon kappa	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-k plus TFF2 in patients with moderate COVID-19
TFF2	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-k plus TFF2 in patients with moderate COVID-19
Hidrocortisona	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 - The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial,
Hidrocortisona	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial
Vitamina D (25-hidroxivitamina D)	Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study
Dexametasona	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial
Terapia celular	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Interferon beta	Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial
Plasma convalescente	Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
Terapia celular	Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
Azitromicina	Safety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial
Hidroxicloroquina	Safety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial
Lopinavir	Safety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial
Ritonavir	Safety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Corticosteroides	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Zinco	Zinc for the prevention and treatment of SARS-CoV-2 and other acute viral respiratory infections: a rapid review
Azitromicina	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Heparina	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Hidroxicloroquina	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Lopinavir	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Prednisona	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Remdesivir	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Ritonavir	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Tocilizumabe	Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Azivudina	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Baloxavir marboxil	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Danoprevir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Darunavir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Favipiravir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Lopinavir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Oseltamivir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Remdesivir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Ritonavir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Triazavirina	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Umifenovir	Directly Acting Antivirals for COVID-19: Where Do We Stand?
Azitromicina	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis
Hidroxicloroquina	Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis
Hidroxicloroquina	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis
Hidroxicloroquina	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis
Hidroxicloroquina	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis
Quercetina	The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review
Quercetina	The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review
Quercetina	The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review
Quercetina	The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review
Remdesivir	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials
Vacina RBD-SpyVLP	A COVID-19 vaccine candidate 1 using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Diferentes estruturas de proteínas de ligação ao receceptor (ACE2) do SARS-CoV-2	Immune response to vaccine candidates based on different types of nanoscaffolded RBD domain of the SARS-CoV-2 spike protein
Diferentes estruturas de proteínas de ligação ao receceptor (ACE2) do SARS-CoV-2	Immune response to vaccine candidates based on different types of nanoscaffolded RBD domain of the SARS-CoV-2 spike protein
Diferentes estruturas de proteínas de ligação ao receceptor (ACE2) do SARS-CoV-2	Immune response to vaccine candidates based on different types of nanoscaffolded RBD domain of the SARS-CoV-2 spike protein
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 28 August 2020
Vacina influenza	The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey
Vacina pneumocócica	The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey
Vacina NVX-CoV2373	Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Vacina NVX-CoV2373	Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Azitromicina	Azithromycin: The First Broad-spectrum Therapeutic
Favipiravir	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Lopinavir	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Ostalmovir	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Remdesivir	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Ritonavir	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Umifenovir	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review
Cloroquina	COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits
Hidroxicloroquina	COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits
Prednisona	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels
Argatrobana	"Argatroban for therapeutic anticoagulation for heparin resistance
associated with Covid-19 infection"
Antagonistas do Receptor da Angiotensina II	Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study
Anticoagulantes	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS‐CoV‐2 infection
Enoxaparina	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS‐CoV‐2 infection
Varfarina	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS‐CoV‐2 infection
Antagonistas do Receptor da Angiotensina II	Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
Metformina	Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19)
Cloroquina	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. view and Meta-Analysis
Hidroxicloroquina	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. view and Meta-Analysis
Antibióticos	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Antivirais	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Cloroquina	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Corticosteroides	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Hidroxicloroquina	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Imunoglobulina	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Interferon	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Terapia de substituição renal	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Tocilizumabe	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis
Hidroxicloroquina	QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
Antagonistas do Receptor da Angiotensina II	Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study
Ruxolitinibe	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
Efavirenz	Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study
Fumarato de tenofovir desoproxila	Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study
Lamivudina	Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study
Lopinavir	Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study
Ritonavir	Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study
Zidovudina	Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study
Hidroxicloroquina	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
Antibióticos	Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19
Hidroxicloroquina	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
Anti-inflamatórios não esteroidais	Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19
Anakinra	Is there any potential management against COVID-19? A systematic review and meta-analysis
Azitromicina	Is there any potential management against COVID-19? A systematic review and meta-analysis
Baloxavir marboxil	Is there any potential management against COVID-19? A systematic review and meta-analysis
Favipiravir	Is there any potential management against COVID-19? A systematic review and meta-analysis
Hidroxicloroquina	Is there any potential management against COVID-19? A systematic review and meta-analysis
Interferon	Is there any potential management against COVID-19? A systematic review and meta-analysis
Lopinavir	Is there any potential management against COVID-19? A systematic review and meta-analysis
Meplazumabe	Is there any potential management against COVID-19? A systematic review and meta-analysis
Plasma convalescente	Is there any potential management against COVID-19? A systematic review and meta-analysis
Prednisona	Is there any potential management against COVID-19? A systematic review and meta-analysis
Remdesivir	Is there any potential management against COVID-19? A systematic review and meta-analysis
Ritonavir	Is there any potential management against COVID-19? A systematic review and meta-analysis
Ruxolitinibe	Is there any potential management against COVID-19? A systematic review and meta-analysis
Tocilizumabe	Is there any potential management against COVID-19? A systematic review and meta-analysis
Umifenovir	Is there any potential management against COVID-19? A systematic review and meta-analysis
Hidroxicloroquina	Hydroxychloroquine is protective to the heart, not Harmful: A systematic review.
Vacina de RNA	RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Ivermectina	Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
Ivermectina	Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
Ivermectina	Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review
Ácido ascórbico	"Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical
trial"
Azul de metileno	"Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical
trial"
N-acetilcisteína	"Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical
trial"
Corticosteroides	Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
Favipiravir	Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
Nafamostato	Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition
Remdesivir	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU
Azitromicina	Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020
Hidroxicloroquina	Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020
Azitromicina	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Corticosteroides	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Hidroxicloroquina	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Lopinavir	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Ritonavir	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Hidroxicloroquina	Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants
Cefalosporina	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Hidroxicloroquina	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Oseltamivir	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Paracetamol	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Remdesivir	Remdesivir is Effective for Moderately Severe Patients: A Re-Analysis of the First Double-Blind, Placebo-Controlled, Randomized Trial on Remdesivir for Treatment of Severe COVID-19 Patients Conducted in Wuhan City
Antagonistas do Receptor da Angiotensina II	Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 25 August 2020
Vacina C-Vac	An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2
Ad5-nCoV	A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
Corticosteroides	Corticosteroid Therapy in COVID-19 Disease
Vacina de adenovírus	An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques
Corticosteroides	Steroids in COVID-19: An overview
Remdesivir	A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19
Exossomos derivados de células-tronco mesenquimais	Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia
Cloroquina	Susceptibility to COVID-19 in patients treated with antimalarials: a population based study in Emilia-Romagna, Northern Italy
Hidroxicloroquina	Susceptibility to COVID-19 in patients treated with antimalarials: a population based study in Emilia-Romagna, Northern Italy
Daclatasvir	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Hidroxicloroquina	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Lopinavir	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Ribavirina	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Ritonavir	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Sofosbuvir	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19
Azitromicina	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
Hidroxicloroquina	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients
Ampicilina	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Antibióticos	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Cefotaxima	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Ceftarolina	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Ceftriaxona	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Levofloxacina	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Moxifloxacina	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Sulbactam	Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study
Prednisona	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
Tocilizumabe	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial
Remdesivir	Remdesivir and its antiviral activity against COVID-19: A systematic review
Remdesivir	Remdesivir and its antiviral activity against COVID-19: A systematic review
Remdesivir	Remdesivir and its antiviral activity against COVID-19: A systematic review
Vacina mRNA-LNP	A Thermostable mRNA Vaccine against COVID-19
Natalizumabe	Fatal COVID-19 in an MS patient on natalizumab: A case report
Adrecizumabe	Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)
Interferon alfa	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Lopinavir	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Novaferon	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Ritonavir	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Umifenovir	Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China
Nadroparina	Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
Daclatasvir	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Daclatasvir	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Ribavirina	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Ribavirina	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Sofosbuvir	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Sofosbuvir	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial
Daclatasvir	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
Sofosbuvir	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial
Anti-inflamatórios não esteroidais	The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. Scientific brief
Hidroxicloroquina	Amiodarone in the COVID‑19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
Ácido acetilsalicílico	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Ácido acetilsalicílico	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Ácido acetilsalicílico	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Ácido acetilsalicílico	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Ácido acetilsalicílico	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Anakinra	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Anakinra	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Anakinra	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Anakinra	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Anakinra	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dexametasona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dexametasona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dexametasona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dexametasona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dexametasona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dobutamina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dobutamina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dobutamina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dobutamina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Dobutamina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Epinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Epinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Epinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Epinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Epinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Heparina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Heparina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Heparina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Heparina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Heparina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Imunoglobulina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Imunoglobulina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Imunoglobulina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Imunoglobulina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Imunoglobulina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Infliximabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Infliximabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Infliximabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Infliximabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Infliximabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Norepinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Norepinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Norepinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Norepinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Norepinefrina	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Prednisona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Prednisona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Prednisona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Prednisona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Prednisona	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Tocilizumabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Tocilizumabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Tocilizumabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Tocilizumabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Tocilizumabe	COVID-19 and multisystem inflammatory syndrome in children and adolescents
Hidroxicloroquina	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Lopinavir	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Piperacilina-tazobactam	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Prednisona	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Ritonavir	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Tocilizumabe	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Vancomicina	Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients
Enoxaparina	Safety of intermediate dose of low molecular weight heparin in COVID-19 patients
Famotidina	Impact of Famotidine Use on Clinical Outcomes of Hospitalized COVID-19 Patients
Baricitinibe	Baricitinib restrains the immune dysregulation in severe COVID-19 patients
Hidroxicloroquina	Baricitinib restrains the immune dysregulation in severe COVID-19 patients
Lopinavir	Baricitinib restrains the immune dysregulation in severe COVID-19 patients
Ritonavir	Baricitinib restrains the immune dysregulation in severe COVID-19 patients
Anticorpo (47D11)	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Anticorpos n3086/n3113	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Auranofina	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Azitromicina	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Beta-d-N4-hydroxycytidine	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Cloroquina	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Corticosteroides	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Darunavir	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Emetine	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Hidroxicloroquina	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Homoharringtonina (HHT)	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Interferon alfa	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Interferon beta	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Ivermectina	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Lianhua Qingwen (Medicina Tradicional Chinesa)	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Lopinavir	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Pudilan Xiaoyan	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Remdesivir	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Ritonavir	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Tocilizumabe	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Umifenovir	Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis
Tocilizumabe	Tocilizumab en infección por COVID-19
Remdesivir	Remdesivir en pacientes con COVID-19
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 20 August 2020
Favipiravir	Recent Updates Published About Favipiravir in COVID-19
Prednisolona	Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient
Favipiravir	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Hidroxicloroquina	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Imunoglobulina	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Meropenem	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Moxifloxacina	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Oseltamivir	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Prednisona	Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia
Azitromicina	Neumonía por COVID-19 y uso de tocilizumab
Enoxaparina	Neumonía por COVID-19 y uso de tocilizumab
Hidroxicloroquina	Neumonía por COVID-19 y uso de tocilizumab
Linezolida	Neumonía por COVID-19 y uso de tocilizumab
Meropenem	Neumonía por COVID-19 y uso de tocilizumab
Piperacilina-tazobactam	Neumonía por COVID-19 y uso de tocilizumab
Prednisona	Neumonía por COVID-19 y uso de tocilizumab
Tocilizumabe	Neumonía por COVID-19 y uso de tocilizumab
Argatrobana	Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports
Heparina	Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports
Cefalosporina	A case report of a pregnant woman infected with coronavirus disease 2019 pneumonia
Corticosteroides	Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?
Hidroxicloroquina	Severe arterial thromboembolism in patients with Covid- 19
Doxiciclina	Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York
Azitromicina	Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan
Ceftriaxona	Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan
Hidroxicloroquina	Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan
Teicoplanina	Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan
Lopinavir	Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia
Ritonavir	Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia
Corticosteroides	"Corticosteroid prevents COVID-19 progression
within its therapeutic window: a multicenter, proof-of-concept, observational study"
Lactoferrina	Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: randomized clinical trial, in vitro and in silico preliminary evidences
Antagonistas do Receptor da Angiotensina II	Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients
Antagonistas do Receptor da Angiotensina II	Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients
Vilobelimabe	Anti-C5a antibody (IFX-1) treatment of severe Covid-19: an exploratory phase 2 randomized controlled trial
Hidroxicloroquina	Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials
Ad5-nCoV	A vaccine for SARS-CoV-2: goals and promises
Ad5-nCoV	A vaccine for SARS-CoV-2: goals and promises
Antagonistas do Receptor da Angiotensina II	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: a new challenge overcome?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: a new challenge overcome?
Corticosteroides	The application of corticosteroids in COVID-19: A two-edged sword
Hidroxicloroquina	Uncontrolled mass use of hydroxychloroquine
Prednisona	Short-term corticosteroid therapy for early exacerbation of COVID-19 pneumonia: a case report
Hidroxicloroquina	Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? International Journal of Antimicrobial Agents
Tocilizumabe	Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
Corticosteroides	"Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation
 in Patients With COVID-19"
Timosina	Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study
Tocilizumabe	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Azitromicina	Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients
Doxiciclina	Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients
Hidroxicloroquina	Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients
Ivermectina	Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients
Anti-inflamatórios não esteroidais	OpenSAFELY: Do adults prescribed Non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?
Auxora	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial
Interferon	INTERFERON PARA PROFILAXIA E TRATAMENTO DE COVID-19. Revisão sistemática rápida
Hidroxicloroquina	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure
Dexametasona	Uso de dexametasona en pacientes internados con COVID-19
Lopinavir	Lopinavir-Ritonavir para infecção por SARS-CoV-2 (Covid-19). Revisão sistemática rápida.
Ritonavir	Lopinavir-Ritonavir para infecção por SARS-CoV-2 (Covid-19). Revisão sistemática rápida.
Sarilumabe	Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
Tocilizumabe	Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis
Oxigênio-ozônio (O2-O3)	Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported.
Ácido acetilsalicílico	Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2
Imunoglobulina	Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2
Hidroxicloroquina	Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine
Hidroxicloroquina	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
Tocilizumabe	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
Heparina	Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad
Hidroxicloroquina	Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad
Lopinavir	Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad
Ritonavir	Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad
Acetato de icatibanto	Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study
Inibidor de C1 esterase/calicreína	Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study
Prednisona	Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial
Cloroquina	Hidroxicloroquina e cloroquina para Covid-19. Revisão sistemática de ensaios clínicos randomizados
Hidroxicloroquina	Hidroxicloroquina e cloroquina para Covid-19. Revisão sistemática de ensaios clínicos randomizados
Vacina ChAdOx1 nCoV-19	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
Vacina mRNA-LNP	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Vacina mRNA-LNP	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Vacina mRNA-LNP	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Vacina mRNA-LNP	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Vacina de RNA	Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
Azitromicina	Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID-19: Quantification and precautions for a busy clinician
Cloroquina	Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID-19: Quantification and precautions for a busy clinician
Hidroxicloroquina	Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID-19: Quantification and precautions for a busy clinician
Cloroquina	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review
Cloroquina	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review
Hidroxicloroquina	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review
Hidroxicloroquina	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review
Medidas de suporte	"Prolonged QT Interval in a Patient
With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin"
Favipiravir	Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
Nafamostato	Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
Hidroxicloroquina	Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review
Acetato de icatibanto	Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19
Antagonistas do Receptor da Angiotensina II	Análisis de la relación entre los inhibidores del sistema renina-angiotensina y la evolución de pacientes hospitalizados por infección respiratoria COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Análisis de la relación entre los inhibidores del sistema renina-angiotensina y la evolución de pacientes hospitalizados por infección respiratoria COVID-19
Tocilizumabe	Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19
Hidroxicloroquina	Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review
Tocilizumabe	Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review
Aprepitanto	Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach
Vacina de vírus inativado	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical
Anakinra	REPORTE BREVE Nº 30 USO DE ANAKINRA PARA EL TRATAMIENTO DE PACIENTES CON EL DIAGNOSTICO DE COVID-19, 2020.  SEGURO SOCIAL DE SALUD - ESSALUD INSTITUTO DE EVALUACION DE TECNOLOGIAS EN SALUD E INVESTIGACIÓN
Dexametasona	Uso de dexametasona en pacientes internados con COVID-19 - Informe de Evaluación de Tecnología Sanitaria
Vacina de vírus inativado	An Inactivated Virus Candidate Vaccine to Prevent COVID-19
Hidroxicloroquina	Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary
Lopinavir	Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary
Ritonavir	Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary
Corticosteroides	No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
Drogas antirreumáticas modificadoras de doenças	No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
Sarilumabe	No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
Tocilizumabe	No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
Cloroquina	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?
Hidroxicloroquina	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?
Argatrobana	Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019
Argatrobana	Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19
Plasmaferese	Plasma exchange in critically ill COVID-19 patients
Ocrelizumabe	Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
Cloreto de potássio	QTc prolongation during antiviral therapy in two COVID-19 patients
Cloroquina	QTc prolongation during antiviral therapy in two COVID-19 patients
Lopinavir	QTc prolongation during antiviral therapy in two COVID-19 patients
Pantoprazol	QTc prolongation during antiviral therapy in two COVID-19 patients
Prednisona	QTc prolongation during antiviral therapy in two COVID-19 patients
Ritonavir	QTc prolongation during antiviral therapy in two COVID-19 patients
Umifenovir	QTc prolongation during antiviral therapy in two COVID-19 patients
Hidroxicloroquina	Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir
Lopinavir	Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir
Ritonavir	Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir
Nadroparina	Impact of implementation of an individualised thromboprophylaxis protocol T in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study
Hidroxicloroquina	Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results
Plasma convalescente	SARS-CoV-2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in COVID-19 Patients
Vitamina D (25-hidroxivitamina D)	Vitamin D deficiency as a predictor of poor prognosis in patients with acute  respiratory failure due to COVID-19
Plasma convalescente	Convalescent Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata Analysis
Plasma convalescente	Convalescent Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata Analysis
Hidroxicloroquina	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials
Hidroxicloroquina	Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysis
Azitromicina	Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience
Hidroxicloroquina	Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience
Hidroxicloroquina	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSCoV-2 infection: a retrospective cohort study
Lopinavir	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSCoV-2 infection: a retrospective cohort study
Ritonavir	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSCoV-2 infection: a retrospective cohort study
Plasma convalescente	Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality
Hidroxicloroquina	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients - Results from a real-life patient cohort
Lopinavir	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients - Results from a real-life patient cohort
Ritonavir	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients - Results from a real-life patient cohort
Hidroxicloroquina	TREATMENT WITH HYDROXYCHLOROQUINE IN PATIENTS WITH COVID-19. EXPERIENCE OF A NEUROLOGY DEPARTMENT
Antagonistas do Receptor da Angiotensina II	Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report
Azitromicina	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial
Colchicina	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial
Hidroxicloroquina	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial
Prednisona	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial
Favipiravir	Favipiravir y/o umifenovir en infección por COVID-19
Umifenovir	Favipiravir y/o umifenovir en infección por COVID-19
Ivermectina	Documento de Evaluación de Tecnologías Sanitarias – Informe de Respuesta Rápida: Ivermectina para COVID-19
Plasma convalescente	Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis
Inibidores de Janus Kinase (JAK)	Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis
Interferon recombinante tipo 1	Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 10 August 2020
Vacina BCG	Effectiveness of booster BCG vaccination in preventing Covid-19 infection
Bromexina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Bromexina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Bromexina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Bromexina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Bromexina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Cloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Cloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Cloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Cloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Cloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Hidroxicloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Hidroxicloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Hidroxicloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Hidroxicloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Hidroxicloroquina	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Lopinavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Lopinavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Lopinavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Lopinavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Lopinavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Remdesivir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Remdesivir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Remdesivir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Remdesivir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Remdesivir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Ritonavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Ritonavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Ritonavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Ritonavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Ritonavir	Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?
Remdesivir	Drug vignettes: Remdesivir
Nitazoxanida	Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Nitazoxanida	Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
Anticorpos	Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Imunoglobulina	Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Plasma convalescente	Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects
Baricitinibe	Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19
Cloroquina	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Favipiravir	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Hidroxicloroquina	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Interferon alfa	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Lopinavir	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Remdesivir	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Ritonavir	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Umifenovir	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Hidroxicloroquina	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review
Lopinavir	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review
Micofenolato de mofetila	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review
Prednisona	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review
Ritonavir	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review
Ácido fólico	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Ácido ursodesoxicólico	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Cotrimoxazol	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Hidroxicloroquina	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Meropenem	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Micofenolato de mofetila	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Prednisolona	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Tacrolimus	COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature
Terapia celular	Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19
Vacina de vírus inativado	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
Corticosteroides	Corticoides sistémicos en COVID-19
Terapia celular	Stem cell therapy for Covid‐19: possibilities and challenges
Ozonioterapia	Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results
Terapia celular	Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells
Vacina BCG	Avoiding COVID-19 complications with diabetic patients could be achieved by multi-dose Bacillus Calmette–Guérin vaccine: A case study of beta cells regeneration by serendipity
Remdesivir	Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series
Plasma convalescente	Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19
Plasma convalescente	Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19
Darunavir	Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy
Ritonavir	Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy
Corticosteroides	Corticosteroid therapy for patients with severe novel Coronavirus disease 2019
Cloroquina	BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?
Cloroquina	BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?
Vacina BCG	BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?
Vacina BCG	BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?
Hidroxicloroquina	Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Tocilizumabe	Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
Tocilizumabe	Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation
Tocilizumabe	Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation
Anakinra	Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab
Tocilizumabe	Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab
Favipiravir	AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Lopinavir	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
Novaferon	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
Ritonavir	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial
Antagonistas do Receptor da Angiotensina II	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis
Dexametasona	The use of dexamethasone in the treatment of COVID-19
Azitromicina	Searching for COVID-19 treatments: First, do no harm
Cloroquina	Searching for COVID-19 treatments: First, do no harm
Hidroxicloroquina	Searching for COVID-19 treatments: First, do no harm
Remdesivir	The role of remdesivir in COVID -19 infection
Interferon	Drug vignettes: Interferons
Anakinra	Anakinra in COVID-19: important considerations for clinical trials
Corticosteroides	Therapeutic response to corticosteroids in a critically ill patient with COVID-19
Lopinavir	A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
Ritonavir	A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
Rituximabe	Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective,single-center trial
Heparina	Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review
Heparina	Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review
Ad5-nCoV	The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts
Vacina ChAdOx1 nCoV-19	The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts
Vacina mRNA-1273	The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts
Vacina NVX-CoV2373	First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine
Vacina NVX-CoV2373	First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine
Corticosteroides	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Hidroxicloroquina	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Imunoglobulina	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tocilizumabe	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Benralizumabe	COVID-19, asthma, and biologic therapies: What we need to know
Corticosteroides	COVID-19, asthma, and biologic therapies: What we need to know
Dupilumabe	COVID-19, asthma, and biologic therapies: What we need to know
Mepolizumabe	COVID-19, asthma, and biologic therapies: What we need to know
Omalizumabe	COVID-19, asthma, and biologic therapies: What we need to know
Reslizumabe	COVID-19, asthma, and biologic therapies: What we need to know
Terapia celular	Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España
Cloroquina	Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID‑19
Hidroxicloroquina	Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID‑19
Azitromicina	COVID-19 in pediatric patients: A case series
Hidroxicloroquina	COVID-19 in pediatric patients: A case series
Oseltamivir	COVID-19 in pediatric patients: A case series
Imunoglobulina	Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report
Corticosteroides	Clinical outcomes of COVID‑19 in Wuhan, China: a large cohort study
Ganciclovir	Clinical outcomes of COVID‑19 in Wuhan, China: a large cohort study
Oseltamivir	Clinical outcomes of COVID‑19 in Wuhan, China: a large cohort study
Ácido ascórbico	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Antibióticos	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Antifúngicos	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Antivirais	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Corticosteroides	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Ganciclovir	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Imunoglobulina	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Interferon alfa	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Oseltamivir	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Ribavirina	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Umifenovir	The characteristics and outcomes of 681 severe cases with COVID-19 in China.
Azitromicina	Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh
Hidroxicloroquina	Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh
Interferon alfa	No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
Lopinavir	No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
Ribavirina	No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
Ritonavir	No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
Vacina BCG	A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization
Imunoglobulina	High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects
Corticosteroides	Critical COVID-19 disease, homeostasis, and the “surprise” of effective glucocorticoid therapy
Corticosteroides	Critical COVID-19 disease, homeostasis, and the “surprise” of effective glucocorticoid therapy
Plasma convalescente	A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals
Colchicina	Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report
Corticosteroides	Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report
Imunoglobulina	Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report
Tocilizumabe	Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report
Metotrexato	Prolonged asymptomatic SARS-CoV-2 infection in a child receiving immunosuppressive therapy
Prednisona	Prolonged asymptomatic SARS-CoV-2 infection in a child receiving immunosuppressive therapy
Interferon alfa	Interferon-α2b spray inhalation did not shorten vírus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
Interferon alfa	Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery
Corticosteroides	Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019
Oseltamivir	Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019
Umifenovir	Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019
Azitromicina	Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Hidroxicloroquina	Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Antibióticos	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Corticosteroides	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Ganciclovir	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Imunoglobulina	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Lopinavir	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Oseltamivir	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Prednisona	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Ritonavir	Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis
Anticorpos	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
Imunoglobulina	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
Interferon	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
Plasma convalescente	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
Terapia celular	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
Tocilizumabe	Tocilizumab for COVID-19: a real ‘miracle drug’?
Tocilizumabe	Tocilizumab for COVID-19: a real ‘miracle drug’?
Etoposídeo	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids
Plasmaferese	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids
Ruxolitinibe	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids
Tocilizumabe	Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids
Azitromicina	Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?
Hidroxicloroquina	Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?
Vitamina D (25-hidroxivitamina D)	Vitamin D for COVID-19: a case to answer?
Azitromicina	Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection
Hidroxicloroquina	Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection
Favipiravir	Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019: A Case Report
Tocilizumabe	COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19
Tocilizumabe	Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients
Inibidores da Ciclooxigenase-2 (COX-2)	Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease  2019
Cloroquina	A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients
Lopinavir	A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients
Ritonavir	A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients
Tocilizumabe	Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study
Tetraciclinas	Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS?
Remdesivir	Remdesivir for severe covid-19: a clinical practice guideline
Anakinra	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Anakinra	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Baricitinibe	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Baricitinibe	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Cloroquina	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Cloroquina	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Corticosteroides	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Corticosteroides	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Hidroxicloroquina	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Hidroxicloroquina	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Imunoglobulina	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Imunoglobulina	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Siltuximabe	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Siltuximabe	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Tocilizumabe	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Tocilizumabe	Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis
Cloroquina	Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
Hidroxicloroquina	Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
Corticosteroides	Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis
Anakinra	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Azitromicina	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Baricitinibe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Canaquinumabe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Cloroquina	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Colchicina	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Darunavir	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Dexametasona	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Favipiravir	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Fedratinibe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Hidroxicloroquina	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Interferon alfa	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Interferon beta	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Lopinavir	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Prednisona	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Remdesivir	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Ritonavir	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Ruxolitinibe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Sarilumabe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Siltuximabe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Tocilizumabe	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Umifenovir	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2
Ácido ascórbico	Ascorbate as Prophylaxis and Therapy for COVID-19—Update From Shanghai and U.S. Medical Institutions
Favipiravir	Effect of favipiravir and an anti- inflammatory strategy for COVID-19
Anakinra	Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report
Anakinra	Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report
Tocilizumabe	COVID-19 in a Patient With Rheumatoid Arthritis During Tocilizumab Treatment
Tocilizumabe	Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab  and NIV in a Patient with COVID-19 Pneumonia/ARDS
Corticosteroides	Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience
Colchicina	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Agentes anti-interleucinas	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Antagonistas de TNF	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Anticorpos neutralizantes direcionados a IL-17	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Corticosteroides	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Hidroxicloroquina	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Inibidores de Janus Kinase (JAK)	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Metotrexato	COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Tocilizumabe	The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City
Antagonistas do Receptor da Angiotensina II	Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Interferon alfa	Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA
Interferon gama	Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA
Corticosteroides	Drug treatments for covid-19: living systematic review and network meta-analysis.
Corticosteroides	Drug treatments for covid-19: living systematic review and network meta-analysis.
Corticosteroides	Drug treatments for covid-19: living systematic review and network meta-analysis.
Corticosteroides	Drug treatments for covid-19: living systematic review and network meta-analysis.
Corticosteroides	Drug treatments for covid-19: living systematic review and network meta-analysis.
Corticosteroides	Drug treatments for covid-19: living systematic review and network meta-analysis.
Hidroxicloroquina	Drug treatments for covid-19: living systematic review and network meta-analysis.
Hidroxicloroquina	Drug treatments for covid-19: living systematic review and network meta-analysis.
Hidroxicloroquina	Drug treatments for covid-19: living systematic review and network meta-analysis.
Hidroxicloroquina	Drug treatments for covid-19: living systematic review and network meta-analysis.
Hidroxicloroquina	Drug treatments for covid-19: living systematic review and network meta-analysis.
Hidroxicloroquina	Drug treatments for covid-19: living systematic review and network meta-analysis.
Lopinavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Lopinavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Lopinavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Lopinavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Lopinavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Lopinavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Remdesivir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Remdesivir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Remdesivir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Remdesivir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Remdesivir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Remdesivir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Ritonavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Ritonavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Ritonavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Ritonavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Ritonavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Ritonavir	Drug treatments for covid-19: living systematic review and network meta-analysis.
Corticosteroides	Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis
Vacina (Ad26.COV2.S)	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Vacina (Ad26.COV2.S)	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Vacina BCG	BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data
Vacina BCG	BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data
Azitromicina	Tratamento precoce para COVID-19 baseado em evidência científica.
Hidroxicloroquina	Tratamento precoce para COVID-19 baseado em evidência científica.
Remdesivir	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19
Remdesivir	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19
Remdesivir	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19
Cloroquina	Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management
Hidroxicloroquina	Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management
Remdesivir	Liver injury in remdesivir-treated COVID-19 patients
Remdesivir	Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)
Sarilumabe	Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
Tocilizumabe	Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
Bevacizumabe	Efficacy and tolerability of bevacizumab 2 in patients with severe Covid -19
Bevacizumabe	Efficacy and tolerability of bevacizumab 2 in patients with severe Covid -19
Bevacizumabe	Efficacy and tolerability of bevacizumab 2 in patients with severe Covid -19
Tocilizumabe	Appropriate use of Tocilizumab in COVID-19 Infection
Itolizumabe	Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
Imunoglobulina	Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial
Hidroxicloroquina	A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 31 July 2020
Vitamina D (25-hidroxivitamina D)	Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection
Hidroxicloroquina	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia
Tocilizumabe	Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy
Heparina	Heparin-Induced Thrombocytopenia in COVID-19
Lopinavir	Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir
Ritonavir	Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir
Prednisona	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Tocilizumabe	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
Tocilizumabe	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients
Tocilizumabe	Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study
Azitromicina	Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU.
Favipiravir	Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU.
Hidroxicloroquina	Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU.
Corticosteroides	Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic
Corticosteroides	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression
Tocilizumabe	Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
Tocilizumabe	Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
Cloroquina	A meta-review of systematic reviews and an updated metaanalysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection
Cloroquina	A meta-review of systematic reviews and an updated metaanalysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection
Hidroxicloroquina	A meta-review of systematic reviews and an updated metaanalysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection
Hidroxicloroquina	A meta-review of systematic reviews and an updated metaanalysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection
Ad5-nCoV	COVID-19: Mechanisms of Vaccination and Immunity
Ad5-nCoV	COVID-19: Mechanisms of Vaccination and Immunity
AG0301-Covid19	COVID-19: Mechanisms of Vaccination and Immunity
AG0301-Covid19	COVID-19: Mechanisms of Vaccination and Immunity
CoronaVac	COVID-19: Mechanisms of Vaccination and Immunity
CoronaVac	COVID-19: Mechanisms of Vaccination and Immunity
COVAC1 (LNP-nCoVsaRNA)	COVID-19: Mechanisms of Vaccination and Immunity
COVAC1 (LNP-nCoVsaRNA)	COVID-19: Mechanisms of Vaccination and Immunity
Gam-COVID-Vac	COVID-19: Mechanisms of Vaccination and Immunity
Gam-COVID-Vac	COVID-19: Mechanisms of Vaccination and Immunity
Vacina BBIBP-CorV	COVID-19: Mechanisms of Vaccination and Immunity
Vacina BBIBP-CorV	COVID-19: Mechanisms of Vaccination and Immunity
Vacina ChAdOx1 nCoV-19	COVID-19: Mechanisms of Vaccination and Immunity
Vacina ChAdOx1 nCoV-19	COVID-19: Mechanisms of Vaccination and Immunity
Vacina Curevac	COVID-19: Mechanisms of Vaccination and Immunity
Vacina Curevac	COVID-19: Mechanisms of Vaccination and Immunity
Vacina INO-4800	COVID-19: Mechanisms of Vaccination and Immunity
Vacina INO-4800	COVID-19: Mechanisms of Vaccination and Immunity
Vacina NVX-CoV2373	COVID-19: Mechanisms of Vaccination and Immunity
Vacina NVX-CoV2373	COVID-19: Mechanisms of Vaccination and Immunity
Azitromicina	Hydroxychloroquine and azithromycin combination could be lethal to covid-19 patients
Hidroxicloroquina	Hydroxychloroquine and azithromycin combination could be lethal to covid-19 patients
Enoxaparina	Practical considerations in prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19
Cloroquina	Hydroxychloroquine and Azithromycin as Treatments for COVID-19
Hidroxicloroquina	Hydroxychloroquine and Azithromycin as Treatments for COVID-19
Imunoglobulina	Neurological Disorders Identified during Treatment of a SARS-CoV-2 Infection
Azitromicina	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids
Lopinavir	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids
Plasma convalescente	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids
Prednisona	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids
Ritonavir	ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids
Tocilizumabe	Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
Cetamina	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Cisatracúrio	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Cloroquina	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Fentanil	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Hidroxicloroquina	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Midazolam	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Propofol	Medication utilization in patients in New York hospitals during the COVID-19 pandemic
Interferon alfa	Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
Cobre	Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
Resveratrol	Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
Anti-inflamatórios não esteroidais	Association between NSAIDs use and adverse clinical outcomes among adults hospitalised with COVID-19 in South Korea: A nationwide study
Cloroquina	Effectiveness and Safety of Chloroquine or hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis
Hidroxicloroquina	Effectiveness and Safety of Chloroquine or hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis
Tocilizumabe	Tocilizumab for severe COVID-19: a systematic review and meta-analysis
Vacina influenza	COVID-19 Severity in Europe and the USA: Could the Seasonal Influenza Vaccination Play a Role?
AG0301-Covid19	Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso
CoronaVac	Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso
MVC-COV1901	Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso
Vacina BBIBP-CorV	Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso
Vacina ChAdOx1 nCoV-19	Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso
Vacina INO-4800	Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso
Vacina mRNA-1273	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Vacina de RNA	Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine
Vacina de RNA	Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine
Remdesivir	Remdesivir—Bringing Hope for COVID-19 Treatment
N-acetilcisteína	Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine
Imunoglobulina	Successful treatment of two Japanese ESRD cases with severe COVID‐19 pneumonia
Tocilizumabe	Successful treatment of two Japanese ESRD cases with severe COVID‐19 pneumonia
Alemtuzumabe	COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab
Infliximabe	Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure – a cautionary case series
Corticosteroides	High‐dose, short‐term corticosteroids for ARDS caused by COVID ‐19: a case series
Ácido ascórbico	Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C
Azitromicina	Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C
Colchicina	Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C
Hidroxicloroquina	Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C
Interferon alfa	An infant with coronavirus disease 2019 in China: A case report
Hidroxicloroquina	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection
Antagonistas do Receptor da Angiotensina II	Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
Bloqueadores do Canal de Cálcio	Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US
Corticosteroides	Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study
Hidroxicloroquina	Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study
Remdesivir	Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study
Tocilizumabe	Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study
Ribavirina	Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study
Remdesivir	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
Remdesivir	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
Remdesivir	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
Remdesivir	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
Remdesivir	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
Antagonistas do Receptor da Angiotensina II	The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
Estatina	The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
Sarilumabe	A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients
Siltuximabe	A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients
Tocilizumabe	A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients
Tocilizumabe	Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 27 July 2020
Vacina BCG	BCG vaccination and COVID-19: Much ado about nothing?
Imunossupressores	Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide
Plasmaferese	Therapeutic Plasma Exchange: a potential management strategy for critically III COVID-19 patients. 2020
Plasma convalescente	Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
Remdesivir	Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy
Hidroxicloroquina	As the COVID-19 pandemic drags on, where have all the STEMIs gone?
Tocilizumabe	As the COVID-19 pandemic drags on, where have all the STEMIs gone?
Hidroxicloroquina	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
Tocilizumabe	Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study
Agentes anti-interleucinas	ISARIC Clinical Data Report 8 June 2020
Agentes anti-interleucinas	ISARIC Clinical Data Report 8 June 2020
Antibióticos	ISARIC Clinical Data Report 8 June 2020
Antibióticos	ISARIC Clinical Data Report 8 June 2020
Antifúngicos	ISARIC Clinical Data Report 8 June 2020
Antifúngicos	ISARIC Clinical Data Report 8 June 2020
Antivirais	ISARIC Clinical Data Report 8 June 2020
Antivirais	ISARIC Clinical Data Report 8 June 2020
Corticosteroides	ISARIC Clinical Data Report 8 June 2020
Corticosteroides	ISARIC Clinical Data Report 8 June 2020
Inotrópicos	ISARIC Clinical Data Report 8 June 2020
Inotrópicos	ISARIC Clinical Data Report 8 June 2020
Plasma convalescente	ISARIC Clinical Data Report 8 June 2020
Plasma convalescente	ISARIC Clinical Data Report 8 June 2020
Plasma convalescente	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study
Agentes bloqueadores neuromusculares	Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study
Anakinra	Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
Vitamina D (25-hidroxivitamina D)	Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study
Leflunomida	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial
Clopidogrel	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology
Heparina	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology
Ticagrelor	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology
Adalimumabe	Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini- Review
Anakinra	Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini- Review
Infliximabe	Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini- Review
Tocilizumabe	Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini- Review
Rituximabe	Rituximab: a safe therapeutic option during the COVID-19 pandemic? Journal of Dermatological Treatment. 22 de julho de 2020;1–3. DOI: 10
Anticoagulantes	Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?
Azitromicina	Azithromycin in COVID‑19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
Tocilizumabe	Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state
Hidroxicloroquina	A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency
Gilteritinibe	Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19
Tocilizumabe	The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report
Darunavir	High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
Hidroxicloroquina	High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
Ritonavir	High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
Heparina	Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy
Terapia celular	Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia
Prednisona	Second Week Methyl-Prednisolone Pulses Improve Prognosis In Patients With Severe Coronavirus Disease 2019 Pneumonia: An Observational Comparative Study Using Routine Care Data.
Tocilizumabe	Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study
Azitromicina	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19.
Hidroxicloroquina	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19.
Remdesivir	Use of remdesivir for patients with Covid-19: a review article
Vacina de DNA	Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic
Vacina de RNA	Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic
Hidroxicloroquina	Hydroxychloroquine for COVID-19: What is Our Current State of Knowledge?
Azitromicina	Anticoagulation, immortality, and observations of COVID-19
Hidroxicloroquina	Anticoagulation, immortality, and observations of COVID-19
Inibidores de Interleucina-1	Anticoagulation, immortality, and observations of COVID-19
Remdesivir	Anticoagulation, immortality, and observations of COVID-19
Estatina	Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)
Heparina	Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!
Ipilimumabe	Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
Nivolumabe	Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
Prednisona	Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
Anti-histamínicos	Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria
Esteroides	Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria
Ruxolitinibe	Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer
Tocilizumabe	Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer
Remdesivir	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection
Almitrina	Acute cor pulmonale in COVID-19-related ARDS: improvement with almitrine infusion
Durvalumabe	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab
Tocilizumabe	"Effectiveness of Tocilizumab in a COVID-19 Patient
with Cytokine Release Syndrome"
Secuquinumabe	SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor
Tocilizumabe	Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation
Prednisona	Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports
Heparina	Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome.
Anti-inflamatórios	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Anticorpos	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Cloroquina	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Enoxaparina	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Fondaparinux	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Heparina	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Hidroxicloroquina	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Lopinavir	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Oxigenoterapia	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Ritonavir	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Tocilizumabe	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Varfarina	A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy
Azitromicina	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
Darunavir	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
Hidroxicloroquina	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
Ritonavir	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
Enoxaparina	The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience
Fondaparinux	The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience
Heparina	The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 21 July 2020
Vacina BCG	The effect of BCG vaccine in the era of COVID-19 pandemic
Cloroquina	How should we treat pregnant women infected with SARS-CoV-2?
Hidroxicloroquina	How should we treat pregnant women infected with SARS-CoV-2?
Lopinavir	How should we treat pregnant women infected with SARS-CoV-2?
Remdesivir	How should we treat pregnant women infected with SARS-CoV-2?
Ribavirina	How should we treat pregnant women infected with SARS-CoV-2?
Ritonavir	How should we treat pregnant women infected with SARS-CoV-2?
Anticorpos	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Cloroquina	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Favipiravir	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Hidroxicloroquina	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Inibidores de interleucina-6	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Lenzilumabe	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Lopinavir	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Plasma convalescente	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Remdesivir	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Ritonavir	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Sarilumabe	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Tocilizumabe	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
Cloroquina	Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns
Hidroxicloroquina	Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns
Corticosteroides	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Imunoglobulina	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Interleucina-6 basal (IL-6)	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Lopinavir	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Oseltamivir	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Oxigenoterapia	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Ritonavir	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Umifenovir	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019
Ruxolitinibe	Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib
Amiodarona	Safety and Efficacy of Amiodarone in a Patient With COVID-19
Azitromicina	Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis
Favipiravir	Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis
Hidroxicloroquina	Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis
Oseltamivir	Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis
Heparina	Heparin‐induced Thrombocytopenia with Thrombosis in COVID‐19 Adult Respiratory Distress Syndrome
Pembrolizumabe	Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2
Tocilizumabe	The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series
Lopinavir	Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19
Ritonavir	Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19
Antibióticos	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Corticosteroides	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Interferon	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Lopinavir	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Medicina Tradicional Chinesa	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Oseltamivir	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Ritonavir	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Umifenovir	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei
Rituximabe	COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience
Tocilizumabe	Use of tocilizumab in kidney transplant recipients with COVID-19
Azitromicina	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Ceftriaxona	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Dexametasona	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Hidroxicloroquina	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Interferon beta	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Lopinavir	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Oseltamivir	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Prednisona	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Ritonavir	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
Azitromicina	Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with pcr positive SARS-Cov-2 infection including drug induced changes in the corrected qt interval (QTc) (2020)
Hidroxicloroquina	Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with pcr positive SARS-Cov-2 infection including drug induced changes in the corrected qt interval (QTc) (2020)
Antagonistas do Receptor da Angiotensina II	Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study
Bloqueadores do Canal de Cálcio	Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study
Corticosteroides	Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort Study
Remdesivir	Remdesivir for the Treatment of Covid-19 - Preliminary Report
Vacina BCG	Do low TB prevalence or lack of BCG Vaccination Contribute to Emergence Multisystem Inflammatory Syndrome?
Ocrelizumabe	Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
Ácido acetilsalicílico	Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
Antibióticos	Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
Corticosteroides	Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
Imunoglobulina	Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study
Tocilizumabe	Gastrointestinal Perforation After Treatment With Tocilizumab: An Unexpected Consequence of COVID-19 Pandemic
Clazakizumab	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report
Antibióticos	Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province
Interferon	Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province
Ribavirina	Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province
Umifenovir	Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province
Azitromicina	QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19
Hidroxicloroquina	QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19
Azitromicina	Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin
Hidroxicloroquina	Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin
Cloroquina	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Cloroquina	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Hidroxicloroquina	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Hidroxicloroquina	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19
Ad5-nCoV	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Plasma convalescente	A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report
Terapia celular	A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report
Vitamina D (25-hidroxivitamina D)	Vitamin D Sufficiency Reduced Risk for Morbidity and Mortality in COVID-19 Patients
Amoxicilina	COVID-19 in two infants in China
Clavulanato de potássio	COVID-19 in two infants in China
Imunoglobulina	COVID-19 in two infants in China
Interferon	COVID-19 in two infants in China
Oseltamivir	COVID-19 in two infants in China
Ribavirina	COVID-19 in two infants in China
Roxitromicina	COVID-19 in two infants in China
Umifenovir	COVID-19 in two infants in China
Azitromicina	The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data
Hidroxicloroquina	The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data
Dexametasona	A critical evaluation of glucocorticoids in the management of severe COVID19
Prednisona	A critical evaluation of glucocorticoids in the management of severe COVID19
Azitromicina	The cardiovascular effects of treatment with hydroxychloroquine and azithromycin
Hidroxicloroquina	The cardiovascular effects of treatment with hydroxychloroquine and azithromycin
Azitromicina	A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study
Heparina	A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study
Hidroxicloroquina	A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study
Lopinavir	A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study
Ritonavir	A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study
Dexametasona	Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
Azitromicina	Effet bénéfique de l'association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19: résultats d'une étude observationnelle
Hidroxicloroquina	Effet bénéfique de l'association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19: résultats d'une étude observationnelle
Tocilizumabe	Mild COVID‐19 infection in an NMO patient treated with tocilizumab: a confrmation of anti‐IL‐6 protective role?
Hidroxicloroquina	Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments
Azitromicina	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Hidroxicloroquina	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
Antagonistas do Receptor da Angiotensina II	Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
Vacina ChAdOx1 nCoV-19	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Abatacept	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Adalimumabe	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Baricitinibe	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Etanercepte	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Hidroxicloroquina	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Tocilizumabe	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Tofacitinibe	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Remdesivir	Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis
Tocilizumabe	Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis
Antagonista de β-adrenérgico	Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock
Cefepima	Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock
Vancomicina	Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock
Hidroxicloroquina	Cardiac Dysfunction and Shock in Pediatric Patients With COVID-19
Tocilizumabe	Cardiac Dysfunction and Shock in Pediatric Patients With COVID-19
Dexametasona	COVID-19 in a patient with active tuberculosis: A rare case-report
Lopinavir	COVID-19 in a patient with active tuberculosis: A rare case-report
Ribavirina	COVID-19 in a patient with active tuberculosis: A rare case-report
Ritonavir	COVID-19 in a patient with active tuberculosis: A rare case-report
Ganciclovir	Multiple Acute Ischemic Strokes in a COVID-19 Patient: a Case Report
Linezolida	Multiple Acute Ischemic Strokes in a COVID-19 Patient: a Case Report
Meropenem	Multiple Acute Ischemic Strokes in a COVID-19 Patient: a Case Report
Oseltamivir	Multiple Acute Ischemic Strokes in a COVID-19 Patient: a Case Report
Rezolsta	Multiple Acute Ischemic Strokes in a COVID-19 Patient: a Case Report
Tocilizumabe	Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study
Hidroxicloroquina	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial
Hidroxicloroquina	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial
Hidroxicloroquina	Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
Interferon beta	Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
Cobicistato	Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19
Darunavir	Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19
Azitromicina	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Azitromicina	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Baloxavir marboxil	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Baloxavir marboxil	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Corticosteroides	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Corticosteroides	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Favipiravir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Favipiravir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Hidroxicloroquina	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Hidroxicloroquina	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Lopinavir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Lopinavir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Plasma convalescente	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Plasma convalescente	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Remdesivir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Remdesivir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Ritonavir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Ritonavir	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Tocilizumabe	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Tocilizumabe	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection
Ad5-nCoV	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
CoronaVac	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Vacina BNT162	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Vacina ChAdOx1 nCoV-19	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Vacina INO-4800	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Vacina mRNA-1273	COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Vacina de DNA	A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
Vacina de RNA	A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
Corticosteroides	Corticosteroid administration for viral pneumonia: COVID-19 and beyond
Terapia celular	Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy
Inibidores de interleucina-6	Rethinking interleukin-6 blockade for treatment of COVID-19
Azitromicina	Severe coronavirus infection in pregnancy: challenging cases report
Ceftriaxona	Severe coronavirus infection in pregnancy: challenging cases report
Corticosteroides	Severe coronavirus infection in pregnancy: challenging cases report
Enoxaparina	Severe coronavirus infection in pregnancy: challenging cases report
Hidroxicloroquina	Severe coronavirus infection in pregnancy: challenging cases report
Meropenem	Severe coronavirus infection in pregnancy: challenging cases report
Oseltamivir	Severe coronavirus infection in pregnancy: challenging cases report
Vancomicina	Severe coronavirus infection in pregnancy: challenging cases report
Antagonistas do Receptor da Angiotensina II	Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy
Bloqueadores do Canal de Cálcio	Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy
Tocilizumabe	Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study
Memantina	A retrospective review of memantine use and COVID-19-associated mortality from a national database
Atorvastatina	Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study
Ácido ascórbico	The Use of IV vitamin C for patients with COVID-19: a single center observational study
Antibióticos	Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis
Azitromicina	Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis
Hidroxicloroquina	Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis
Lopinavir	Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis
Ritonavir	Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis
Tocilizumabe	Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis
Tocilizumabe	Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study
Cloroquina	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Hidroxicloroquina	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Antibióticos	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Cloroquina	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Heparina	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Hidroxicloroquina	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Lopinavir	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Oseltamivir	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Ritonavir	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Tocilizumabe	Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 15 July 2020
Anakinra	Anakinra for patients with COVID-19
Anakinra	Anakinra for patients with COVID-19
Anticoagulantes	The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Fibrinolíticos	The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management
Hidroxicloroquina	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making
Ocrelizumabe	COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
Rituximabe	COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
Darunavir	Covid-19: A systemic disease treated with a wide-ranging approach: A case report
Dexametasona	Covid-19: A systemic disease treated with a wide-ranging approach: A case report
Enoxaparina	Covid-19: A systemic disease treated with a wide-ranging approach: A case report
Hidroxicloroquina	Covid-19: A systemic disease treated with a wide-ranging approach: A case report
Ritonavir	Covid-19: A systemic disease treated with a wide-ranging approach: A case report
Tocilizumabe	Covid-19: A systemic disease treated with a wide-ranging approach: A case report
Lopinavir	A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock
Oxigenação por membrana extracorpórea (ECMO)	A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock
Ritonavir	A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock
Hidroxicloroquina	First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test
Tocilizumabe	Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
Antagonistas do Receptor da Angiotensina II	Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients
Esomeprazol	Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?
Omeprazol	Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?
Pantoprazol	Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?
Azivudina	A Randomized, Open‐label, Controlled Clinical Trial of Azivudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study
Obinutuzumabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Obinutuzumabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Ocrelizumabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Ocrelizumabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Ofatumumabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Ofatumumabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Rituximabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Rituximabe	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Vacina mRNA-1273	An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Atazanavir	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Azitromicina	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Cloroquina	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Dipiridamol	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Famotidina	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Favipiravir	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Hidroxicloroquina	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Lopinavir	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Nitazoxanida	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Remdesivir	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Ribavirina	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Ritonavir	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Tocilizumabe	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents
Azitromicina	Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic
Hidroxicloroquina	Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic
Lopinavir	Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic
Ritonavir	Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic
Corticosteroides	Pros and cons of corticosteroid therapy for COVID-19 patients
Corticosteroides	Pros and cons of corticosteroid therapy for COVID-19 patients
Secuquinumabe	Coronavirus disease 2019 rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?
Hidroxicloroquina	Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection
Lopinavir	Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection
Ritonavir	Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection
Corticosteroides	Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases
Imunoglobulina	Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases
Lopinavir	Management of the first severe case of COVID-19 in the small islands of Maldives
Oseltamivir	Management of the first severe case of COVID-19 in the small islands of Maldives
Ritonavir	Management of the first severe case of COVID-19 in the small islands of Maldives
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
Vacina BCG	Bacillus Calmette–Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study
Hidroxicloroquina	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Lopinavir	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Ritonavir	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
Azitromicina	QT prolongation in adiverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
Cloroquina	QT prolongation in adiverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
Hidroxicloroquina	QT prolongation in adiverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin
Azitromicina	Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
Hidroxicloroquina	Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
Cloroquina	The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine
Hidroxicloroquina	A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
Azitromicina	Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an 1 Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)
Hidroxicloroquina	Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an 1 Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)
Cloroquina	Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality
Hidroxicloroquina	Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality
Vacina BCG	Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 13 July 2020
Anakinra	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Baricitinibe	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Canaquinumabe	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Corticosteroides	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Heparina	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Sarilumabe	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Tocilizumabe	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Tofacitinibe	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Vitamina D (25-hidroxivitamina D)	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept
Angiotensina II	Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single-center experience
Remdesivir	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Tocilizumabe	An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19
Iloprosta	Iloprost for COVID-19-related vasculopathy
Azitromicina	Portal vein thrombosis in a patient with COVID-19
Enoxaparina	Portal vein thrombosis in a patient with COVID-19
Hidroxicloroquina	Portal vein thrombosis in a patient with COVID-19
Vacina BCG	BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)
Tocilizumabe	SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS
Tocilizumabe	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab
Interferon recombinante tipo 1	Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysi
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living  systematic review
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living  systematic review
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living  systematic review
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living  systematic review
Ivermectina	Eficácia da Ivermectina para o Tratamento da Covid-19. Revisão sistemática rápida
Tocilizumabe	Addition of Tocilizumab to standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis
Hidroxicloroquina	Is Hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19?
Agonistas de TLRs	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
AS01B	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
AS03A	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
Delta inulin	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
Hidróxido de alumínio	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
MF59	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
Montanide ISA-51	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
Protollin	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
rOv-ASP-1	Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses
Ivermectina	Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency
Ivermectina	Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses
Ivermectina	Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses
Ivermectina	Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses
Vitamina D (25-hidroxivitamina D)	Role of vitamin D in preventing of COVID-19 infection, progression and severity
Lítio	Lithium Toxicity in Two Coronavirus Disease 2019 (COVID-19) Patients
Fingolimode	Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal
Venetoclax	COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Venetoclax	COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Venetoclax	COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Tocilizumabe	Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases
Esteroides	Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study
Imunoglobulina	Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study
Infliximabe	Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study
Rituximabe	Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study
Tocilizumabe	Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study
Baricitinibe	Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
Secuquinumabe	Coronavirus disease 2019 (COVID‑19) in a patient with ankylosing spondylitis treated with secukinumab: a case‑based review
Plasma convalescente	Severe refractory COVID-19 patients responding to convalescent plasma; A case series
Plasma convalescente	Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia
Tocilizumabe	Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management
Cloroquina	Treating COVID-19 with Chloroquine
Antagonistas do Receptor da Angiotensina II	The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Estatina	The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Hidroxicloroquina	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials
Hidroxicloroquina	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials
Vacina de DNA	New international guidance on quality, safety and efﬁcacy of DNA vaccines
Vacina de RNA	New international guidance on quality, safety and efﬁcacy of DNA vaccines
Vacina de vírus inativado	New international guidance on quality, safety and efﬁcacy of DNA vaccines
Vacina (SCB-2019)	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina (SCB-2019)	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina (SCB-2019)	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina (SCB-2019)	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina ChAdOx1 nCoV-19	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina ChAdOx1 nCoV-19	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina ChAdOx1 nCoV-19	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina ChAdOx1 nCoV-19	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina Curevac	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina Curevac	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina Curevac	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina Curevac	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina INO-4800	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina INO-4800	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina INO-4800	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina INO-4800	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina mRNA-1273	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina mRNA-1273	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina mRNA-1273	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina mRNA-1273	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina NVX-CoV2373	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina NVX-CoV2373	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina NVX-CoV2373	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Vacina NVX-CoV2373	SARS-CoV-2: Virology, epidemiology, immunology and vaccine development
Ivermectina	COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution
Cloroquina	Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
Hidroxicloroquina	Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
Cloroquina	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Emetine	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Hidroxicloroquina	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Homoharringtonina (HHT)	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Interferon recombinante tipo 1	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Ivermectina	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Lopinavir	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Molnupiravir	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Nitazoxanida	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Remdesivir	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Ribavirina	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Ritonavir	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Umifenovir	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Antibióticos	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Corticosteroides	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Imunoglobulina	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Interferon	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Lopinavir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Oseltamivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Remdesivir	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ribavirina	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Ritonavir	Rapid advice guidelines for management of children with COVID-19
Hidroxicloroquina	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline
Lopinavir	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline
Plasma convalescente	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline
Remdesivir	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline
Ritonavir	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline
Cloroquina	Primum non nocere _ Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Cloroquina	Primum non nocere _ Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Hidroxicloroquina	Primum non nocere _ Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Hidroxicloroquina	Primum non nocere _ Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
Azitromicina	No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
Hidroxicloroquina	No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
Plasma convalescente	Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications
Cateter nasal de oxigênio	Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report
Cloridrato de ambroxol	Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report
Ganciclovir	Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report
Interferon alfa	Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report
Moxifloxacina	Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report
Prednisona	Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report
Plasma convalescente	First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia
Tocilizumabe	Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review
Ciclesonida	Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide
Antagonistas do Receptor da Angiotensina II	Association between angiotensin blockade and COVID-19 severity in Hong Kong
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association between angiotensin blockade and COVID-19 severity in Hong Kong
Apixabana	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era
Dabigatrana	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era
Edoxabana	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era
Heparina	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era
Rivaroxabana	Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era
Antagonistas do Receptor da Angiotensina II	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Antagonistas do Receptor da Angiotensina II	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Antagonistas do Receptor da Angiotensina II	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Enoxaparina	Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis
Fondaparinux	Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis
Drogas antirreumáticas modificadoras de doenças	Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
Hidroxicloroquina	Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
Prednisona	Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
Plasma convalescente	Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy
Antagonistas do Receptor da Angiotensina II	Association between angiotensin-converting enzyme inhibitors and angiotensin II 2 receptor blockers use and the risk of infection and clinical outcome of COVID-19: a 3 comprehensive systematic review and meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association between angiotensin-converting enzyme inhibitors and angiotensin II 2 receptor blockers use and the risk of infection and clinical outcome of COVID-19: a 3 comprehensive systematic review and meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review
Lopinavir	Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
Ritonavir	Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
Azitromicina	No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
Hidroxicloroquina	No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
Betrixabana	Emergence of institutional antithrombotic protocols for coronavirus 2019
Betrixabana	Emergence of institutional antithrombotic protocols for coronavirus 2019
Clopidogrel	Emergence of institutional antithrombotic protocols for coronavirus 2019
Clopidogrel	Emergence of institutional antithrombotic protocols for coronavirus 2019
Enoxaparina	Emergence of institutional antithrombotic protocols for coronavirus 2019
Enoxaparina	Emergence of institutional antithrombotic protocols for coronavirus 2019
Heparina	Emergence of institutional antithrombotic protocols for coronavirus 2019
Heparina	Emergence of institutional antithrombotic protocols for coronavirus 2019
Lopinavir	Emergence of institutional antithrombotic protocols for coronavirus 2019
Lopinavir	Emergence of institutional antithrombotic protocols for coronavirus 2019
Prasugrel	Emergence of institutional antithrombotic protocols for coronavirus 2019
Prasugrel	Emergence of institutional antithrombotic protocols for coronavirus 2019
Ritonavir	Emergence of institutional antithrombotic protocols for coronavirus 2019
Ritonavir	Emergence of institutional antithrombotic protocols for coronavirus 2019
Rivaroxabana	Emergence of institutional antithrombotic protocols for coronavirus 2019
Rivaroxabana	Emergence of institutional antithrombotic protocols for coronavirus 2019
Ticagrelor	Emergence of institutional antithrombotic protocols for coronavirus 2019
Ticagrelor	Emergence of institutional antithrombotic protocols for coronavirus 2019
Cloroquina	Obstetric Management of COVID-19 in Pregnant Women
Cloroquina	Obstetric Management of COVID-19 in Pregnant Women
Interferon alfa	Obstetric Management of COVID-19 in Pregnant Women
Interferon alfa	Obstetric Management of COVID-19 in Pregnant Women
Lopinavir	Obstetric Management of COVID-19 in Pregnant Women
Lopinavir	Obstetric Management of COVID-19 in Pregnant Women
Ritonavir	Obstetric Management of COVID-19 in Pregnant Women
Ritonavir	Obstetric Management of COVID-19 in Pregnant Women
Colchicina	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature
Colchicina	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature
Ocrelizumabe	Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
Plasma convalescente	Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles
Antagonistas da vitamina K (AVK)	Mortality and the use of antithrombotic therapies among nursing home residents with COVID ‐19
Anticoagulantes	Mortality and the use of antithrombotic therapies among nursing home residents with COVID ‐19
Ativador do plasminogênio tecidual (tPA)	Successful use of tPA for thrombolysis in COVID related ARDS: a case series
Hidroxicloroquina	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Lopinavir	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Tocilizumabe	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Antibióticos	Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study
Antivirais	Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study
Corticosteroides	Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study
Hidroxicloroquina	COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Lopinavir	COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Ritonavir	COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Hidroxicloroquina	Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19
Tocilizumabe	Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)
Azitromicina	An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can’t Get No) Satisfaction
Hidroxicloroquina	An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can’t Get No) Satisfaction
Corticosteroides	Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study
Ad5-nCoV	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Ad5-nCoV	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Ad5-nCoV	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Vacina ChAdOx1 nCoV-19	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Vacina ChAdOx1 nCoV-19	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Vacina ChAdOx1 nCoV-19	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Vacina de adenovírus	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Vacina de adenovírus	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Vacina de adenovírus	Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
Anakinra	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Emapalumabe	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Etanercepte	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Infliximabe	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Inibidores de proteassoma	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Micofenolato de mofetila	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Plerixafor	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Tocilizumabe	Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Vitamina D (25-hidroxivitamina D)	Strong Correlation Between Prevalence of Severe Vitamin D Deficiency and Population Mortality Rate from COVID-19 in Europe
Hidroxicloroquina	Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk
Ivermectina	Ivermectin: potential candidate for the treatment of Covid 19
Cloroquina	Janus sword actions of chloroquine and hydroxychloroquine against COVID-19
Hidroxicloroquina	Janus sword actions of chloroquine and hydroxychloroquine against COVID-19
Cloroquina	Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
Varfarina	A Case of COVID-19 Infection With Delayed Thromboembolic Complication on Warfarin
Cloroquina	Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19
Lopinavir	Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19
Oseltamivir	Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19
Ritonavir	Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19
Umifenovir	Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19
Hidroxicloroquina	Serious adverse events associated with hydroxychloroquine amidst COVID-19 pandemic: case series and literature review
Doxiciclina	Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities
Hidroxicloroquina	Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities
Corticosteroides	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Hidroxicloroquina	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Leflunomida	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Metotrexato	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Micofenolato de mofetila	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Amoxicilina	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Azitromicina	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Ceftriaxona	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Esteroides	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Hidroxicloroquina	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Lopinavir	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Ritonavir	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Tocilizumabe	Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain
Hidroxicloroquina	Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Hidroxicloroquina	Characteristics, treatment outcomes and role of hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: an epidemio-clinical study
Cloroquina	Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy
Hidroxicloroquina	Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy
Hidroxicloroquina	Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies
Hidroxicloroquina	Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies
Remdesivir	Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Cloroquina	Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
Hidroxicloroquina	Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
Antagonistas do Receptor da Angiotensina II	RAAS inhibitors do not increase the risk of COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	RAAS inhibitors do not increase the risk of COVID-19
Remdesivir	Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)
Tocilizumabe	Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)
Remdesivir	Case reports study of the first five patients COVID-19 treated with remdesivir in France
Favipiravir	Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
Nafamostato	Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
Corticosteroides	A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001
Fármaco inibidor da aldose redutase (AT-001)	A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001
Tocilizumabe	A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001
Gamaglobulina	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China
Interferon beta	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China
Lopinavir	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China
Oseltamivir	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China
Ritonavir	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China
Umifenovir	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China
Lopinavir	Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study
Ritonavir	Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study
Favipiravir	Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multicenter Observational Study
Hidroxicloroquina	Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19
Sarilumabe	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Azitromicina	Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
Hidroxicloroquina	Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
Hidroxicloroquina	Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Azitromicina	Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Hidroxicloroquina	Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Plasma convalescente	Convalescent Plasma for COVID-19. A randomized clinical trial
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 06 July 2020
Cloroquina	Hydroxychloroquine as Prophylaxis or Treatment for COVID-19: What Does the Evidence Say?
Hidroxicloroquina	Hydroxychloroquine as Prophylaxis or Treatment for COVID-19: What Does the Evidence Say?
Terapia celular	Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19
Heparina	Massive Pulmonary Thromboembolism in Patients with COVID-19; Report of Three Cases
Hidroxicloroquina	COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
Azitromicina	Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas
Hidroxicloroquina	Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas
Plasma convalescente	Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas
Tocilizumabe	Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas
Hidroxicloroquina	Effects of Hydroxychloroquine Treatment on QT Interval
Antagonistas do Receptor da Angiotensina II	Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis
Vacina BCG	BCG is a Good Immunotherapeutic Agent for Viral and Autoimmune Diseases: Is it a New Weapon against Coronavirus (COVID-19)?
Zinco	Does zinc improve symptoms of viral upper respiratory tract infection? Evidence-Based Pract
Baricitinibe	Use of Baricitinib in Patients with Moderate and Severe COVID-19
Hidroxicloroquina	Use of Baricitinib in Patients with Moderate and Severe COVID-19
Lenzilumabe	First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia
Hidroxicloroquina	Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice
Hidroxicloroquina	Severe COVID-19 Infection While on Long Standing Therapy with Hydroxychloroquine
Imatinibe	Imatinib for COVID-19: A case report
Remdesivir	Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with Pglycoprotein inhibitors
Fingolimode	Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Belatacept	Belatacept, kidney transplantation and COVID-19: successful management of the first reported case within the United Kingdom
Corticosteroides	Tratamiento y evolucion del sindrome de tormenta de citoquinas asociados a infeccion por SARS-CoV-2 en pacientes octogenários
Antagonistas do Receptor da Angiotensina II	Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Antagonistas do Receptor da Angiotensina II	Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry
Corticosteroides	Role of corticosteroid in the management of COVID-19: A systemic review and a clinician’s perspective.
Ivermectina	Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Modelos de Infecção Humana Controlada (CHIM)	Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models
Vacina de RNA	Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Vacina de RNA	Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Anti-inflamatórios não esteroidais	Coronavirus disease-19 and rheumatological disorders: A narrative review
Antirreumáticos	Coronavirus disease-19 and rheumatological disorders: A narrative review
Corticosteroides	Coronavirus disease-19 and rheumatological disorders: A narrative review
Esteroides	Coronavirus disease-19 and rheumatological disorders: A narrative review
Hidroxicloroquina	Coronavirus disease-19 and rheumatological disorders: A narrative review
Ibuprofeno	Coronavirus disease-19 and rheumatological disorders: A narrative review
Prednisolona	Coronavirus disease-19 and rheumatological disorders: A narrative review
Sulfassalazina	Coronavirus disease-19 and rheumatological disorders: A narrative review
Heparina	Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment
Heparina	Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment
Favipiravir	A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient
Tocilizumabe	A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient
Anakinra	Use of anakinra to prevent mechanical ventilation in severe COVID‐19: a case series
Hidroxicloroquina	Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatological and rheumatological patients already under treatment
Prednisona	Methylprednisolone added to tocilizumab reduces mortality in SARS‐CoV‐2 pneumonia: an observational study
Tocilizumabe	Methylprednisolone added to tocilizumab reduces mortality in SARS‐CoV‐2 pneumonia: an observational study
Hidroxicloroquina	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
Hidroxicloroquina	Association of Hydroxychloroquine with QTc Interval in Patients
Colchicina	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Colchicina	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Colchicina	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Febuxostato	Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial
Azitromicina	Associação hidroxicloroquina/ cloroquina e azitromicina para Covid-19
Cloroquina	Associação hidroxicloroquina/ cloroquina e azitromicina para Covid-19
Hidroxicloroquina	Associação hidroxicloroquina/ cloroquina e azitromicina para Covid-19
Tocilizumabe	Tocilizumabe para infecção por SARS-CoV-2 (COVID-19) Revisão sistemática rápida
Corticosteroides	Corticoides para infecção por SARS-CoV-2 (Covid-19) Revisão sistemática rápida.
Ad5-nCoV	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Ad5-nCoV	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Ad5-nCoV	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina BNT162	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina BNT162	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina BNT162	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina ChAdOx1 nCoV-19	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina ChAdOx1 nCoV-19	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina ChAdOx1 nCoV-19	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de DNA	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de DNA	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de DNA	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de RNA	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de RNA	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de RNA	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de vírus inativado	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de vírus inativado	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina de vírus inativado	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina INO-4800	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina INO-4800	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina INO-4800	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina mRNA-1273	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina mRNA-1273	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Vacina mRNA-1273	Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Remdesivir	Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
Terapia celular	Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19
Vitamina D (25-hidroxivitamina D)	A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19
Anakinra	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Antibióticos	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Azitromicina	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Hidroxicloroquina	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Lopinavir	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Prednisona	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Ritonavir	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Tocilizumabe	Pneumococcal superinfection in COVID-19 patients: a series of 5 cases
Hidroxicarbamida	Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID‐19 pneumonia
Anakinra	Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Corticosteroides	Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Imunoglobulina	Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Siltuximabe	Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Tocilizumabe	Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Ivermectina	ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19
Imunossupressores	Prior treatment with immunosuppressants among COVID‐19 inpatients at one hospital in Spain
Corticosteroides	Multisystem Inflammatory Syndrome in Children in New York State
Imunoglobulina	Multisystem Inflammatory Syndrome in Children in New York State
Estatina	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
Azitromicina	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Colchicina	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Drogas antirreumáticas modificadoras de doenças	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Hidroxicloroquina	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Inibidores de Janus Kinase (JAK)	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Prednisona	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Vacina	Ensuring Uptake of Vaccines against SARS-CoV-2
Vacina influenza	Influenza Vaccination and COVID19 Mortality in the USA
Vacina BCG	TB infection and BCG vaccination: are we protected from COVID-19?
Antagonistas do Receptor da Angiotensina II	The Association Between the Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The Association Between the Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study
Cloroquina	Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?
Hidroxicloroquina	Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?
Lopinavir	Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?
Ritonavir	Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?
Colchicina	Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis
Interferon alfa	A case series of COVID‐19 patients with chronic hepatitis B virus infection
Lopinavir	A case series of COVID‐19 patients with chronic hepatitis B virus infection
Oseltamivir	A case series of COVID‐19 patients with chronic hepatitis B virus infection
Ritonavir	A case series of COVID‐19 patients with chronic hepatitis B virus infection
Umifenovir	A case series of COVID‐19 patients with chronic hepatitis B virus infection
Ruxolitinibe	Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis
Ruxolitinibe	Ruxolitinib for Tocilizumab-Refractory Severe COVID-19 Infection
Tocilizumabe	Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome
Prednisona	A case of erythema multiforme major in a patient with COVID 19: The role of corticosteroid treatment
Plasma convalescente	Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery
Heparina	A case of Covid-19 patient with acute limb ischemia and heparin resistance
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study
Azitromicina	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Hidroxicloroquina	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Azitromicina	QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection
Hidroxicloroquina	QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection
Cloroquina	Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review
Hidroxicloroquina	Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review
Cloroquina	Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world
Hidroxicloroquina	Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world
Vacina ChAdOx1 nCoV-19	Covid-19: Oxford team begins vaccine trials in Brazil and South Africa to determine efficacy
Lopinavir	Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
Ritonavir	Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
Dexametasona	Short-Term Dexamethasone in Sars-CoV-2 Patients
Ruxolitinibe	Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
Tocilizumabe	Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia
Plasma convalescente	Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest
Anakinra	Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
Prednisona	Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia
Plasma convalescente	Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study
Azitromicina	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study
Lopinavir	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study
Naproxeno	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study
Prednisolona	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study
Ritonavir	The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study
Tocilizumabe	Tocilizumab for treatment of mechanically ventilated patients with COVID-19
Tocilizumabe	Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Eculizumabe	Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
Ruxolitinibe	Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 24 June 2020
Terapia celular	SARS-CoV-2 infection and stem cells: Interaction and intervention.
Corticosteroides	Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic.
Tocilizumabe	Tocilizumab’s efficacy in COVID-19 patients is determined by the presence of cytokine storm.
Tocilizumabe	Tocilizumab’s efficacy in COVID-19 patients is determined by the presence of cytokine storm.
Anakinra	Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. Rheumatology.
Ixequizumab	Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Rituximabe	Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis
Tocilizumabe	Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab
Interferon alfa	Clinical features and the treatment of children with COVID-19: A case series from Wenzhou, China
Lopinavir	A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Prednisona	A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Ritonavir	A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Tocilizumabe	A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Azitromicina	Bradycardia in Patients With COVID-19: A Calm Before the Storm?
Dexmedetomidina	Bradycardia in Patients With COVID-19: A Calm Before the Storm?
Hidroxicloroquina	Bradycardia in Patients With COVID-19: A Calm Before the Storm?
Propofol	Bradycardia in Patients With COVID-19: A Calm Before the Storm?
Acitretina	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Adalimumabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Apremilast	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Brodalumabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Certolizumabe Pegol	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Ciclosporina	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Etanercepte	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Guselkumabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Infliximabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Ixequizumab	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Metotrexato	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Risankizumabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Secuquinumabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Ustekinumabe	Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19
Plasma convalescente	Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion
Metformina	Observational Study of Metformin and Risk of Mortality in Persons Hospitalized with Covid-19
Dexametasona	Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
Hidroxicloroquina	Pre exposure Hydroxychloroquine Prophylaxis for COVID-19 in healthcare workers: a retrospective cohort
Corticosteroides	Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis
Vacina BCG	BCG Vaccination in infancy does not protect against COVID‐19. Evidence from a natural experiment in Sweden
Cloroquina	Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.
Hidroxicloroquina	Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.
Inibidores de interleucina-6	Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.
Plasma convalescente	Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.
Remdesivir	Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.
Hidroxicloroquina	Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
Plasma convalescente	Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
Cloreto de sódio	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Ganciclovir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Lianhua Qingwen (Medicina Tradicional Chinesa)	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Lopinavir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Oseltamivir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Penciclovir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Peramivir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Ribavirina	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Ritonavir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Umifenovir	Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.
Cloroquina	Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population.
Hidroxicloroquina	Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population.
Tocilizumabe	Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab – A Case- Controlled Study.
Cloroquina	Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study.
Hidroxicloroquina	Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study.
Vacina	Vaccine development and therapeutic design for 2019‐ncov/SARS‐cov‐2: challenges and chances.
Tocilizumabe	A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
Heparina	Coagulopathy, thromboembolic complications and the use of heparin in COVID-19 Pneumonia,
Tocilizumabe	Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes.
Corticosteroides	COVID-19 in patients with rheumatic diseases in northern Italy : a single-centre observational and case – control study.
Drogas antirreumáticas modificadoras de doenças	COVID-19 in patients with rheumatic diseases in northern Italy : a single-centre observational and case – control study.
Hidroxicloroquina	Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.
Clozapina	Clozapine treatment and risk of COVID-19.
Antagonistas do Receptor da Angiotensina II	Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Hidroxicloroquina	Effect of hydroxychloroquine on SARS-CoV-2 viral load in patients with COVID-19.
Lopinavir	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Ritonavir	Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Antitrombina	Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.
Ativador do plasminogênio tecidual (tPA)	Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.
Clopidogrel	Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.
Heparina	Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.
Hidroxicloroquina	Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.
Cloroquina	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Cloroquina	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Hidroxicloroquina	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Hidroxicloroquina	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Plasma convalescente	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Plasma convalescente	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Remdesivir	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Remdesivir	Vaccines and Therapies in Development for SARS-CoV-2 Infections
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 22 June 2020.
Heparina	Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy.
Nafamostato	Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Plasma convalescente	Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.
Cefoperazona	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Imunoglobulina	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Lopinavir	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Moxifloxacina	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Oseltamivir	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Prednisona	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Ritonavir	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Zadaxina	Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.
Heparina	A child with a severe multi-system inflammatory syndrome following an asymptomatic COVID-19 infection: a novel management for a new disease?
Prednisona	A child with a severe multi-system inflammatory syndrome following an asymptomatic COVID-19 infection: a novel management for a new disease?
Lopinavir	COVID-19 in a young man with hypertension: A case study of missed opportunities in intensive progression.
Moxifloxacina	COVID-19 in a young man with hypertension: A case study of missed opportunities in intensive progression.
Oseltamivir	COVID-19 in a young man with hypertension: A case study of missed opportunities in intensive progression.
Prednisona	GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia.
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 18 June 2020.
Antagonistas de TNF	COVID-19 in patients with rheumatological diseases treated with anti-TNF.
Azitromicina	COVID-19 in patients with rheumatological diseases treated with anti-TNF.
Corticosteroides	COVID-19 in patients with rheumatological diseases treated with anti-TNF.
Lenzilumabe	Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Tocilizumabe	Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.
Omalizumabe	COVID-19 in a patient with severe asthma treated with Omalizumab.
Hidroxicloroquina	Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19
Amantadina	Use of amantadine in a patient with SARS‐Cov‐2.
Amantadina	Use of amantadine in a patient with SARS‐Cov‐2.
Hidroxicloroquina	Hydroxychloroquine treatment in COVID‐19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China.
Tocilizumabe	Tocilizumab in patients with severe COVID-19: a single-center observational analysis.
Corticosteroides	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Hidroxicloroquina	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Leflunomida	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Metotrexato	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Oxigenoterapia	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Prednisolona	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Prednisona	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Talidomida	"Clinical characteristics of 17 patients with COVID-19
and systemic autoimmune diseases: a
retrospective study."
Cloroquina	Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
Cloroquina	Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
Cloroquina	Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
Hidroxicloroquina	Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
Hidroxicloroquina	Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
Hidroxicloroquina	Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19
Plasma convalescente	Uso de plasma de pacientes recuperados no tratamento de COVID-19. Revisão sistemática rápida.
Remdesivir	Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic Review.
Vacina de RNA	Amplifying RNA Vaccine Development.
Hidroxicloroquina	Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Lopinavir	Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Ritonavir	Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Hidroxicloroquina	Hydroxychloroquine for covid-19: the end of the line?
Baricitinibe	Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.
Antimaláricos	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.
Antivirais	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.
Óxido nítrico	Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.
Hidroxicloroquina	Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Interferon beta	Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Lopinavir	Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Ritonavir	Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
Antibióticos	Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19.
Interferon alfa	Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19.
Medicina Tradicional Chinesa	Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19.
Tocilizumabe	Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late.
Mavrilimumabe	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.
Interferon beta	Subcutaneous administrationof interferon beta-1a for COVID-19: A noncontrolled prospective trial.
Azitromicina	The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study.
Lincocin	The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study.
Heparina	Heparina para Covid-19. Revisão sistemática rápida.
Antagonistas do Receptor da Angiotensina II	Eficácia, segurança e prognóstico associados ao uso de Inibidores da Enzima Conversora de Angiotensina (IECA) e Bloqueadores do Receptor de Angiotensina 2 (BRA) para COVID-19. Revisão sistemática rápida.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Eficácia, segurança e prognóstico associados ao uso de Inibidores da Enzima Conversora de Angiotensina (IECA) e Bloqueadores do Receptor de Angiotensina 2 (BRA) para COVID-19. Revisão sistemática rápida.
Vacinas	DRAFT landscape of COVID-19 candidate vaccines - 16 June 2020
Vacina BCG	Explore the Possible Impact of BCG Vaccination Policy on the Morbidity, Mortality, and Recovery Rates due to COVID-19 Infection.
Dexametasona	"Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe
respiratory complications of COVID-19"
Vacina de DNA	Vaccination strategies to combat novel corona virus SARS-CoV-2.
Vacina de RNA	Vaccination strategies to combat novel corona virus SARS-CoV-2.
Anticorpos	Monoclonal Antibodies for Prevention and Treatment of COVID-19.
Plasma convalescente	Convalescent Plasma and COVID-19.
Remdesivir	Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir.
Hidroxicloroquina	Hydroxychloroquine-Induced Stevens-Johnson Syndrome in COVID-19: A rare Case Report.
Plasma convalescente	Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors.
Azitromicina	Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
Remdesivir	Flight of the COVID-19 patient: experience with a Wuhan evacuee: a case report.
Imunoglobulina	Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.
Ceftriaxona	A Case Series of Patients Coinfected With Influenza and COVID-19.
Hidroxicloroquina	A Case Series of Patients Coinfected With Influenza and COVID-19.
Oseltamivir	A Case Series of Patients Coinfected With Influenza and COVID-19.
Prednisona	Can steroids reverse the severe COVID-19 induced 'cytokine storm'?
OncoTherad	A 78-year Old Urothelial Cancer Patient with Faster Recovery from COVID-19: Potential Benefit from Adjuvant Active Immunotherapy.
Natalizumabe	COVID-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role?
Corticosteroides	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.
Imunoglobulina	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.
Interferon alfa	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.
Lopinavir	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.
Oseltamivir	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.
Ritonavir	Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Association between renin-angiotensin system inhibitors and COVID-19 complications.
Corticosteroides	Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2.
Tocilizumabe	Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2.
Ciclosporina	Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?
Lopinavir	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.
Ritonavir	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.
Vacina	COVID-19 vaccines for all?
Vacina de vírus inativado	Can existing live vaccines prevent COVID-19?
Vacina de vírus inativado	Can existing live vaccines prevent COVID-19?
Vacina de vírus inativado	Can existing live vaccines prevent COVID-19?
Vacinas	DRAFT landscape of COVID-19 candidate vaccines - 9 June 2020
Terapia celular	Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Heparina	Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.
Amoxicilina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Azitromicina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Betametasona	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Ceftriaxona	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Cloroquina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Estatina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Heparina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Hidroxicloroquina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Interferon	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Lopinavir	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Metformina	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Pioglitazona	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Plasma convalescente	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Remdesivir	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Ritonavir	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Tocilizumabe	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review
Plasma convalescente	Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns.
Heparina	Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
Benralizumabe	COVID-19 in a severe eosinophilic asthmatic receiving benralizumab – a case study.
Zinco	Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients
Ruxolitinibe	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Antibióticos	Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.
Interferon alfa	Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.
Medicina Tradicional Chinesa	Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.
Imunoglobulina	Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.
Antibióticos	Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review.
Hidroxicloroquina	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review.
Agentes para tratamento da insuficiência venosa	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Agentes para tratamento da insuficiência venosa	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Anti-inflamatórios	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Anti-inflamatórios	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antibióticos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antibióticos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Anticoagulantes	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Anticoagulantes	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antimaláricos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antimaláricos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antineoplásicos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antineoplásicos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antirretrovirais	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antirretrovirais	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antirreumáticos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Antirreumáticos	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Carrimicina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Carrimicina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Cloroquina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Cloroquina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Danoprevir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Danoprevir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Hidroxicloroquina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Hidroxicloroquina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Inibidor da fosfodiesterase	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Inibidor da fosfodiesterase	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Lopinavir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Lopinavir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Remdesivir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Remdesivir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Ritonavir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Ritonavir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Sedativo-hipnótico	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Sedativo-hipnótico	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Tetrandrina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Tetrandrina	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Umifenovir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Umifenovir	The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Terapia celular	MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
Heparina	COVID-19 related coagulopathy: a distinct entity?
Vacina ChAdOx1 nCoV-19	The Current Update of Vaccines for SARS-CoV-2.
Vacina Curevac	The Current Update of Vaccines for SARS-CoV-2.
Vacina de adenovírus	The Current Update of Vaccines for SARS-CoV-2.
Vacina de DNA	The Current Update of Vaccines for SARS-CoV-2.
Vacina de RNA	The Current Update of Vaccines for SARS-CoV-2.
Vacina INO-4800	The Current Update of Vaccines for SARS-CoV-2.
Vacina mRNA-1273	The Current Update of Vaccines for SARS-CoV-2.
Vacina NVX-CoV2373	The Current Update of Vaccines for SARS-CoV-2.
Corticosteroides	A case of Bacillus cereus bacteremia in a COVID-19 patient treated with steroids.
Argatrobana	Anticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID -19.
Tocilizumabe	Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study.
Tocilizumabe	Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.
Interferon alfa	Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience.
Tocilizumabe	Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study.
Anti-inflamatórios não esteroidais	Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs tested positive for SARS-CoV-2: a danish nationwide cohort study.
Nitazoxanida	Nitazoxanida no tratamento de covid-19. Revisão sistemática rápida.
Vacina	COVID-19 vaccine development pipeline gears up.
Agentes anti-interleucinas	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Agentes anti-interleucinas	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Agentes anti-interleucinas	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anti-inflamatórios	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anti-inflamatórios	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anti-inflamatórios	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anticoagulantes	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anticoagulantes	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anticoagulantes	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Antiplaquetários	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Antiplaquetários	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Antiplaquetários	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Antivirais	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Antivirais	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Antivirais	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Imunomoduladores	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Imunomoduladores	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Imunomoduladores	Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19
Anakinra	Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
Corticosteroides	Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
Imunoglobulina	Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
Infliximabe	Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.
Corticosteroides	Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City
Imunoglobulina	Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City
Tocilizumabe	Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City
Antagonistas do Receptor da Angiotensina II	Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.
Tocilizumabe	Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
Vitamina D (25-hidroxivitamina D)	Association of Vitamin D Deficiency and Treatment with COVID-19 Incidence.
Umifenovir	A study on clinical effect of Arbidol combined with adjuvant therapy on COVID‐19.
Almitrina	Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome
Azitromicina	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Corticosteroides	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Hidroxicloroquina	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Interferon	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Lopinavir	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Moxifloxacina	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Oseltamivir	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Remdesivir	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Ribavirina	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Ritonavir	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Umifenovir	Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1
Cloroquina	Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis.
Hidroxicloroquina	Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis.
Antagonistas do Receptor da Angiotensina II	Association of Renin-Angiotensin-Aldosterone System Inhibition with Risk of COVID-19, Inflammation Level, Severity and Death in Patients With COVID-19: A Rapid Systematic Review and Meta-Analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of Renin-Angiotensin-Aldosterone System Inhibition with Risk of COVID-19, Inflammation Level, Severity and Death in Patients With COVID-19: A Rapid Systematic Review and Meta-Analysis.
Tocilizumabe	Tocilizumabe para infecção por SARS-CoV-2 (COVID-19) Revisão sistemática rápida.
Antagonistas do Receptor da Angiotensina II	Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis.
Antagonistas do Receptor da Angiotensina II	Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis.
Cobre	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Cobre	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Colchicina	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Colchicina	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Molnupiravir	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Molnupiravir	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
N-acetilcisteína	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
N-acetilcisteína	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Óxido nítrico	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Óxido nítrico	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Remdesivir	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Remdesivir	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Danoprevir	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
Lopinavir	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
Ritonavir	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
Interferon alfa	Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Lopinavir	Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Ritonavir	Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Umifenovir	Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Cloroquina	Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Gamaglobulina	Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Prednisona	Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Tocilizumabe	Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Umifenovir	Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Prednisolona	High‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series. Respirology Case Reports.
Prednisona	High‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series. Respirology Case Reports.
Tocilizumabe	Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
Famotidina	Famotidine use and quantitative symptom tracking for COVID-19 in non- hospitalised patients: a case series.
Famotidina	Famotidine use and quantitative symptom tracking for COVID-19 in non- hospitalised patients: a case series.
Imunoglobulina	Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report.
Prednisona	Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report.
Umifenovir	Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report.
Tocilizumabe	Tocilizumab administration in a refractory case of COVID-19.
Vacina BCG	A shred of evidence that BCG vaccine may protect against COVID-19: Comparing cohorts in Spain and Italy.
Tocilizumabe	Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection.
Vacina BCG	Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.
Vacina BCG	Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.
Vacina influenza	Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.
Vacina influenza	Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.
Vacina pneumocócica	Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.
Vacina pneumocócica	Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.
Ozonioterapia	Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study.
Antibióticos	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Azitromicina	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Cloroquina	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Cobicistato	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Darunavir	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Enoxaparina	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Hidroxicloroquina	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Lopinavir	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Prednisona	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Remdesivir	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Ribavirina	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Ritonavir	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Tocilizumabe	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.
Azitromicina	A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Hidroxicloroquina	A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
Ácido ascórbico	Anticardiolipin antibodies and COVID-19 - A Case Report from America.
Azitromicina	Anticardiolipin antibodies and COVID-19 - A Case Report from America.
Ceftriaxona	Anticardiolipin antibodies and COVID-19 - A Case Report from America.
Enoxaparina	Anticardiolipin antibodies and COVID-19 - A Case Report from America.
Hidroxicloroquina	Anticardiolipin antibodies and COVID-19 - A Case Report from America.
Canaquinumabe	Canakinumab in subgroup of patients with COVID-19.
Tocilizumabe	Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.
Prednisona	Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
Talidomida	Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
Hidroxicloroquina	HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern
Antagonistas do Receptor da Angiotensina II	Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.
Lopinavir	Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
Ritonavir	Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
Azitromicina	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
Hidroxicloroquina	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
Cloroquina	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Favipiravir	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Hidroxicloroquina	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Interferon	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Lopinavir	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Ribavirina	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Ritonavir	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Umifenovir	Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Tocilizumabe	Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Ivermectina	USO DE IVERMECTINA PARA EL TRATAMIENTO DE PACIENTES ADULTOS CON COVID-19
Corticosteroides	Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.
Favipiravir	Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
Plasma convalescente	Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
Tocilizumabe	Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.
Plasma convalescente	The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.
Remdesivir	The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.
Remdesivir	Remdesivir and Tocilizumab: Mix or Match.
Tocilizumabe	Remdesivir and Tocilizumab: Mix or Match.
Interferon	Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
Lopinavir	Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
Ritonavir	Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
Interferon	COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.
Oseltamivir	COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.
Ribavirina	COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.
Umifenovir	COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.
Plasma convalescente	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial
Hidroxicloroquina	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Hidroxicloroquina	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Agentes imunológicos	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Agentes imunológicos	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Anticorpos	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Anticorpos	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
ASC09F	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
ASC09F	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Azivudina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Azivudina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Baloxavir marboxil	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Baloxavir marboxil	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Cloroquina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Cloroquina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Corticosteroides	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Corticosteroides	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Danoprevir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Danoprevir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Darunavir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Darunavir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Favipiravir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Favipiravir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Interferon	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Interferon	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Lopinavir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Lopinavir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Oxigenação por membrana extracorpórea (ECMO)	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Oxigenação por membrana extracorpórea (ECMO)	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Oxigenoterapia	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Oxigenoterapia	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Plasma convalescente	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Plasma convalescente	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Ribavirina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Ribavirina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Ritonavir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Ritonavir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Sangue do cordão umbilical	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Sangue do cordão umbilical	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia celular	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia celular	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia de inalação hidrogênio-oxigênio	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia de inalação hidrogênio-oxigênio	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia de inalação óxido nítrico	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia de inalação óxido nítrico	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia psicológica	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Terapia psicológica	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Triazavirina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Triazavirina	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Umifenovir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Umifenovir	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Vitaminas	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Vitaminas	Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.
Cloroquina	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Corticosteroides	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Hidroxicloroquina	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Imunoglobulina	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Tocilizumabe	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Anti-inflamatórios não esteroidais	COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.
Corticosteroides	Use of corticosteroids in asthma and COPD patients with or without COVID-19.
Corticosteroides	Use of corticosteroids in asthma and COPD patients with or without COVID-19.
Tocilizumabe	Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients.
Rituximabe	Persisting SARS-CoV-2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature.
Dexmedetomidina	Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A case report.
Ciclosporina	Covid-19 infection in psoriasis patients treated with cyclosporin.
Tocilizumabe	Feasibility of Tocilizumab in ICU patients with COVID-19.
Leflunomida	Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study.
Azitromicina	Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.
Hidroxicloroquina	Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.
Tocilizumabe	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
Corticosteroides	Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.
Cloroquina	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Hidroxicloroquina	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Interferon	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Lopinavir	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Remdesivir	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Ribavirina	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Ritonavir	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Umifenovir	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Favipiravir	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Hidroxicloroquina	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Lopinavir	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Meplazumabe	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Remdesivir	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Ritonavir	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Tocilizumabe	A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.
Cloroquina	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials.
Cloroquina	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials.
Hidroxicloroquina	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials.
Hidroxicloroquina	Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials.
Cloroquina	Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
Hidroxicloroquina	Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence
Antimaláricos	Trials and tribulations: so many potential treatments, so few answers
Tocilizumabe	COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Tocilizumabe	COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Tocilizumabe	COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Cloroquina	Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.
Tocilizumabe	Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.
Azitromicina	Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring
Hidroxicloroquina	Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring
Tocilizumabe	First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19.
Tocilizumabe	Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2.
Prednisona	Successful use of methylprednisolone for treating severe COVID-19.
Nafamostato	Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.
Heparina	The association between treatment with heparin and survival in patients with Covid-19.
Heparina	The association between treatment with heparin and survival in patients with Covid-19.
Umifenovir	Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission—A Preliminary Report of a Retrospective Cohort Study.
Azitromicina	Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.
Hidroxicloroquina	Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.
Lopinavir	Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.
Ritonavir	Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.
Profilaxia para tromboembolismo	Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
Remdesivir	Remdesivir para infecção por SARS-CoV-2 (COVID-19). Revisão sistemática.
Remdesivir	Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
Corticosteroides	Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient
Terapia celular	Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
Plasma convalescente	Treatment of COVID-19 Patients with Convalescent Plasma
Azitromicina	A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois
Cefalosporina	A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois
Hidroxicloroquina	A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois
Lopinavir	Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
Ritonavir	Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
Ácido acetilsalicílico	Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study
Anticoagulantes	Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study
Azitromicina	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
Hidroxicloroquina	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
Lopinavir	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
Ritonavir	Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
Anakinra	Anakinra for severe forms of COVID-19 : a cohort study
Antagonistas do Receptor da Angiotensina II	COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome
Ruxolitinibe	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, singleblind, randomized controlled trial
Ramipril	Ramipril in High Risk Patients with COVID-19
Cloroquina	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review
Cloroquina	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review
Hidroxicloroquina	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review
Hidroxicloroquina	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review
Terapia celular	Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome
Remdesivir	Remdesivir para el tratamiento de infeccion por Covid-19. Informe de Revisión Rápida
Hidroxicloroquina	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease‑19 (COVID‑19)
Cloroquina	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Favipiravir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Interferon	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Lopinavir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Oseltamivir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Remdesivir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Ribavirina	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Ritonavir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Sofosbuvir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Umifenovir	Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
Azitromicina	Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis
Hidroxicloroquina	Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis
Remdesivir	Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis
Zinco	Can Zn Be a Critical Element in COVID-19 Treatment?
Atazanavir	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Cloroquina	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Hidroxicloroquina	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Ivermectina	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Lopinavir	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Remdesivir	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Ritonavir	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Tocilizumabe	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments
Vacina BCG	Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
Plasma convalescente	Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma
Peginterferon alfa 2a	Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
Inibidores da DPP-4	Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes.
Azitromicina	QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
Azitromicina	QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
Hidroxicloroquina	QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
Hidroxicloroquina	QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin
Ácido acetilsalicílico	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Brometo de ipratrópio	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Claritromicina	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Ibuprofeno	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Interferon alfa	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Naproxeno	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Oseltamivir	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Paracetamol	Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence
Azitromicina	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Favipiravir	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Ganciclovir	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Heparina	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Hidroxicloroquina	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Imunoglobulina	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Interferon alfa-beta	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Lopinavir	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Moxifloxacina	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Oseltamivir	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Prednisona	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Ribavirina	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Ritonavir	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Umifenovir	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Profilaxia para tromboembolismo	Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID‐19
hzVSF-v13	Compassionate use of hzVSF-v13 in two patients with severe COVID-19
Azitromicina	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Cefditoren	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Ceftriaxona	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Hidroxicloroquina	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Interferon beta	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Lopinavir	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Prednisona	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Ritonavir	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Tocilizumabe	A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics
Rituximabe	Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab
Corticosteroides	Early tocilizumab treatment could improve survival among COVID-19 patients
Tocilizumabe	Early tocilizumab treatment could improve survival among COVID-19 patients
Hidroxicloroquina	COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults
Lopinavir	"Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a
 2 retrospective cohort study"
Ritonavir	"Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a
 2 retrospective cohort study"
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Remdesivir	Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature
Antagonistas do Receptor da Angiotensina II	Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis
Cloroquina	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review
Cloroquina	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review
Hidroxicloroquina	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review
Hidroxicloroquina	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review
Cloroquina	A review on possible modes of actions of Chloroquine / Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
Cloroquina	A review on possible modes of actions of Chloroquine / Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
Hidroxicloroquina	A review on possible modes of actions of Chloroquine / Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
Hidroxicloroquina	A review on possible modes of actions of Chloroquine / Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
Azitromicina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Cloroquina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Cobicistato	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Elvitegravir	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Emtricitabina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Enoxaparina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Gentamicina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Levofloxacina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Meropenem	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Oseltamivir	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Piperacilina-tazobactam	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Tenofovir	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Vancomicina	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus
Hidroxicloroquina	Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed
Terapia celular	Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury
Prednisona	Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review
Plasmaferese	Efficacy of therapeutic plasma exchange in severe COVID-19 patients
Apremilast	Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient
Esteroides	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab
Hidroxicloroquina	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab
Lopinavir	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab
Ritonavir	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab
Tocilizumabe	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab
Tocilizumabe	Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
Cloroquina	COVID-19 and systemic lupus erythematosus: a case series
Esteroides	COVID-19 and systemic lupus erythematosus: a case series
Hidroxicloroquina	COVID-19 and systemic lupus erythematosus: a case series
Imunossupressores	COVID-19 and systemic lupus erythematosus: a case series
Ácido acético	Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19
Corticosteroides	Impact of glucocorticoid treatment in Sars-CoV-2 infection mortality: a retrospective controlled Cohort Study
Antagonistas do Receptor da Angiotensina II	Renin-angiotensin-aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID19: systematic review &meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-angiotensin-aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID19: systematic review &meta-analysis
Corticosteroides	Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis
Hidroxicloroquina	Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis
Lopinavir	Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis
Remdesivir	Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis
Ritonavir	Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis
Antagonistas do Receptor da Angiotensina II	Use of inhibitors of the renin angiotensin system and COVID-19 prognosis: a systematic review and meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Use of inhibitors of the renin angiotensin system and COVID-19 prognosis: a systematic review and meta-analysis
Hidroxicloroquina	Dermatologic manifestations of hydroxychloroquine therapy: a closer look at the nails
Ozonioterapia	A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19
Corticosteroides	COVID-19 and Liver Transplantation: lessons learned from three reported cases
Imunossupressores	COVID-19 and Liver Transplantation: lessons learned from three reported cases
Tocilizumabe	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients
Metformina	Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis
Hidroxicloroquina	Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study
Tocilizumabe	Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study
Azitromicina	Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
Hidroxicloroquina	Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
Interferon alfa	Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study
Umifenovir	Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study
Plasma convalescente	Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis
Plasma convalescente	Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis
Plasma convalescente	Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis
Plasma convalescente	Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis
Anakinra	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Plasma convalescente	Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases
Remdesivir	Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19
Remdesivir	Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19
Vacina	COVID-19 vaccines: knowing the unknown
Vacina	COVID-19 vaccines: knowing the unknown
Antibióticos	Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
Antivirais	Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
Corticosteroides	Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
Imunomoduladores	Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
Medicamentos sintomáticos de suporte	Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
Medicina tradicional chinesa	Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019
Azitromicina	COVID-19 and QT interval prolongation: more than just drug toxicity?
Hidroxicloroquina	COVID-19 and QT interval prolongation: more than just drug toxicity?
Heparina	Heparin resistance in COVID-19 patients in the intensive care unit
Azitromicina	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Cefalosporina	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Interferon alfa-beta	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Medicina Tradicional Chinesa	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Oseltamivir	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Ribavirina	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Umifenovir	Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes
Tocilizumabe	Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy [published online ahead of print
Antagonistas do Receptor da Angiotensina II	Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Remdesivir	Remdesivir for the Treatment of Covid-19 — Preliminary Report
Cloroquina	Hidroxicloroquina e cloroquina para Covid-19. Revisão sistemática rápida
Hidroxicloroquina	Hidroxicloroquina e cloroquina para Covid-19. Revisão sistemática rápida
Antibióticos	Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis
Antivirais	Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis
Corticosteroides	Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis
Oxigenoterapia	Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis
Cloroquina	QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review
Cloroquina	QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review
Hidroxicloroquina	QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review
Hidroxicloroquina	QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review
Hidroxicloroquina	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Hidroxicloroquina	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Hidroxicloroquina	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Hidroxicloroquina	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Hidroxicloroquina	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Lopinavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Lopinavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Lopinavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Lopinavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Lopinavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Remdesivir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Remdesivir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Remdesivir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Remdesivir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Remdesivir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Ritonavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Ritonavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Ritonavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Ritonavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Ritonavir	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Tocilizumabe	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Tocilizumabe	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Tocilizumabe	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Tocilizumabe	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Tocilizumabe	A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
Anakinra	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
Canaquinumabe	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
Etanercepte	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
Infliximabe	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
Terapia celular	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
Tocilizumabe	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy
Lopinavir	Hepatic complications of COVID‐19 and its treatment
Ritonavir	Hepatic complications of COVID‐19 and its treatment
Umifenovir	Hepatic complications of COVID‐19 and its treatment
Plasma convalescente	Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19
Vacina ChAdOx1 nCoV-19	ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
Vacina ChAdOx1 nCoV-19	ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
Imunomoduladores	The immunology of COVID-19: is immune modulation an option for treatment?
Cloroquina	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Corticosteroides	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Heparina	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Hidroxicloroquina	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Lopinavir	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Plasma convalescente	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Remdesivir	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Ritonavir	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Terapia celular	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Tocilizumabe	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Umifenovir	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Corticosteroides	Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019
Corticosteroides	Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019
Corticosteroides	Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019
Corticosteroides	Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019
Ativador do plasminogênio tecidual (tPA)	Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report
Oxigenação por membrana extracorpórea (ECMO)	Extracorporeal Membrane Oxygenation as Treatment of Severe COVID-19 Infection: A Case Report
Baricitinibe	Baricitinib: a chance to treat COVID‐19?
Fingolimode	COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Hidroxicloroquina	COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Oseltamivir	COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Piperacilina-tazobactam	COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Ativador do plasminogênio tecidual (tPA)	Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases
Insulina	Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control?
Cloroquina	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hidroxicloroquina	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Macrolídeos	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Lopinavir	Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
Ritonavir	Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
Anticoagulantes	SARS2-CoV-2 and Stroke in a New York Healthcare System
Corticosteroides	Adjuvant corticosteroid therapy for critically ill patients with COVID-19
Inibidores da BRAF	Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients
Inibidores da MEK	Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients
Inibidores de PD-1	Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients
Ad5-nCoV	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Hidroxicloroquina	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence
Hidroxicloroquina	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence
Tocilizumabe	Clinical Outcomes in COVID-19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review
Hidroxicloroquina	Hydroxychloroquine for COVID-19: A review and a debate based on available clinical trials/case studies
Antagonistas do Receptor da Angiotensina II	COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
Ibuprofeno	COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
Heparina	Thrombotic risk in COVID-19: a case series and case–control study
Furoato de mometasona	Therapy for probable COVID-19 associated erythema pernio-like lesions in pediatric age. Case report
Heparina	Therapy for probable COVID-19 associated erythema pernio-like lesions in pediatric age. Case report
Ácido acetilsalicílico	Pericarditis aguda secundaria a COVID-19
Azitromicina	Pericarditis aguda secundaria a COVID-19
Colchicina	Pericarditis aguda secundaria a COVID-19
Interferon beta	Pericarditis aguda secundaria a COVID-19
Lopinavir	Pericarditis aguda secundaria a COVID-19
Ritonavir	Pericarditis aguda secundaria a COVID-19
Imunoglobulina	Successful Intravenous Immunoglobulin Treatment in Severe COVID-19 Pneumonia
Interferon beta	Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Angiotensina II	Effective Use of Angiotensin II in Coronavirus Disease 19–Associated Mixed Shock State: A Case Report
Alteplase	Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series
Albuterol	Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically 2 ventilated COVID-19 patients: A case series
Dornase alfa	Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically 2 ventilated COVID-19 patients: A case series
Antagonistas de TNF	The potential role of TNFα in 2019 novel coronavirus pneumonia
Antagonistas de TNF	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Azatioprina	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Corticosteroides	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Mercaptopurina	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Metotrexato	Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
Antagonistas do Receptor da Angiotensina II	Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome
Antivirais	Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome
Heparina	Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome
Tocilizumabe	Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
Antibióticos	Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
Hidroxicloroquina	Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
Lopinavir	Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
Ritonavir	Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
Magnésio	The Effect of Potential Therapeutic Agents on QT Interval in Patients With COVID-19 Infection: The Importance of Close Monitoring and Correction of Electrolytes
Potássio	The Effect of Potential Therapeutic Agents on QT Interval in Patients With COVID-19 Infection: The Importance of Close Monitoring and Correction of Electrolytes
Corticosteroides	Early Short Course Corticosteroids in Hospitalized Patients with COVID-19
Azitromicina	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
Hidroxicloroquina	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
Zinco	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
Ácido alfa lipóico	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Cloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Corticosteroides	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Danoprevir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Darunavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Favipiravir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Heparina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Hidroxicloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Interferon alfa	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Ivermectina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Lopinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Meplazumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Nelfinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Plasma convalescente	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Remdesivir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Ritonavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Siltuximabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Tocilizumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Umifenovir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020
Lopinavir	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Oseltamivir	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Prednisona	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Ritonavir	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Umifenovir	A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients
Favipiravir	Antivirals for COVID-19
Lopinavir	Antivirals for COVID-19
Oseltamivir	Antivirals for COVID-19
Remdesivir	Antivirals for COVID-19
Ritonavir	Antivirals for COVID-19
Umifenovir	Antivirals for COVID-19
Plasma convalescente	Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Anti-inflamatórios não esteroidais	Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection
Cloroquina	Chloroquine and hydroxychloroquine during pregnancy: What do we know?
Hidroxicloroquina	Chloroquine and hydroxychloroquine during pregnancy: What do we know?
Vitamina D (25-hidroxivitamina D)	Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease
Antimaláricos	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Azitromicina	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Colchicina	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Favipiravir	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Interferon	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Lopinavir	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Oseltamivir	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Remdesivir	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Ribavirina	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Ritonavir	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Umifenovir	Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs
Antibióticos	Recovery from COVID-19 in two patients with coexisted HIV infection
Oseltamivir	Recovery from COVID-19 in two patients with coexisted HIV infection
Ribavirina	Recovery from COVID-19 in two patients with coexisted HIV infection
Umifenovir	Recovery from COVID-19 in two patients with coexisted HIV infection
Ampicilina	Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?
Anti-inflamatórios não esteroidais	Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?
Claritromicina	Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?
Levofloxacina	Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?
Prednisolona	Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?
Sulbactam	Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?
Corticosteroides	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Heparina	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Interferon alfa	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Lopinavir	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Medicina Tradicional Chinesa	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Prednisona	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Ritonavir	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Timosina	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Ventilação não invasiva precoce	COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report
Inibidor de IL-1β	Precision Medicine in COVID-19: IL-1β a Potential Target
Oxigenação por membrana extracorpórea (ECMO)	Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series
Anakinra	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
Anakinra	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
Remdesivir	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
Remdesivir	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report
Lopinavir	Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
Ritonavir	Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
Azitromicina	‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Cloroquina	‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Hidroxicloroquina	‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Lopinavir	‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Ritonavir	‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers
Terapia celular	Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects
Imunoglobulina	Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic
Anticorpos	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
Corticosteroides	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
Imunoglobulina	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
Interferon recombinante tipo 1	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
Plasma convalescente	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
Tocilizumabe	Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids
Inibidores de interleucina-6	SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc
Terapia celular	Is COVID-19 a New Hematologic Disease?
Antagonistas do Receptor da Angiotensina II	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Antiarrítmicos	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Antifúngicos	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Azitromicina	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Corticosteroides	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Levofloxacina	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Lopinavir	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Moxifloxacina	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Prednisona	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Remdesivir	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Ritonavir	Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases
Anti-histamínicos	A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?
Antibióticos	A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?
Anticoagulantes	A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?
Antivirais	A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?
Esteroides	A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?
Tocilizumabe	Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report
Dupilumabe	COVID-19 infection in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab
Remdesivir	Early experience with remdesivir in SARS-CoV-2 pneumonia
Prednisona	Coronavirus disease 2019 in renal transplant recipients: report of two cases
Corticosteroides	Coronavirus Disease 2019 in Heart Transplant Recipients in Southeastern Michigan – Case Series
Hidroxicloroquina	Coronavirus Disease 2019 in Heart Transplant Recipients in Southeastern Michigan – Case Series
Tocilizumabe	Coronavirus Disease 2019 in Heart Transplant Recipients in Southeastern Michigan – Case Series
Ciclesonida	A Case of Coronavirus Disease 2019 Treated With Ciclesonide
Imunomoduladores	B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran
Imunomoduladores	B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran
Imunossupressores	B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran
Imunossupressores	B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran
Tocilizumabe	Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study
Hidroxicloroquina	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study
Lopinavir	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study
Ritonavir	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study
Hidroxicloroquina	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
Sarilumabe	Sarilumab use in severe SARS-CoV-2 pneumonia
Sistema complemento	Complement activation in patientswith COVID-19: A novel therapeutictarget
Hidroxicloroquina	Hydroxychloroquine in COVID-19: A systematic review and meta-analysis
Anticorpos	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Vacinas	DRAFT landscape of COVID-19 candidate vaccines - 15 May 2020
Cloroquina	SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
Azitromicina	Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
Hidroxicloroquina	Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
Plasma convalescente	The role of passive immunization in the age of SARS‑CoV‑2: an update
Plasma convalescente	The role of passive immunization in the age of SARS‑CoV‑2: an update
Plasma convalescente	The role of passive immunization in the age of SARS‑CoV‑2: an update
Plasma convalescente	The role of passive immunization in the age of SARS‑CoV‑2: an update
Tocilizumabe	A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19
Hidroxicloroquina	Appearance of Skin Rash in Pediatric Patients with COVID-19: Three Case Presentations
Tocilizumabe	Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia
Azitromicina	Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit
Hidroxicloroquina	Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit
Tocilizumabe	Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration
Hidroxicloroquina	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19
Amoxicilina	An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic
Azitromicina	An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic
Cloroquina	An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic
Imunoglobulina	An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study
Prednisona	An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study
Anlodipina	Nifedipine and Amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19
Nifedipino	Nifedipine and Amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19
Tocilizumabe	Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
Plasma convalescente	Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients
Corticosteroides	Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China
Fluoroquinolona	Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China
Interferon alfa	Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China
Lopinavir	Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China
Novaferon	Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China
Ritonavir	Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China
Remdesivir	Compassionate  remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status
Corticosteroides	Corticoides para infecção por SARS-CoV-2 (Covid-19) Revisão sistemática rápida
Azitromicina	Associação hidroxicloroquina/cloroquina e azitromicina para Covid-19.
Cloroquina	Associação hidroxicloroquina/cloroquina e azitromicina para Covid-19.
Hidroxicloroquina	Associação hidroxicloroquina/cloroquina e azitromicina para Covid-19.
Azitromicina	Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?
Cloroquina	Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?
Hidroxicloroquina	Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?
Favipiravir	A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
Remdesivir	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies
Terapia celular	Combating COVID-19 with Mesenchymal Stem Cell therapy
Tocilizumabe	Uso de Tocilizumab para el tratamiento de pacientes con COVID-19. Reporte breve n° 01.
Oseltamivir	Uso de Oseltamivir para el tratamiento de pacientes con COVID-19. Reporte breve n° 01.
Atazanavir	Uso de atazanavir para el tratamiento de pacientes con diagnóstico de COVID-19. Reporte breve n° 02.
Ibuprofeno	Uso de AINES en pacientes con diagnóstico de COVID-19. Reporte breve n° 013.
Cloroquina	A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials
Hidroxicloroquina	A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials
Hidroxicloroquina	Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine
Hidroxicloroquina	Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19
Lopinavir	Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19
Ritonavir	Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19
Tocilizumabe	Tolicizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome
Terapia celular	Allogeneic cardiosphere‐derived cells (CAP‐1002) in critically ill COVID‐19 patients: compassionate‐use case series
Anakinra	Use of anakinra in severe COVID-19: a case report
Anakinra	Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis
Anakinra	Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis
Anakinra	Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study
Interferon alfa	Interferon-α2b Treatment for COVID-19. 2020
Umifenovir	Interferon-α2b Treatment for COVID-19. 2020
Tocilizumabe	Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Tocilizumabe	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
Hidroxicloroquina	Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review
Plasma convalescente	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review
Hidroxicloroquina	Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis
Azitromicina	Should azithromycin be used to treat COVID-19? A rapid review
Cloroquina	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Cloroquina	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Cloroquina	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Favipiravir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Favipiravir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Favipiravir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Hidroxicloroquina	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Hidroxicloroquina	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Hidroxicloroquina	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Lopinavir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Lopinavir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Lopinavir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Plasma convalescente	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Plasma convalescente	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Plasma convalescente	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Remdesivir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Remdesivir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Remdesivir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Ritonavir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Ritonavir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Ritonavir	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Tocilizumabe	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Tocilizumabe	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Tocilizumabe	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Vacina de DNA	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Vacina de DNA	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Vacina de DNA	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Vacina de RNA	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Vacina de RNA	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Vacina de RNA	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions
Antagonistas do Receptor da Angiotensina II	SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors
Vacina	SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults
Azitromicina	Drug vignettes: Azithromycin
Azitromicina	Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
Hidroxicloroquina	Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
Ivermectina	Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance
Baricitinibe	Perspectives for repurposing drugs for the coronavirus disease 2019
Cloroquina	Perspectives for repurposing drugs for the coronavirus disease 2019
Cobicistato	Perspectives for repurposing drugs for the coronavirus disease 2019
Darunavir	Perspectives for repurposing drugs for the coronavirus disease 2019
Favipiravir	Perspectives for repurposing drugs for the coronavirus disease 2019
Interferon	Perspectives for repurposing drugs for the coronavirus disease 2019
Lopinavir	Perspectives for repurposing drugs for the coronavirus disease 2019
Oseltamivir	Perspectives for repurposing drugs for the coronavirus disease 2019
Remdesivir	Perspectives for repurposing drugs for the coronavirus disease 2019
Ribavirina	Perspectives for repurposing drugs for the coronavirus disease 2019
Ritonavir	Perspectives for repurposing drugs for the coronavirus disease 2019
Umifenovir	Perspectives for repurposing drugs for the coronavirus disease 2019
Cloroquina	A recommendation for the use of chloroquine, hydroxychloroquine, primaquine or tafenoquine for prophylaxis againts the 2019 novel coronavirus (COVD-19) with note to the ophthalmic considerations
Hidroxicloroquina	A recommendation for the use of chloroquine, hydroxychloroquine, primaquine or tafenoquine for prophylaxis againts the 2019 novel coronavirus (COVD-19) with note to the ophthalmic considerations
Primaquina	A recommendation for the use of chloroquine, hydroxychloroquine, primaquine or tafenoquine for prophylaxis againts the 2019 novel coronavirus (COVD-19) with note to the ophthalmic considerations
Tafenoquina	A recommendation for the use of chloroquine, hydroxychloroquine, primaquine or tafenoquine for prophylaxis againts the 2019 novel coronavirus (COVD-19) with note to the ophthalmic considerations
Antagonistas do Receptor da Angiotensina II	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Baricitinibe	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Cloroquina	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Darunavir	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Hidroxicloroquina	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Lopinavir	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Remdesivir	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Ritonavir	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms
Anticoagulantes	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Cloroquina	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Favipiravir	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Hidroxicloroquina	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Remdesivir	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Tocilizumabe	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
Oseltamivir	2019 Novel Coronavirus Pneumonia With Onset of Dizziness: a Case Report
Umifenovir	2019 Novel Coronavirus Pneumonia With Onset of Dizziness: a Case Report
Darunavir	COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients
Emtricitabina	COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients
Lamivudina	COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients
Ritonavir	COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients
Tenofovir	COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients
Oxigenação por membrana extracorpórea (ECMO)	Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report
Remdesivir	Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report
Vacina BCG	COVID-19 vaccines: breaking record times to first-in-human trials
Antagonistas do Receptor da Angiotensina II	The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension
Corticosteroides	A global treatments for coronaviruses including COVID-19
Hidroxicloroquina	A global treatments for coronaviruses including COVID-19
Lopinavir	A global treatments for coronaviruses including COVID-19
Ribavirina	A global treatments for coronaviruses including COVID-19
Ritonavir	A global treatments for coronaviruses including COVID-19
Teicoplanina	A global treatments for coronaviruses including COVID-19
Umifenovir	A global treatments for coronaviruses including COVID-19
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
Antagonistas do Receptor da Angiotensina II	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Antagonistas do Receptor da Angiotensina II	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Cloroquina	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Cloroquina	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Corticosteroides	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Corticosteroides	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Hidroxicloroquina	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Hidroxicloroquina	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Lopinavir	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Lopinavir	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Plasma convalescente	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Plasma convalescente	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Ritonavir	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Ritonavir	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Terapia celular	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Terapia celular	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Terapia com ervas	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Terapia com ervas	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Tocilizumabe	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Tocilizumabe	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019
Cefoperazona	A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis
Prednisona	A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis
Sulbactam	A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis
Umifenovir	A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis
Plasmaferese	Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series
Azitromicina	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Hidroxicloroquina	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Lopinavir	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Meropenem	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Oseltamivir	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Ribavirina	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Ritonavir	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Vancomicina	A Hemodialysis Patient with Severe COVID-19 Pneumonia
Azitromicina	Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Hidroxicloroquina	Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Plasma convalescente	Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Remdesivir	Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Tocilizumabe	Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units
Hidroxicloroquina	Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study
Lopinavir	Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study
Ritonavir	Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study
Antimaláricos	COVID-19 cases are less prevalent in countries where malaria is endemic, suggesting a role for anti-malarial drugs as prophylaxis
Antimaláricos	COVID-19 cases are less prevalent in countries where malaria is endemic, suggesting a role for anti-malarial drugs as prophylaxis
Anticoagulantes	Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study
Esteroides	Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study
Hidroxicloroquina	Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study
Plasma convalescente	Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study
Remdesivir	Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study
Antagonistas do Receptor da Angiotensina II	ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust
Hidroxicloroquina	Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19
Corticosteroides	Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
Corticosteroides	Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
Corticosteroides	Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
Corticosteroides	Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
Corticosteroides	Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature
Cloroquina	Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making
Hidroxicloroquina	Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making
Vacinas	Draft landscape of COVID 19 candidate vaccines - 11 May 2020
Antagonistas do Receptor da Angiotensina II	Covid‐19 and drug therapy, what we learned
Azitromicina	Covid‐19 and drug therapy, what we learned
Camostato	Covid‐19 and drug therapy, what we learned
Cloroquina	Covid‐19 and drug therapy, what we learned
Hidroxicloroquina	Covid‐19 and drug therapy, what we learned
Interferon alfa	Covid‐19 and drug therapy, what we learned
Ivermectina	Covid‐19 and drug therapy, what we learned
Lopinavir	Covid‐19 and drug therapy, what we learned
Remdesivir	Covid‐19 and drug therapy, what we learned
Ribavirina	Covid‐19 and drug therapy, what we learned
Ritonavir	Covid‐19 and drug therapy, what we learned
Tocilizumabe	Covid‐19 and drug therapy, what we learned
Umifenovir	Covid‐19 and drug therapy, what we learned
Azitromicina	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Cloroquina	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Cobicistato	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Corticosteroides	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Darunavir	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Hidroxicloroquina	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Lopinavir	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Plasma convalescente	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Remdesivir	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Ritonavir	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Tocilizumabe	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Azitromicina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Azitromicina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Azitromicina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Cloroquina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Cloroquina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Cloroquina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Favipiravir	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Favipiravir	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Favipiravir	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Hidroxicloroquina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Hidroxicloroquina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Hidroxicloroquina	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Remdesivir	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Remdesivir	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Remdesivir	A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review
Remdesivir	The FDA has authorised remdesivir for use in COVID-19 patients: but there’s no good evidence it reduces mortality
Hidroxicloroquina	Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19
Lopinavir	Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
Ritonavir	Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
Natalizumabe	COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
Cloroquina	Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection.
Hidroxicloroquina	Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection.
Azitromicina	Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hidroxicloroquina	Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Tocilizumabe	Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
Antagonistas do Receptor da Angiotensina II	Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
Antagonistas do Receptor da Angiotensina II	Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
Ozonioterapia	Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19
Hidroxicloroquina	COVID-19 Informal consultation on the dose of chloroquine and hydroxychloroquine for the SOLIDARITY Clinical Trial
Cloroquina	COVID-19: treating and managing severe cases
Corticosteroides	COVID-19: treating and managing severe cases
Hidroxicloroquina	COVID-19: treating and managing severe cases
Lopinavir	COVID-19: treating and managing severe cases
Remdesivir	COVID-19: treating and managing severe cases
Ritonavir	COVID-19: treating and managing severe cases
Tocilizumabe	“Toxic erythema” and eosinophilia associated to tocilizumab therapy in a COVID-19 patient
Corticosteroides	Steroid-responsive encephalitis in Covid-19 disease
Hidroxicloroquina	Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options
Imunoglobulina	Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options
Lopinavir	Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options
Prednisona	Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options
Ritonavir	Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options
Tocilizumabe	Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options
Ácido ascórbico	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. Medicine (Baltimore)
Azitromicina	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. Medicine (Baltimore)
Hidroxicloroquina	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. Medicine (Baltimore)
Remdesivir	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. Medicine (Baltimore)
Tocilizumabe	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. Medicine (Baltimore)
Hidroxicloroquina	Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with Novel Coronavirus Disease (COVID-19) Treated with Hydroxychloroquine
Anticorpo IgG	A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender
Colchicina	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
Colchicina	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
Hidroxicloroquina	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
Hidroxicloroquina	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
Tocilizumabe	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Anakinra	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Hidroxicloroquina	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Lopinavir	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Ritonavir	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Interferon beta	Triple combination of interferon beta-1b , lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial
Lopinavir	Triple combination of interferon beta-1b , lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial
Ribavirina	Triple combination of interferon beta-1b , lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial
Ritonavir	Triple combination of interferon beta-1b , lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial
Cloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Cloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Cloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Cloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Favipiravir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Favipiravir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Favipiravir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Favipiravir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Hidroxicloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Hidroxicloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Hidroxicloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Hidroxicloroquina	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Lopinavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Lopinavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Lopinavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Lopinavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Plasma convalescente	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Plasma convalescente	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Plasma convalescente	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Plasma convalescente	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Remdesivir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Remdesivir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Remdesivir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Remdesivir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Ritonavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Ritonavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Ritonavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Ritonavir	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Tocilizumabe	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Tocilizumabe	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Tocilizumabe	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Tocilizumabe	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19
Remdesivir	Rapid review for the anti-coronavirus effect of remdesivir
Remdesivir	Rapid review for the anti-coronavirus effect of remdesivir
Vacinas	DRAFT landscape of COVID-19 candidate vaccines - 5 May 2020
Metformina	Metformin in COVID-19: A possible role beyond diabetes
Azitromicina	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Cloroquina	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Favipiravir	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Hidroxicloroquina	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Lopinavir	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Ritonavir	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Sarilumabe	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Tocilizumabe	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
Cloroquina	Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
Cloroquina	Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
Cloroquina	Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
Hidroxicloroquina	Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
Hidroxicloroquina	Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
Hidroxicloroquina	Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
Anti-inflamatórios não esteroidais	NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?
Baricitinibe	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Cloroquina	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Corticosteroides	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Hidroxicloroquina	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Metformina	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Plasma convalescente	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Remdesivir	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Tocilizumabe	A new era for the therapeutic management of the ongoing COVID-19 pandemic
Remdesivir	Emergency Use Authorization of remdesivir by the US Food and Drug Administration
Anti-histamínicos	Drug-induced vasculitis in a patient with COVID-19
Corticosteroides	Drug-induced vasculitis in a patient with COVID-19
Prednisolona	Drug-induced vasculitis in a patient with COVID-19
Hidroxicloroquina	Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight
Tocilizumabe	Tocilizumab for the Treatment of Severe COVID-19
Hidroxicloroquina	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Corticosteroides	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Corticosteroides	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
Antagonistas do Receptor da Angiotensina II	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Camostato	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Lopinavir	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Medicina Tradicional Chinesa	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Meplazumabe	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Metuximabe	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Metuzumabe	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Plasma convalescente	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Proteína spike	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Ribavirina	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Ritonavir	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Soro convalescente	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Tocilizumabe	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Vacina	Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
Hidroxicloroquina	Favourable outcome of Coronavirus-19 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression
Lopinavir	Favourable outcome of Coronavirus-19 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression
Ritonavir	Favourable outcome of Coronavirus-19 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression
Teicoplanina	Favourable outcome of Coronavirus-19 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression
Tocilizumabe	IL-6 blockade treatment for severe COVID-19 in two patients with multiple myeloma
Vacina BCG	Does BCG protect against SARS-CoV-2 infection ?: elements of proof
Vacina BCG	COVID-19 Related Mortality: Is the BCG Vaccine Truly Effective?
Vitamina D (25-hidroxivitamina D)	Evidence Supports a Causal Model for Vitamin D in COVID-19 Outcomes
Vitamina D (25-hidroxivitamina D)	Evidence Supports a Causal Model for Vitamin D in COVID-19 Outcomes
Azitromicina	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061cases in Marseille, France
Hidroxicloroquina	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061cases in Marseille, France
Anticorpos	A human monoclonal antibody blocking SARS-CoV-2 infection
Cloroquina	Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
Tocilizumabe	Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
Ciclesonida	Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases
Abatacept	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Adalimumabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Anakinra	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Baricitinibe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Certolizumabe Pegol	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Etanercepte	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Golimumabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Infliximabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Inibidores da fosfodiesterase-4	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Ixequizumab	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Ruxolitinibe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Sarilumabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Secuquinumabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Tocilizumabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Tofacitinibe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Ustekinumabe	Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Antagonistas do Receptor da Angiotensina II	Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for Coronavirus Disease 2019 (COVID-19)
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for Coronavirus Disease 2019 (COVID-19)
Anticorpos	Cytokine storm intervention in the early stages of COVID-19 pneumonia
Corticosteroides	Cytokine storm intervention in the early stages of COVID-19 pneumonia
Imunoterapia	Cytokine storm intervention in the early stages of COVID-19 pneumonia
Interferon	Cytokine storm intervention in the early stages of COVID-19 pneumonia
Plasma convalescente	Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic
Cloroquina	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19
Cloroquina	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19
Cloroquina	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19
Hidroxicloroquina	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19
Hidroxicloroquina	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19
Hidroxicloroquina	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19
Camostato	Candidate drugs against SARS-CoV-2 and COVID-19
Camostato	Candidate drugs against SARS-CoV-2 and COVID-19
Cefarantina	Candidate drugs against SARS-CoV-2 and COVID-19
Cefarantina	Candidate drugs against SARS-CoV-2 and COVID-19
Cloridrato de mefloquina	Candidate drugs against SARS-CoV-2 and COVID-19
Cloridrato de mefloquina	Candidate drugs against SARS-CoV-2 and COVID-19
Cloroquina	Candidate drugs against SARS-CoV-2 and COVID-19
Cloroquina	Candidate drugs against SARS-CoV-2 and COVID-19
Favipiravir	Candidate drugs against SARS-CoV-2 and COVID-19
Favipiravir	Candidate drugs against SARS-CoV-2 and COVID-19
Hidroxicloroquina	Candidate drugs against SARS-CoV-2 and COVID-19
Hidroxicloroquina	Candidate drugs against SARS-CoV-2 and COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Candidate drugs against SARS-CoV-2 and COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Candidate drugs against SARS-CoV-2 and COVID-19
Inibidores da protease SARS-CoV-2 Mpro (3Clpro)	Candidate drugs against SARS-CoV-2 and COVID-19
Inibidores da protease SARS-CoV-2 Mpro (3Clpro)	Candidate drugs against SARS-CoV-2 and COVID-19
Lopinavir	Candidate drugs against SARS-CoV-2 and COVID-19
Lopinavir	Candidate drugs against SARS-CoV-2 and COVID-19
Nafamostato	Candidate drugs against SARS-CoV-2 and COVID-19
Nafamostato	Candidate drugs against SARS-CoV-2 and COVID-19
Remdesivir	Candidate drugs against SARS-CoV-2 and COVID-19
Remdesivir	Candidate drugs against SARS-CoV-2 and COVID-19
Ritonavir	Candidate drugs against SARS-CoV-2 and COVID-19
Ritonavir	Candidate drugs against SARS-CoV-2 and COVID-19
Selamectina	Candidate drugs against SARS-CoV-2 and COVID-19
Selamectina	Candidate drugs against SARS-CoV-2 and COVID-19
Umifenovir	Candidate drugs against SARS-CoV-2 and COVID-19
Umifenovir	Candidate drugs against SARS-CoV-2 and COVID-19
Azitromicina	What is the evidence for using macrolide antibiotics to treat COVID-19?
Interferon alfa	Quadruple therapy for asymptomatic COVID-19 infection patients
Lianhua Qingwen (Medicina Tradicional Chinesa)	Quadruple therapy for asymptomatic COVID-19 infection patients
Lopinavir	Quadruple therapy for asymptomatic COVID-19 infection patients
Ritonavir	Quadruple therapy for asymptomatic COVID-19 infection patients
Umifenovir	Quadruple therapy for asymptomatic COVID-19 infection patients
Interferon alfa	Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again
Lopinavir	Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again
Ribavirina	Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again
Ritonavir	Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again
AMY-101 - inibidor do complemento C3	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Lopinavir	Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial
Ritonavir	Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial
Umifenovir	Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial
Antagonistas do Receptor da Angiotensina II	Evidence for Use or Disuse of Renin–Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Evidence for Use or Disuse of Renin–Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder
Cloroquina	Rethinking the role of hydroxychloroquine in the treatment of COVID-19
Hidroxicloroquina	Rethinking the role of hydroxychloroquine in the treatment of COVID-19
Azitromicina	Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?
Cloroquina	Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?
Hidroxicloroquina	Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?
Vitamina D (25-hidroxivitamina D)	Does vitamin D status impact mortality from SARS-CoV-2 infection?
Vesículas extracelulares contendo inibidores de protease	Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19
Tocilizumabe	Drug vignettes: Tocilizumab
Azitromicina	COVID-19: Immunology and treatment options
Corticosteroides	COVID-19: Immunology and treatment options
Enzima Conversora de Angiotensina 2 recombinante	COVID-19: Immunology and treatment options
Hidroxicloroquina	COVID-19: Immunology and treatment options
Imunoglobulina	COVID-19: Immunology and treatment options
Inibidores de Janus Kinase (JAK)	COVID-19: Immunology and treatment options
Interferon recombinante tipo 1	COVID-19: Immunology and treatment options
Lopinavir	COVID-19: Immunology and treatment options
Plasma convalescente	COVID-19: Immunology and treatment options
Remdesivir	COVID-19: Immunology and treatment options
Ritonavir	COVID-19: Immunology and treatment options
Tocilizumabe	COVID-19: Immunology and treatment options
Azitromicina	COVID-19: Therapeutics and Their Toxicities
Cloroquina	COVID-19: Therapeutics and Their Toxicities
Enzima Conversora de Angiotensina 2 recombinante	COVID-19: Therapeutics and Their Toxicities
Favipiravir	COVID-19: Therapeutics and Their Toxicities
Hidroxicloroquina	COVID-19: Therapeutics and Their Toxicities
Leronlimab	COVID-19: Therapeutics and Their Toxicities
Lopinavir	COVID-19: Therapeutics and Their Toxicities
Plasma convalescente	COVID-19: Therapeutics and Their Toxicities
Remdesivir	COVID-19: Therapeutics and Their Toxicities
Ritonavir	COVID-19: Therapeutics and Their Toxicities
Plasma convalescente	Convalescent plasma: possible therapy for novel coronavirus disease 2019
Hidroxicloroquina	A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine
Antagonistas do Receptor da Angiotensina II	Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
Antagonistas do Receptor da Angiotensina II	Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
Tocilizumabe	Effective treatment of severe COVID-19 patients with tocilizumab
Antagonista de β-adrenérgico	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Antagonistas do Receptor da Angiotensina II	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Bloqueadores do Canal de Cálcio	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Diuréticos	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Azitromicina	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
Hidroxicloroquina	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
Hidroxicloroquina	Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study
Cloroquina	Chloroquine-induced QTc prolongation in COVID-19 patients
Heparina	Heparinas para infecção por SARS-CoV-2 (COVID-19). Revisão sistemática rápida
Remdesivir	"Remdesivir para
infecção por SARS-CoV-2 (COVID-19). Revisão sistemática"
Plasma convalescente	Convalescent plasma transfusion for the treatment of COVID-19: Systematic review
Hidroxicloroquina	Ocular toxicity and Hydroxychloroquine: A Rapid Meta-Analysis
Vitamina D (25-hidroxivitamina D)	Vitamin D: A rapid review of the evidence for treatment or prevention in COVID-19
Cloroquina	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19
Hidroxicloroquina	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19
Tocilizumabe	Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
Anticorpos	Coronavirus Infections in Children Including COVID-19
Cloroquina	Coronavirus Infections in Children Including COVID-19
Corticosteroides	Coronavirus Infections in Children Including COVID-19
Imunoglobulina	Coronavirus Infections in Children Including COVID-19
Inibidores da síntese de RNA	Coronavirus Infections in Children Including COVID-19
Inibidores de protease	Coronavirus Infections in Children Including COVID-19
Interferon alfa	Coronavirus Infections in Children Including COVID-19
Lopinavir	Coronavirus Infections in Children Including COVID-19
Ritonavir	Coronavirus Infections in Children Including COVID-19
Resiniferatoxina	The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis of patients in advanced disease state: A review
Vitamina D (25-hidroxivitamina D)	A rapid review of the evidence for treatment or prevention in COVID-19
Remdesivir	Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
Plasma convalescente	Treatment for emerging viruses: Convalescent plasma and COVID-19
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
Azitromicina	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report
Ceftriaxona	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report
Hidroxicloroquina	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report
Lopinavir	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report
Ritonavir	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report
Antagonistas do Receptor da Angiotensina II	Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study
Plasma convalescente	Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
Azitromicina	An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19
Hidroxicloroquina	An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19
Favipiravir	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cloroquina	Will the antimalarial drug take over to combat COVID-19?
Hidroxicloroquina	Will the antimalarial drug take over to combat COVID-19?
Remdesivir	Will the antimalarial drug take over to combat COVID-19?
Vacinas	DRAFT landscape of COVID-19 candidate vaccines - 20 April 2020
Melatonina	Can melatonin reduce the severity of COVID-19 pandemic?
Melatonina	Can melatonin reduce the severity of COVID-19 pandemic?
Melatonina	Can melatonin reduce the severity of COVID-19 pandemic?
Antagonistas do Receptor da Angiotensina II	Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19
Ácido ascórbico	Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?
Plasma convalescente	Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
Vacina	Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
Darunavir	Darunavir does not prevent SARS-CoV-2 infection in HIV patients
Tocilizumabe	Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report
Hidroxicloroquina	SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis
Prednisona	A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
Umifenovir	Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study
Lopinavir	Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study
Ritonavir	Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study
Umifenovir	Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study
Remdesivir	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Cloroquina	Interim Guidelines on Antiviral Therapy for COVID-19
Favipiravir	Interim Guidelines on Antiviral Therapy for COVID-19
Hidroxicloroquina	Interim Guidelines on Antiviral Therapy for COVID-19
Interferon	Interim Guidelines on Antiviral Therapy for COVID-19
Lopinavir	Interim Guidelines on Antiviral Therapy for COVID-19
Remdesivir	Interim Guidelines on Antiviral Therapy for COVID-19
Ribavirina	Interim Guidelines on Antiviral Therapy for COVID-19
Ritonavir	Interim Guidelines on Antiviral Therapy for COVID-19
Anakinra	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Anakinra	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Anti-inflamatórios não esteroidais	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Anti-inflamatórios não esteroidais	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Cloroquina	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Cloroquina	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Corticosteroides	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Corticosteroides	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Hidroxicloroquina	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Hidroxicloroquina	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Imunoglobulina	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Imunoglobulina	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Inibidores de Janus Kinase (JAK)	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Inibidores de Janus Kinase (JAK)	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Mavrilimumabe	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Mavrilimumabe	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Micofenolato de mofetila	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Micofenolato de mofetila	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Tocilizumabe	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Tocilizumabe	COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs
Antagonistas do Receptor da Angiotensina II	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Azitromicina	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Cloroquina	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Favipiravir	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Hidroxicloroquina	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Ibuprofeno	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Indometacina	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Lopinavir	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Plasma convalescente	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Remdesivir	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Ribavirina	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Ritonavir	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Sarilumabe	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Tocilizumabe	Pharmacotherapy in COVID-19; A narrative review for emergency providers
Cloroquina	COVID-19: An update on diagnostic and therapeutic approaches
Cloroquina	COVID-19: An update on diagnostic and therapeutic approaches
Hidroxicloroquina	COVID-19: An update on diagnostic and therapeutic approaches
Hidroxicloroquina	COVID-19: An update on diagnostic and therapeutic approaches
Plasma convalescente	COVID-19: An update on diagnostic and therapeutic approaches
Plasma convalescente	COVID-19: An update on diagnostic and therapeutic approaches
Cloroquina	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Cloroquina	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Darunavir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Darunavir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Favipiravir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Favipiravir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Hidroxicloroquina	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Hidroxicloroquina	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Ivermectina	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Ivermectina	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Lopinavir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Lopinavir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Plasma convalescente	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Plasma convalescente	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Ritonavir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Ritonavir	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Tocilizumabe	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Tocilizumabe	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
Cloroquina	Covid-19 treatment update: follow the scientific evidence
Hidroxicloroquina	Covid-19 treatment update: follow the scientific evidence
Cloroquina	Treatment of SARS-CoV-2: How far have we reached?
Darunavir	Treatment of SARS-CoV-2: How far have we reached?
Favipiravir	Treatment of SARS-CoV-2: How far have we reached?
Hidroxicloroquina	Treatment of SARS-CoV-2: How far have we reached?
Interferon	Treatment of SARS-CoV-2: How far have we reached?
Lopinavir	Treatment of SARS-CoV-2: How far have we reached?
Plasma convalescente	Treatment of SARS-CoV-2: How far have we reached?
Remdesivir	Treatment of SARS-CoV-2: How far have we reached?
Ritonavir	Treatment of SARS-CoV-2: How far have we reached?
Sarilumabe	Treatment of SARS-CoV-2: How far have we reached?
Umifenovir	Treatment of SARS-CoV-2: How far have we reached?
Famotidina	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Hidroxicloroquina	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Leflunomida	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Lopinavir	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Meloxicam	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Prednisona	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Ritonavir	Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Azitromicina	Two distinct cases with COVID-19 in kidney transplant recipients
Hidroxicloroquina	Two distinct cases with COVID-19 in kidney transplant recipients
Lopinavir	Two distinct cases with COVID-19 in kidney transplant recipients
Ritonavir	Two distinct cases with COVID-19 in kidney transplant recipients
Lopinavir	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
Ritonavir	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
Cloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Corticosteroides	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Danoprevir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Darunavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Favipiravir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Heparina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Hidroxicloroquina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Interferon alfa	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ivermectina	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Lopinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Meplazumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Nelfinavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Plasma convalescente	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Remdesivir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Ritonavir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Siltuximabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Tocilizumabe	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Umifenovir	Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Antagonistas do Receptor da Angiotensina II	The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis
Azitromicina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Azitromicina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Azitromicina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Cloroquina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Cloroquina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Cloroquina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Corticosteroides	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Corticosteroides	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Corticosteroides	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Hidroxicloroquina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Hidroxicloroquina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Hidroxicloroquina	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Lopinavir	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Lopinavir	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Lopinavir	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Ritonavir	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Ritonavir	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Ritonavir	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Tocilizumabe	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Tocilizumabe	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Tocilizumabe	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Tocilizumabe	Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
Hidroxicloroquina	Combating Devastating COVID -19 by Drug Repurposing
Lopinavir	Combating Devastating COVID -19 by Drug Repurposing
Oseltamivir	Combating Devastating COVID -19 by Drug Repurposing
Remdesivir	Combating Devastating COVID -19 by Drug Repurposing
Ribavirina	Combating Devastating COVID -19 by Drug Repurposing
Ritonavir	Combating Devastating COVID -19 by Drug Repurposing
Ibuprofeno	Headache medication and the COVID-19 pandemic
Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)	Headache medication and the COVID-19 pandemic
Glicirrizina	Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
Cloroquina	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Favipiravir	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Hidroxicloroquina	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Imunoglobulina	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Lopinavir	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Plasma convalescente	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Remdesivir	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Ritonavir	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Tocilizumabe	Update on treatment of COVID-19: ongoing studies between promising and disappointing results
Tocilizumabe	The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
Ácido ascórbico	Current status of potential therapeutic candidates for the COVID-19 crisis
Ácido ascórbico	Current status of potential therapeutic candidates for the COVID-19 crisis
Anti-inflamatórios não esteroidais	Current status of potential therapeutic candidates for the COVID-19 crisis
Anti-inflamatórios não esteroidais	Current status of potential therapeutic candidates for the COVID-19 crisis
Anticoagulantes	Current status of potential therapeutic candidates for the COVID-19 crisis
Anticoagulantes	Current status of potential therapeutic candidates for the COVID-19 crisis
Anticorpos	Current status of potential therapeutic candidates for the COVID-19 crisis
Anticorpos	Current status of potential therapeutic candidates for the COVID-19 crisis
Azitromicina	Current status of potential therapeutic candidates for the COVID-19 crisis
Azitromicina	Current status of potential therapeutic candidates for the COVID-19 crisis
Baricitinibe	Current status of potential therapeutic candidates for the COVID-19 crisis
Baricitinibe	Current status of potential therapeutic candidates for the COVID-19 crisis
Cloroquina	Current status of potential therapeutic candidates for the COVID-19 crisis
Cloroquina	Current status of potential therapeutic candidates for the COVID-19 crisis
Corticosteroides	Current status of potential therapeutic candidates for the COVID-19 crisis
Corticosteroides	Current status of potential therapeutic candidates for the COVID-19 crisis
Favipiravir	Current status of potential therapeutic candidates for the COVID-19 crisis
Favipiravir	Current status of potential therapeutic candidates for the COVID-19 crisis
Gamaglobulina	Current status of potential therapeutic candidates for the COVID-19 crisis
Gamaglobulina	Current status of potential therapeutic candidates for the COVID-19 crisis
Hidroxicloroquina	Current status of potential therapeutic candidates for the COVID-19 crisis
Hidroxicloroquina	Current status of potential therapeutic candidates for the COVID-19 crisis
Interferon	Current status of potential therapeutic candidates for the COVID-19 crisis
Interferon	Current status of potential therapeutic candidates for the COVID-19 crisis
Lopinavir	Current status of potential therapeutic candidates for the COVID-19 crisis
Lopinavir	Current status of potential therapeutic candidates for the COVID-19 crisis
Molnupiravir	Current status of potential therapeutic candidates for the COVID-19 crisis
Molnupiravir	Current status of potential therapeutic candidates for the COVID-19 crisis
Plasma convalescente	Current status of potential therapeutic candidates for the COVID-19 crisis
Plasma convalescente	Current status of potential therapeutic candidates for the COVID-19 crisis
Remdesivir	Current status of potential therapeutic candidates for the COVID-19 crisis
Remdesivir	Current status of potential therapeutic candidates for the COVID-19 crisis
Ritonavir	Current status of potential therapeutic candidates for the COVID-19 crisis
Ritonavir	Current status of potential therapeutic candidates for the COVID-19 crisis
Sarilumabe	Current status of potential therapeutic candidates for the COVID-19 crisis
Sarilumabe	Current status of potential therapeutic candidates for the COVID-19 crisis
Terapia celular	Current status of potential therapeutic candidates for the COVID-19 crisis
Terapia celular	Current status of potential therapeutic candidates for the COVID-19 crisis
Tocilizumabe	Current status of potential therapeutic candidates for the COVID-19 crisis
Tocilizumabe	Current status of potential therapeutic candidates for the COVID-19 crisis
Vacina	Current status of potential therapeutic candidates for the COVID-19 crisis
Vacina	Current status of potential therapeutic candidates for the COVID-19 crisis
Vitamina D (25-hidroxivitamina D)	Current status of potential therapeutic candidates for the COVID-19 crisis
Vitamina D (25-hidroxivitamina D)	Current status of potential therapeutic candidates for the COVID-19 crisis
Zinco	Current status of potential therapeutic candidates for the COVID-19 crisis
Zinco	Current status of potential therapeutic candidates for the COVID-19 crisis
Carbapenêmicos	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Carbapenêmicos	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Carbapenêmicos	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Cefalosporina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Cefalosporina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Cefalosporina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Cloroquina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Cloroquina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Cloroquina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Favipiravir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Favipiravir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Favipiravir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ganciclovir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ganciclovir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ganciclovir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Lopinavir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Lopinavir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Lopinavir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Nafamostato	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Nafamostato	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Nafamostato	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Nitazoxanida	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Nitazoxanida	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Nitazoxanida	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Oseltamivir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Oseltamivir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Oseltamivir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Penciclovir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Penciclovir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Penciclovir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Proteínas de fusão	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Proteínas de fusão	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Proteínas de fusão	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Quinolonas	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Quinolonas	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Quinolonas	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Remdesivir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Remdesivir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Remdesivir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ribavirina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ribavirina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ribavirina	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ritonavir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ritonavir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Ritonavir	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Terapia celular	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Terapia celular	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Terapia celular	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Vacina de RNA	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Vacina de RNA	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Vacina de RNA	The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment
Antagonistas do Receptor da Angiotensina II	A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance
Interferon lambda	COVID-19: lambda interferon against viral load and hyperinflammation
Baricitinibe	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Anakinra	A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections
Inibidores de interleucina-6	A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections
Claritromicina	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin
Cloroquina	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin
Hidroxicloroquina	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine
Ativador do plasminogênio tecidual (tPA)	Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thromobolytic drugs to treat COVID-19
Favipiravir	Current pharmacological treatments for COVID-19: what’s next?
Lopinavir	Current pharmacological treatments for COVID-19: what’s next?
Remdesivir	Current pharmacological treatments for COVID-19: what’s next?
Ritonavir	Current pharmacological treatments for COVID-19: what’s next?
Tocilizumabe	Current pharmacological treatments for COVID-19: what’s next?
Umifenovir	Current pharmacological treatments for COVID-19: what’s next?
Antagonistas do Receptor da Angiotensina II	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Antagonistas do Receptor da Angiotensina II	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Azitromicina	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Azitromicina	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Cloroquina	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Cloroquina	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Hidroxicloroquina	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Hidroxicloroquina	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Inibidor de protease vinil sulfona	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Inibidor de protease vinil sulfona	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Lopinavir	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Lopinavir	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Peptídeo baseado em ECA 2	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Peptídeo baseado em ECA 2	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Proteína spike	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Proteína spike	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Remdesivir	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Remdesivir	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Ritonavir	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Ritonavir	SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options
Vacinas	DRAFT landscape of COVID-19 candidate vaccines - 23 April 2020
Antagonistas do Receptor da Angiotensina II	Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence
Anakinra	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Azitromicina	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Baricitinibe	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Camostato	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Corticosteroides	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Emodina	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Hidroxicloroquina	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Imunoglobulina	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Interferon alfa	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Interferon beta	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Lopinavir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Medicina Tradicional Indiana	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Nafamostato	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Nelfinavir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Oseltamivir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Plasma convalescente	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Promazina	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Remdesivir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Ribavirina	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Ritonavir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Ruxolitinibe	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Sofosbuvir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Tocilizumabe	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Upadacitinibe	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Zanamivir	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future
Antagonistas de TNF	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Anti-inflamatórios não esteroidais	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Cloroquina	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Colchicina	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Corticosteroides	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Fator estimulador de colônias de granulócitos-monócitos (GM-FEC)	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Hidroxicloroquina	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Imunoglobulina	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Inibidores de Janus Kinase (JAK)	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Leflunomida	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Metotrexato	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Micofenolato de mofetila	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Tocilizumabe	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Deferasirox	Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival
Deferiprona	Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival
Deferoxamina	Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival
Cloroquina	COVID-19 therapeutic options for patients with kidney disease
Cloroquina	COVID-19 therapeutic options for patients with kidney disease
Favipiravir	COVID-19 therapeutic options for patients with kidney disease
Favipiravir	COVID-19 therapeutic options for patients with kidney disease
Hidroxicloroquina	COVID-19 therapeutic options for patients with kidney disease
Hidroxicloroquina	COVID-19 therapeutic options for patients with kidney disease
Lopinavir	COVID-19 therapeutic options for patients with kidney disease
Lopinavir	COVID-19 therapeutic options for patients with kidney disease
Remdesivir	COVID-19 therapeutic options for patients with kidney disease
Remdesivir	COVID-19 therapeutic options for patients with kidney disease
Ritonavir	COVID-19 therapeutic options for patients with kidney disease
Ritonavir	COVID-19 therapeutic options for patients with kidney disease
Tocilizumabe	COVID-19 therapeutic options for patients with kidney disease
Tocilizumabe	COVID-19 therapeutic options for patients with kidney disease
Eculizumabe	Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
Lopinavir	A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report
Oxigenação por membrana extracorpórea (ECMO)	A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report
Ritonavir	A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report
Antagonistas do Receptor da Angiotensina II	Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
Hidrocortisona	Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes
Cloroquina	Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System
Lopinavir	Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System
Ritonavir	Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System
Umifenovir	Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System
Heparina	High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients
Dipiridamol	Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
Lopinavir	A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19
Ritonavir	A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19
Nitazoxanida	Nitazoxanida para tratamento de COVID-19: Revisão Sistemática Rápida
Cloroquina	Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings
Hidroxicloroquina	Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings
Hidroxicloroquina	COVID-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine
Tocilizumabe	COVID-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine
Hidroxicloroquina	COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency
Hidroxicloroquina	A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant
Azitromicina	Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine
Cloroquina	Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine
Hidroxicloroquina	Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine
Cloroquina	Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
Cloroquina	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial
Anticorpos	Emerging Therapeutic Strategies for COVID-19 patients
Cloroquina	Emerging Therapeutic Strategies for COVID-19 patients
Lopinavir	Emerging Therapeutic Strategies for COVID-19 patients
Remdesivir	Emerging Therapeutic Strategies for COVID-19 patients
Ritonavir	Emerging Therapeutic Strategies for COVID-19 patients
Terapia celular	Emerging Therapeutic Strategies for COVID-19 patients
Umifenovir	Emerging Therapeutic Strategies for COVID-19 patients
Vacina	Emerging Therapeutic Strategies for COVID-19 patients
Anticoagulantes	Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines
Anticoagulantes	Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines
Baricitinibe	Janus Kinase inhibitor baricitinib is not an ideal option for management of COVID-19
Azitromicina	PAK1-blockers: Potential Therapeutics against COVID-19
Hidroxicloroquina	PAK1-blockers: Potential Therapeutics against COVID-19
Ivermectina	PAK1-blockers: Potential Therapeutics against COVID-19
Melatonina	PAK1-blockers: Potential Therapeutics against COVID-19
Pimenta de Sichuan	PAK1-blockers: Potential Therapeutics against COVID-19
Própolis	PAK1-blockers: Potential Therapeutics against COVID-19
Proteínas quinases PKA	PAK1-blockers: Potential Therapeutics against COVID-19
Triptolide	PAK1-blockers: Potential Therapeutics against COVID-19
Cloroquina	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Corticosteroides	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Favipiravir	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Hidroxicloroquina	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Inibidores de interleucina-6	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Interferon alfa-beta	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Interferon beta	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Interferon gama	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Lopinavir	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Remdesivir	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Ribavirina	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Ritonavir	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Sarilumabe	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Siltuximabe	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Tocilizumabe	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities
Ativador do plasminogênio tecidual (tPA)	Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis
Ocrelizumabe	COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Imunoglobulina	Intravenous Immunoglobulin of COVID-19 Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: A Rapid Review
Corticosteroides	The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis
Plasma convalescente	Points to consider in the preparation and transfusion of COVID-19 convalescent plasma
Hidroxicloroquina	Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19)
Hidroxicloroquina	Hydroxychloroquine for the management of COVID-19: Hope or Hype? A Systematic review of the current evidence
Medicina Tradicional Chinesa	Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MSE analysis
Medicina Tradicional Chinesa	Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MSE analysis
Medicina Tradicional Chinesa	In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus
Carfilzomibe	Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
Elbasvir	Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
Eravaciclina	Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
Estreptomicina	Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
Lopinavir	Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
Valrubicina	Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
Enisamium	Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
Anticorpos	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
Azitromicina	CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Lianhua Qingwen (Medicina Tradicional Chinesa)	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
Apicidina	Peptide-like and small-molecule inhibitors against Covid-19
Carfilzomibe	Peptide-like and small-molecule inhibitors against Covid-19
Darunavir	Peptide-like and small-molecule inhibitors against Covid-19
Dobutamina	Peptide-like and small-molecule inhibitors against Covid-19
Lopinavir	Peptide-like and small-molecule inhibitors against Covid-19
Nelfinavir	Peptide-like and small-molecule inhibitors against Covid-19
Ritonavir	Peptide-like and small-molecule inhibitors against Covid-19
Saquinavir	Peptide-like and small-molecule inhibitors against Covid-19
Teniposídeo	Peptide-like and small-molecule inhibitors against Covid-19
Azelastina	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Conivaptano	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Idelalisibe	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Loxapina	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Olaparibe	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Perampanel	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Ponatinibe	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Sonidegibe	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Suvorexant	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Tolvaptano	Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Ácido folínico	Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Composto ITX5061	Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Oberadilol	Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Poziotinibe	Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Vidupiprant	Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Ziprasidona	Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Ciclosporina	Therapeutic strategies for critically ill patients with COVID-19
Corticosteroides	Therapeutic strategies for critically ill patients with COVID-19
Favipiravir	Therapeutic strategies for critically ill patients with COVID-19
Gamaglobulina	Therapeutic strategies for critically ill patients with COVID-19
Interferon	Therapeutic strategies for critically ill patients with COVID-19
Lopinavir	Therapeutic strategies for critically ill patients with COVID-19
Plasma convalescente	Therapeutic strategies for critically ill patients with COVID-19
Remdesivir	Therapeutic strategies for critically ill patients with COVID-19
Ribavirina	Therapeutic strategies for critically ill patients with COVID-19
Ritonavir	Therapeutic strategies for critically ill patients with COVID-19
Timosina	Therapeutic strategies for critically ill patients with COVID-19
Tocilizumabe	Therapeutic strategies for critically ill patients with COVID-19
Umifenovir	Therapeutic strategies for critically ill patients with COVID-19
Anticorpos	A short review on antibody therapy for COVID-19
Plasma convalescente	A short review on antibody therapy for COVID-19
Luz ultravioleta	Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment
Riboflavina	Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment
Azitromicina	Treatment options for COVID-19: The reality and challenges
Cloroquina	Treatment options for COVID-19: The reality and challenges
Favipiravir	Treatment options for COVID-19: The reality and challenges
Heparina	Treatment options for COVID-19: The reality and challenges
Hidroxicloroquina	Treatment options for COVID-19: The reality and challenges
Lopinavir	Treatment options for COVID-19: The reality and challenges
Plasma convalescente	Treatment options for COVID-19: The reality and challenges
Prednisona	Treatment options for COVID-19: The reality and challenges
Remdesivir	Treatment options for COVID-19: The reality and challenges
Ribavirina	Treatment options for COVID-19: The reality and challenges
Ritonavir	Treatment options for COVID-19: The reality and challenges
Produtos naturais	Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data
Produtos naturais	Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data
Produtos naturais	Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data
Adeflavin	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Coenzima A	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Indinavir	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Narcissoside	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Remdesivir	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Saquinavir	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Zanamivir	A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Cinamaldeído	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Guanosina trifosfato	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
IDX-184	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Remdesivir	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Ribavirina	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Sofosbuvir	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Timoquinona	Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Silenciadores de RNA	A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2
Silenciadores de RNA	A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2
Medicina Tradicional Chinesa	Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China
Antibióticos	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Antifúngicos	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Antiparasitários	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Corticosteroides	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Imunoglobulina	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Interferon	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Lopinavir	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Oseltamivir	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Prednisona	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Ribavirina	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Ritonavir	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Umifenovir	"Antiviral Therapy in Man-
agement of COVID-19: a Systematic Review on Current Evidence"
Cloroquina	Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
Hidroxicloroquina	Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
Prednisona	Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
Tocilizumabe	Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
Ulinastatina	Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
Remdesivir	Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
Cloroquina	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Hidroxicloroquina	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Lopinavir	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Plasma convalescente	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Remdesivir	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Ritonavir	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Ruxolitinibe	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Terapia celular	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Tocilizumabe	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States
Inibidores de protease	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Células Th17	The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement
Composto ZINC000000702323	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Composto ZINC000012481889	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Composto ZINC000015988935	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Composto ZINC000103558522	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Loprazolam	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Lurasidona	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Rubitecan	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Talampicilina	Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
Anticorpos	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Anticorpos	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Anticorpos	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Cloroquina	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Cloroquina	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Cloroquina	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ebselen	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ebselen	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ebselen	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ivermectina	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ivermectina	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ivermectina	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Lopinavir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Lopinavir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Lopinavir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Plasma convalescente	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Plasma convalescente	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Plasma convalescente	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Remdesivir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Remdesivir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Remdesivir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ritonavir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ritonavir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Ritonavir	Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment
Heparina	Heparin therapy improving hypoxia in COVID-19 patients - a case series
Corticosteroides	COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster
Ácido alfa lipóico	A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019（COVID-19).
Vacina contra SARS-CoV-2	Progress and Prospects on Vaccine Development against SARS-CoV-2
Vacina contra SARS-CoV-2	Progress and Prospects on Vaccine Development against SARS-CoV-2
Vacina contra SARS-CoV-2	Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis
Antagonistas do Receptor da Angiotensina II	Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Antagonistas do Receptor da Angiotensina II	Clinical Implications of SARS-CoV-2 Interaction with Renin Angiotensin System
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Clinical Implications of SARS-CoV-2 Interaction with Renin Angiotensin System
Cloroquina	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
Cloroquina	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
Cloroquina	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
Cloroquina	Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19
Hidroxicloroquina	Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Hidroxicloroquina	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19
Azitromicina	Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19
Hidroxicloroquina	Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19
Amodiaquina	Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage
Lopinavir	Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage
Nelfinavir	Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage
Ritonavir	Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage
Antagonistas do Receptor da Angiotensina II	Angiotensin Receptor Blockers and 2019-nCoV
Ácido ascórbico	Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19
Ozonioterapia	Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19
Plasma convalescente	Challenges of Convalescent Plasma Therapy on COVID-19
Antagonistas do Receptor da Angiotensina II	Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and reninangiotensin system blockers in SARS-CoV-2 infections
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and reninangiotensin system blockers in SARS-CoV-2 infections
Vacina de vírus inativado	Rapid development of an inactivated vaccine for SARS-CoV-2
Favipiravir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Favipiravir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Favipiravir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Hidroxicloroquina	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Hidroxicloroquina	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Hidroxicloroquina	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Lopinavir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Lopinavir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Lopinavir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Ritonavir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Ritonavir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Ritonavir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Umifenovir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Umifenovir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Umifenovir	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis
Anticoagulantes	Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action
Anticoagulantes	Inaccurate conclusions by Tang and colleagues
Hidroxicloroquina	Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine
Cloroquina	Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes
Antagonista de P2Y12	Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings
Heparina	Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings
Ticagrelor	Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings
Acenocoumarol	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Apixabana	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Dabigatrana	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Darunavir	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Edoxabana	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Heparina	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Lopinavir	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Ritonavir	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Rivaroxabana	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Varfarina	Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
Antagonistas do Receptor da Angiotensina II	Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
Interferon lambda	Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19
Antirreumáticos	Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19
Antirreumáticos	Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19
Corticosteroides	Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19
Corticosteroides	Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19
Cloroquina	Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis
Hidroxicloroquina	Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis
Antagonistas do Receptor da Angiotensina II	The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments
Antagonistas do Receptor da Angiotensina II	EMA advice on renin-angiotensin system medicines during covid-19 pandemic
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	EMA advice on renin-angiotensin system medicines during covid-19 pandemic
Azitromicina	Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19
Sildenafila	"Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19
 infections? A lesson from urology"
Anticoagulantes	"Reply to ""Anticoagulant treatment is associated with decreased mortality in severe
 coronavirus disease 2019 patients with coagulopathy"
Anticorpos neutralizantes direcionados a IL-17	Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2
Cloroquina	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
Hidroxicloroquina	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
Plasma convalescente	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
Remdesivir	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department
Tocilizumabe	Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection
Sarilumabe	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Siltuximabe	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Tocilizumabe	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Heparina	Potential of Heparin and Nafamostat Combination Therapy for COVID-19
Nafamostato	Potential of Heparin and Nafamostat Combination Therapy for COVID-19
Amiodarona	Amiodarone as a possible therapy for coronavirus infection
Cloroquina	Antiviral treatment of COVID-19
Favipiravir	Antiviral treatment of COVID-19
Ivermectina	Antiviral treatment of COVID-19
Lopinavir	Antiviral treatment of COVID-19
Nitazoxanida	Antiviral treatment of COVID-19
Remdesivir	Antiviral treatment of COVID-19
Ritonavir	Antiviral treatment of COVID-19
Cassine xylocarpa	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Cloroquina	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Derivados de andrografolideo	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Gluconato de clorexidina	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Limeciclina	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Lopinavir	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Platycodon grandiflorus	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Remdesivir	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Ribavirina	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Ritonavir	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Scutellaria baicalensis	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Valganciclovir	Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
Favipiravir	A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Hidroxicloroquina	A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Lopinavir	A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Remdesivir	A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Ritonavir	A Review of SARS-CoV-2 and the Ongoing Clinical Trials
Lopinavir	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient
Ritonavir	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient
Ivermectina	Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view
Nitazoxanida	Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies
Hidroxicloroquina	Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials
Remdesivir	Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials
Resiniferatoxina	Standing out from the crowd in treating COVID-19
Medicina Tradicional Chinesa	Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19
Cloroquina	The epidemiology and clinical information about COVID-19
Interferon	The epidemiology and clinical information about COVID-19
Lopinavir	The epidemiology and clinical information about COVID-19
Oseltamivir	The epidemiology and clinical information about COVID-19
Remdesivir	The epidemiology and clinical information about COVID-19
Ritonavir	The epidemiology and clinical information about COVID-19
Umifenovir	The epidemiology and clinical information about COVID-19
Tocilizumabe	Why tocilizumab could be an efective treatment for severe COVID-19?
Vacina	Coronavirus Vaccines: Light at the End of the Tunnel
Antagonistas do Receptor da Angiotensina II	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Anti-inflamatórios	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Azitromicina	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Baricitinibe	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Camostato	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Cloroquina	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Corticosteroides	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Emapalumabe	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Hidroxicloroquina	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Inibidores de fusão	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Lopinavir	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Plasma convalescente	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Remdesivir	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Ritonavir	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Sinvastatina	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Tocilizumabe	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Vacina contra SARS-CoV-2	COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies
Imunoglobulina	Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
Plasmaferese	Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
Plasma convalescente	Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
Darunavir	Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
Interferon alfa	Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
Lopinavir	Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
Ritonavir	Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
Umifenovir	Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China
Lopinavir	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment
Ritonavir	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment
Corticosteroides	Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
Prednisona	Steroid-responsive severe encephalopathy in SARS-CoV-2 infection
Hidroxicloroquina	Hydroxychloroquine and covid-19
Hidroxicloroquina	Hydroxychloroquine and covid-19
Hidroxicloroquina	Hydroxychloroquine prophylaxis for COVID-19 contacts in India
Cloroquina	Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
Hidroxicloroquina	Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
Azitromicina	An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.
Cloroquina	An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.
Hidroxicloroquina	An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.
Lidocaína	An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.
Azitromicina	Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis
Hidroxicloroquina	Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
Lopinavir	Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms
Ritonavir	Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms
Cloroquina	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Corticosteroides	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Hidroxicloroquina	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Lopinavir	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Nitazoxanida	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Remdesivir	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Ribavirina	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Ritonavir	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Tocilizumabe	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
Antivirais	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Corticosteroides	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Inibidores de interleucina-6	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Tocilizumabe	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Didanosina	Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
Atazanavir	Atazanavir para COVID-19. Revisão sistemática rápida
Remdesivir	Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Remdesivir	Remdesivir, la esperanza antiviral frente al SARS-CoV-2
Terapia celular	Mesenchymal stem cells and management of COVID-19 pneumonia
Terapia celular	Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use
Plasma convalescente	Uso de plasma de pacientes recuperados no tratamento de COVID-19. Revisão sistemática rápida
Hidroxicloroquina	Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base
Azitromicina	Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study
Hidroxicloroquina	Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study
Anakinra	Cytokine Storm in COVID-19 and Treatment
Antagonistas de TNF	Cytokine Storm in COVID-19 and Treatment
Cloroquina	Cytokine Storm in COVID-19 and Treatment
Corticosteroides	Cytokine Storm in COVID-19 and Treatment
Imunoglobulina	Cytokine Storm in COVID-19 and Treatment
Inibidores de IFN-αβ	Cytokine Storm in COVID-19 and Treatment
Interferon lambda	Cytokine Storm in COVID-19 and Treatment
Tocilizumabe	Cytokine Storm in COVID-19 and Treatment
Ulinastatina	Cytokine Storm in COVID-19 and Treatment
Vacina Hepatite A	Can Hepatitis A Vaccine Provide Protection Against COVID-19?
Auranofina	The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells
Ativador do plasminogênio tecidual (tPA)	Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)?
Darunavir	Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach
Derivados cumarínicos e flavonas (origem natural)	Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach
Remdesivir	Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach
Saquinavir	Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach
Remdesivir	Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Terapia celular	Mesenchymal Stem Cell Therapy for COVID-19: Present or Future
Talidomida	Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces
Atazanavir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Atazanavir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Dolutegravir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Dolutegravir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Efavirenz	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Efavirenz	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Remdesivir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Remdesivir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Ritonavir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Ritonavir	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
Inibidores da via Rho quinase	Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
Lopinavir	Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19
Ritonavir	Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19
Umifenovir	Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19
Prednisona	Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19
Corticosteroides	The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis
Imunoglobulina	Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19
Imunoglobulina	Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study
Plasma convalescente	COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy
Plasma convalescente	Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
Cloroquina	Pharmaceutical are of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19)
Hidroxicloroquina	Drug Evaluation during the Covid-19 Pandemic
Cloroquina	Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review
Hidroxicloroquina	Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review
Hidroxicloroquina	Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
Ivermectina	Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
Cloroquina	Chloroquine and hydroxychloroquine in covid-19.
Hidroxicloroquina	Chloroquine and hydroxychloroquine in covid-19.
Hidroxicloroquina	Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial
Asunaprevir	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Indinavir	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Lopinavir	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Remdesivir	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Ritonavir	In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Cloroquina	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Corticosteroides	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Favipiravir	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Hidroxicloroquina	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Lopinavir	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Plasma convalescente	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Remdesivir	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Ribavirina	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Ritonavir	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Tocilizumabe	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
Agentes anti-tuberculose	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Agentes anti-tuberculose	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Antineoplásicos	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Antineoplásicos	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Antivirais	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Antivirais	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Nicotinamida	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Nicotinamida	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Ribavirina	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Ribavirina	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Telbivudina	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Telbivudina	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Vitamina B12	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Vitamina B12	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Vitaminas	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Vitaminas	Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Medicina Tradicional Chinesa	Traditional Chinese medicine for treatment of coronavirus disease 2019: a review.
Cloroquina	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Hidroxicloroquina	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Metformina	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Nitazoxanida	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Remdesivir	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Teicoplanina	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Vancomicina	Drug repositioning an alternative for the treatment of coronavirus COVID-19
Remdesivir	Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.
Inibidores de Janus Kinase (JAK)	Inibidores da janus associated kinases para COVID-19.
Antagonistas do receptor de endotelina	Antagonistas do receptor da endotelina para o tratamento de pacientes com COVID-19
Ivermectina	Antagonistas do receptor da ivermectina para o tratamento de pacientes com COVID-19
Anticorpos	The possible of immunotherapy for COVID-19: A systematic review
Vacina	The possible of immunotherapy for COVID-19: A systematic review
Tocilizumabe	First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
Tocilizumabe	Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
Cloroquina	G6PD and chloroquine: selecting the treatment against SARS-CoV-2?
Hidroxicloroquina	G6PD and chloroquine: selecting the treatment against SARS-CoV-2?
Hidroxicloroquina	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial
Cloroquina	COVID-19: A promising cure for the global panic
Cloroquina	COVID-19: A promising cure for the global panic
Cloroquina	COVID-19: A promising cure for the global panic
Favipiravir	COVID-19: A promising cure for the global panic
Favipiravir	COVID-19: A promising cure for the global panic
Favipiravir	COVID-19: A promising cure for the global panic
Interferon alfa	COVID-19: A promising cure for the global panic
Interferon alfa	COVID-19: A promising cure for the global panic
Interferon alfa	COVID-19: A promising cure for the global panic
Lopinavir	COVID-19: A promising cure for the global panic
Lopinavir	COVID-19: A promising cure for the global panic
Lopinavir	COVID-19: A promising cure for the global panic
Medicamentos homeopáticos	COVID-19: A promising cure for the global panic
Medicamentos homeopáticos	COVID-19: A promising cure for the global panic
Medicamentos homeopáticos	COVID-19: A promising cure for the global panic
Medicina Tradicional Indiana	COVID-19: A promising cure for the global panic
Medicina Tradicional Indiana	COVID-19: A promising cure for the global panic
Medicina Tradicional Indiana	COVID-19: A promising cure for the global panic
Naturopatia	COVID-19: A promising cure for the global panic
Naturopatia	COVID-19: A promising cure for the global panic
Naturopatia	COVID-19: A promising cure for the global panic
Oseltamivir	COVID-19: A promising cure for the global panic
Oseltamivir	COVID-19: A promising cure for the global panic
Oseltamivir	COVID-19: A promising cure for the global panic
Remdesivir	COVID-19: A promising cure for the global panic
Remdesivir	COVID-19: A promising cure for the global panic
Remdesivir	COVID-19: A promising cure for the global panic
Ribavirina	COVID-19: A promising cure for the global panic
Ribavirina	COVID-19: A promising cure for the global panic
Ribavirina	COVID-19: A promising cure for the global panic
Ritonavir	COVID-19: A promising cure for the global panic
Ritonavir	COVID-19: A promising cure for the global panic
Ritonavir	COVID-19: A promising cure for the global panic
Sofosbuvir	COVID-19: A promising cure for the global panic
Sofosbuvir	COVID-19: A promising cure for the global panic
Sofosbuvir	COVID-19: A promising cure for the global panic
Azitromicina	Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
Hidroxicloroquina	Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
Ruxolitinibe	Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
Tocilizumabe	Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
Hidroxicloroquina	Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society
Cobicistato	Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)
Darunavir	Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)
Hidroxicloroquina	Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)
Lopinavir	Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)
Ritonavir	Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)
Tacrolimus	Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)
Cloroquina	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Corticosteroides	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Ganciclovir	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Hidroxicloroquina	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Lopinavir	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Oseltamivir	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Oxigenoterapia	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Plasma convalescente	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Remdesivir	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Ressuscitação com fluidoterapia	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Ritonavir	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Tocilizumabe	Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)
Cloroquina	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Corticosteroides	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Hidroxicloroquina	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Interferon	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Lopinavir	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Ribavirina	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Ritonavir	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Tocilizumabe	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Umifenovir	Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience
Interferon recombinante tipo 1	Type 1 interferons as a potential treatment against COVID-19
Ácido ascórbico	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ácido ascórbico	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ácido ascórbico	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ácido ascórbico	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ácido ascórbico	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ácido ascórbico	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Anticorpos	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Anticorpos	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Anticorpos	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Anticorpos	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Anticorpos	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Anticorpos	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Cloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Cloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Cloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Cloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Cloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Cloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Darunavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Darunavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Darunavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Darunavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Darunavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Darunavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Emodina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Emodina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Emodina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Emodina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Emodina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Emodina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ervas com atividade inibitória de protease quimiotripsina-like 3	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ervas com atividade inibitória de protease quimiotripsina-like 3	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ervas com atividade inibitória de protease quimiotripsina-like 3	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ervas com atividade inibitória de protease quimiotripsina-like 3	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ervas com atividade inibitória de protease quimiotripsina-like 3	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ervas com atividade inibitória de protease quimiotripsina-like 3	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Favipiravir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Favipiravir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Favipiravir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Favipiravir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Favipiravir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Favipiravir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Hidroxicloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Hidroxicloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Hidroxicloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Hidroxicloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Hidroxicloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Hidroxicloroquina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Inibidor de protease transmembrana serina 2 (TMPRSS2)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Lopinavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Lopinavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Lopinavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Lopinavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Lopinavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Lopinavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Plasma convalescente	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Plasma convalescente	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Plasma convalescente	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Plasma convalescente	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Plasma convalescente	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Plasma convalescente	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Promazina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Promazina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Promazina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Promazina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Promazina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Promazina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Remdesivir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Remdesivir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Remdesivir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Remdesivir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Remdesivir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Remdesivir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ritonavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ritonavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ritonavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ritonavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ritonavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Ritonavir	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Selênio	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Selênio	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Selênio	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Selênio	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Selênio	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Selênio	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Viperina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Viperina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Viperina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Viperina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Viperina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Viperina	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina A	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina A	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina A	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina A	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina A	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina A	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina D (25-hidroxivitamina D)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina D (25-hidroxivitamina D)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina D (25-hidroxivitamina D)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina D (25-hidroxivitamina D)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina D (25-hidroxivitamina D)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Vitamina D (25-hidroxivitamina D)	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Zinco	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Zinco	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Zinco	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Zinco	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Zinco	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Zinco	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Imunoglobulina	Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens
Anakinra	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Baricitinibe	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Hidroxicloroquina	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Sarilumabe	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Tocilizumabe	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
Mio-inositol	Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
Tocilizumabe	Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?
Medicina Tradicional Chinesa	Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the treatment of Novel Coronavirus Pneumonia by network pharmacology
Profilaxia para tromboembolismo	Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19
Tetraciclinas	Therapeutic Potential for Tetracyclines in the Treatment of COVID-19
Mefloquina	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model
Selamectina	Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model
Estatina	Considerations for statin therapy in patients with COVID-19
Merimepodib	The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro
Oxigenação por membrana extracorpórea (ECMO)	Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report
Eritropoetina humana recombinante (rhEPO)	Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?
Corticosteroides	Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
Corticosteroides	Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)
Ativador do plasminogênio tecidual (tPA)	Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
Prednisona	Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust
Lopinavir	Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
Ritonavir	Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir	Compassionate Use of Remdesivir for Patients with Severe Covid-19
Antagonistas do Receptor da Angiotensina II	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Cloroquina	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Interferon alfa	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Lopinavir	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Ritonavir	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Umifenovir	The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
Interferon alfa	Interferon-α2b treatment for COVID-19
Interferon alfa	Interferon-α2b treatment for COVID-19
Interferon alfa	Interferon-α2b treatment for COVID-19
Anakinra	Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
Favipiravir	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical
Antibióticos	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Antibióticos	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Cloroquina	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Cloroquina	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Hidroxicloroquina	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Hidroxicloroquina	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Oxigenoterapia	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Oxigenoterapia	COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes
Vacina BCG	BCG protects against COVID-19? A word of caution
Plasma convalescente	Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences
Cloroquina	Human monoclonal antibodies block the binding of SARS CoV 2 spike protein
Azitromicina	Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)
Hidroxicloroquina	Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)
Cloroquina	Regulators split on antimalarials for COVID-19
Hidroxicloroquina	Regulators split on antimalarials for COVID-19
Cloroquina	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
Hidroxicloroquina	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
Hidroxicloroquina	Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: A Quasi-Randomized Comparative Study
Hidroxicloroquina	Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population
Azitromicina	Tratamento precoce de 1061 pacientes COVID-19 com hidroxicloroquina e azitromicina, Marselha, França
Hidroxicloroquina	Tratamento precoce de 1061 pacientes COVID-19 com hidroxicloroquina e azitromicina, Marselha, França
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Azitromicina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Hidroxicloroquina	Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Cloroquina	Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)
Cloroquina	Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review
Hidroxicloroquina	Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review
Remdesivir	Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
Vacina	SARS-CoV-2 Vaccines: Status Report
Molnupiravir	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Anti-inflamatórios não esteroidais	COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
Corticosteroides	COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
Azitromicina	COVID-19: Important Therapy Considerations and Approaches in this Hour of Need
Hidroxicloroquina	COVID-19: Important Therapy Considerations and Approaches in this Hour of Need
Bictegravir	Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase
Dolutegravir	Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase
Paritaprevir	Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase
Raltegravir	Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase
Vitamina D (25-hidroxivitamina D)	Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths
Vitamina D (25-hidroxivitamina D)	Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths
Metronidazol	Metronidazole; a Potential Novel Addition to the COVID-19 Regimen
Tocilizumabe	Tocilizumab treatment in COVID-19: a single center experience
Imunoglobulina	High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
Amicacina	Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report
Medidas de suporte	Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report
Oseltamivir	Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report
Vancomicina	Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report
Vacina BCG	Differential COVID-19-attributable mortality and BCG vaccine use in countries
Vacina BCG	Differential COVID-19-attributable mortality and BCG vaccine use in countries
Vacina BCG	Association of BCG vaccination policy with prevalence and mortality of COVID-19
Vacina BCG	Association of BCG vaccination policy with prevalence and mortality of COVID-19
Doxazosina	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
Prazosina	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
Silodosina	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
Tansulosina	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
Terazosina	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Terapia celular	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Imunossupressores	Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
Plasma convalescente	Deployment of convalescent plasma for the prevention and treatment of COVID-19
Plasma convalescente	Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Azitromicina	Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
Hidroxicloroquina	Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
Azitromicina	COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?
Hidroxicloroquina	COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?
Hidroxicloroquina	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients
Hidroxicloroquina	Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Hidroxicloroquina	Comunicado a la opinión pública uso de Hidroxicloroquina / Public opinion on the use of Hydroxychloroquine
Darunavir	Lack of Antiviral Activity of Darunavir against SARS-CoV-2
Emetine	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Homoharringtonina (HHT)	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Lopinavir	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Remdesivir	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ritonavir	Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Amprenavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Atazanavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Darunavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Fosamprenavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Indinavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Lopinavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Paritaprevir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Ritonavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Saquinavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Tipranavir	Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking
Baricitinibe	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Cloroquina	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Corticosteroides	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Hidroxicloroquina	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Interferon alfa	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Lopinavir	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Nelfinavir	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Nitazoxanida	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Plasma convalescente	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Remdesivir	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Ribavirina	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Tocilizumabe	Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019
Vacina	Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Cloroquina	Current Drugs with Potential for Treatment of COVID-19: A Literature Review
Hidroxicloroquina	Current Drugs with Potential for Treatment of COVID-19: A Literature Review
Medicamentos homeopáticos	Estudo Preliminar de Sintomas e Medicamentos Prevalentes do “Gênio Pandêmico” da Pandemia de Covid-19 no Brasil
Heparina	The potential of low molecular weight heparin to mitigatie cytokine storm in severe covid-19 patients: a retrospective clinical study
Azitromicina	Macrolide treatment for COVID-19: Will this be the way forward?
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Cloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Favipiravir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Hidroxicloroquina	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Lopinavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Plasma convalescente	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Remdesivir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Ritonavir	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Tocilizumabe	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Metformina	Infuenza and obesity: its odd relationship and the lessons for COVID‑19 pandemic
Pioglitazona	Infuenza and obesity: its odd relationship and the lessons for COVID‑19 pandemic
Vacina	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
Heparina	Diference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2
Corticosteroides	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Lopinavir	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Moxifloxacina	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Oseltamivir	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Ritonavir	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Tigeciclina	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Umifenovir	Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review
Cloroquina	Potential therapeutic agents against COVID-19: What we know so far
Favipiravir	Potential therapeutic agents against COVID-19: What we know so far
Hidroxicloroquina	Potential therapeutic agents against COVID-19: What we know so far
Interferon	Potential therapeutic agents against COVID-19: What we know so far
Lopinavir	Potential therapeutic agents against COVID-19: What we know so far
Remdesivir	Potential therapeutic agents against COVID-19: What we know so far
Ribavirina	Potential therapeutic agents against COVID-19: What we know so far
Ritonavir	Potential therapeutic agents against COVID-19: What we know so far
Sarilumabe	Potential therapeutic agents against COVID-19: What we know so far
Tocilizumabe	Potential therapeutic agents against COVID-19: What we know so far
Favipiravir	Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection
Heparina	The versatile heparin in COVID-19. Journal of thrombosis and haemostasis
Plasma convalescente	Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how
Vacinas	DRAFT landscape of COVID-19 candidate vaccines – 4 April 2020
Plasma convalescente	Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection
Siltuximabe	Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
Azitromicina	The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin
Hidroxicloroquina	The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin
Carbapenêmicos	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Cefalosporina	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Imunoglobulina	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Lopinavir	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Oseltamivir	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Prednisona	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Quinolonas	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Umifenovir	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin
Tocilizumabe	Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis
Lopinavir	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Lopinavir	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Meropenem	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Meropenem	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Moxifloxacina	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Moxifloxacina	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Oseltamivir	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Oseltamivir	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Umifenovir	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series
Umifenovir	Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series